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Abstract 
Fully-realised three-dimensional patterning strategies enable the development of 
heterogeneous constructs which can recreate tissue architecture and cellular 
microenvironments over a large range of length scales.  This in turn allows the 
development of more effective tissue models and tissue engineering therapies.  The 
work presented in this thesis was designed to address the development of patterning 
methodologies and compatible biomaterial formulations. 
Poly(lactic-co-glycolic acid)-based (PLGA-based) microspheres were utilised for 
temporally-controlled protein delivery.  Robust protocols were developed for the 
production of microspheres with two different mean sizes to provide distinct release 
kinetics which could be further tailored by the addition of a PLGA-poly(ethylene 
glycol)-PLGA (PLGA-PEG-PLGA) triblock copolymer.  A semi-automated 
microinjection/micromanipulation (MM) system was used to precisely position 
individual microspheres into cell culture substrates.  This approach has the potential 
to replicate complex interacting signal environments as seen in developmental and 
repair processes. 
Demineralised bovine bone, processed with or without a decellularisation step, was 
enzymatically digested to form solutions capable of gelation under physiological 
conditions.  The resulting hydrogels outperformed collagen as in vitro culture 
substrates for bone-derived cells and are promising injectable scaffold materials.  
They were also formed into beads which could encapsulate exogenous proteins and 
which may be utilised in MM-based patterning strategies. 
Bioplotting was used to produce alginate hydrogel constructs containing highly viable 
cell populations.  This technique was also used to deposit a PLGA-PEG 
microparticulate material which could be sintered under physiological conditions to 
achieve bone appropriate mechanical properties.  PLGA-PEG/alginate dual material 
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constructs could also be produced incorporating independent patterns of these two 
materials and of two cell populations and two protein signals.  Bioplotting could 
therefore be used to produce sophisticated tissue engineering constructs for the 
repair of large, complex defects.  Though this work focused on osteochondral 
applications much of the data is also more widely-applicable.
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Figure 3.30 5HSUHVHQWDWLYH LPDJH VKRZLQJ  ǋO YROXPHV RI 
ZY VXVSHQVLRQ RI µ ǋP¶ IOXRUHVFHQW PLGA 
microspheres in 0.5% (w/v) CMC delivered into 0.75% 
(w/v) agar gel at nominal spacings of 1 mm using a 
manual micromanipulator in conjunction with a plunger-
in-needle microlitre syringe. 
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Figure 3.31 5HSUHVHQWDWLYH LPDJHV VKRZLQJ µ ǋP¶ 3/*$
microspheres positioned individually into 1% (w/v) 
agarose hydrogel using a manual microinjector in 
conjunction with a semi-automated, programmable 
micromanipulator. 
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Figure 4.1 Representative images showing the appearance of 
bovine bone-derived materials at various stages of 
processing. 
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Figure 4.2 5HSUHVHQWDWLYHWUDQVPLVVLRQLPDJHVIURPǋ&7DQDOysis of 
milled bone chips and DBM to show qualitative loss of 
mineral during processing. 
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Figure 4.3 Representative bright field microscopy images of sections 
of DBM and DECM stained with haemotoxylin to show 
cell nuclei and counterstained with eosin to show matrix 
constituents. 
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Figure 4.4 Quantification of dsDNA for DBM and DECM via 
phenol/chloroform/isoamyl alcohol extraction and the 
PicoGreen® assay.  Also shown is a widely-used criterion 
for consideration of a material as successfully 
decellularised (50 ng dsDNA per mg dry material). 
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Figure 4.5 Quantification of the collagen content (fraction of dry 
weight) of DBM and DECM powders via quantification of 
the non-proteinogenic amino acid hydroxyproline. 
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Figure 4.6 Spectrophotometric assessment of gelation kinetics for 
collagen, DBM and DECM via absorbance measurements 
at 405 nm.  Shown are both raw values and values 
which are normalised such that the initial reading is zero 
and the maximum value reached is one. 
 
150 
Figure 4.7 Rheological assessment of gelling solutions of collagen, 
DBM and DECM via the application of an oscillating 1% 
shear strain at a constant strain rate of 1 rad s-1 in a 
humidified atmosphere at 37oC.  Assessment was 
performed at 3 mg mL-1 (a) and 6 mg mL-1 (b) final gel 
concentrations. 
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Figure 4.8 Rheological assessment of hydrogels derived from 
collagen, DBM and DECM.  An amplitude sweep was 
performed covering the strain range 0.1 ± 200% at a 
constant shear rate of 1 rad s-1 in a humidified 
atmosphere at 37oC.  All materials were assessed at 3 
mg mL-1 and 6 mg mL-1 gel concentrations and were 
allowed to undergo gelation for one hour prior to testing. 
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Figure 4.9 Representative SEM images of 3 mg mL-1 and 6 mg mL-1 
DECM, DBM and collagen hydrogels. 
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Figure 4.10 Metabolic activity of hOS cells seeded on collagen, DBM 
and DECM hydrogels or on tissue culture plastic (TCP) 
assessed via the MTS assay.  Cells were seeded at 
FHOOVSHUZHOORQWRǋ/JHOs in 96-well plates 
after the gels had been allowed to form for one hour at 
37oC. 
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and DECM hydrogels or on tissue culture plastic (TCP) 
assessed via the MTS assay.  Cells were seeded at 
FHOOVSHUZHOORQWRǋ/JHOV LQ-well plates 
after the gels had been allowed to form for one hour at 
37oC. 
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Figure 4.12 Representative bright field microscopy images of 
hydrogel beads composed of alginate alone, beads 
produced from a 2:1 (v:v) ratio of DECM digest to 
alginate solution and beads produced from the same 
ratio of DECM to alginate imaged after treatment for 10 
minutes with 0.25 M sodium citrate to remove the 
alginate component. 
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Figure 5.1 Representative images of constructs produced via 
bioplotting of 2% alginate hydrogels. 
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Figure 5.2 Representative images of constructs produced via 
bioplotting PLGA-PEG microparticles suspended in 3% 
medium viscosity CMC at a 1.5:1 (v:w) ratio of solid to 
aqueous carrier.  Images are shown of constructs both 
before and after 24 hours sintering. 
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Figure 5.3 Representative images of constructs produced via 
bioplotting of PLGA-3(* PLFURSDUWLFOHV DQG µ ǋP¶
PLGA microspheres suspended in 3% (w/v) medium 
viscosity CMC at a 1.5:1 (v:w) ratio of solid to aqueous 
carrier.  The ratio of microparticles to microspheres was 
3:1 (w:w).  Images are shown of constructs both before 
and after 24 hours sintering. 
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Figure 5.4 Representative SEM images of constructs produced via 
bioplotting of PLGA-3(* PLFURSDUWLFOHV DQG µ ǋP¶
PLGA microspheres suspended in 3% (w/v) medium 
viscosity CMC at a 1.5:1 (v:w) ratio of solid to aqueous 
carrier.  The ratio of microparticles to microspheres was 
3:1 (w:w).  Images show construct surface and cross-
section after 24 hours sintering. 
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Figure 5.5 5HSUHVHQWDWLYH ǋ&7-derived cross-sectional images of 
constructs produced via bioplotting of PLGA-PEG 
PLFURSDUWLFOHV DQG µ ǋP¶ 3/*$ PLFURVSKHUHV
suspended in 3% (w/v) medium viscosity CMC at a 1.5:1 
(v:w) ratio of solid to aqueous carrier.  The ratio of 
microparticles to microspheres was 3:1 (w:w) and 
constructs were imaged after 24 hours sintering. 
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Figure 5.6 Representative images of constructs produced via 
bioplotting of PGLA-PEG microparticulate and 2% 
alginate hydrogel phases.  PLGA-PEG phase consisted of 
microparticles suspended in 3% (w/v) medium viscosity 
CMC at a 1.5:1 (v:w) ratio of solid to aqueous carrier.  
Images are shown before and after 24 hours sintering in 
0.9% (w/v) sodium chloride or 0.66% (w/v) calcium 
chloride. 
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Figure 5.7 Representative fluorescence microscopy images of 
MC3T3-E1 cells and bovine chondrocytes bioplotted in 
2% alginate hydrogel at 500,000 cells mL-1.  Cells have 
been live/dead VWDLQHGIRUPLQXWHVZLWKǋ0Falcein 
AM and ethidium homodimer-1 respectively. 
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Figure 5.8 Schematic showing design of four phase construct and 
confocal microscopy image of bioplotted construct 
produced from design.  Phases consisted of 2% alginate 
hydrogel containing MC3T3-E1 cells labelled with a far 
red dye, 2% alginate hydrogel containing bovine 
chondrocytes labelled with DAPI, PLGA-PEG microparticle 
paste containing blank PLGA microspheres and PLGA-
PEG microparticle paste containing PLGA microspheres 
encapsulating FITC-lysozyme.  Alginate phases contained 
500,000 cells mL-1 and PLGA-PEG pastes consisted of 
PLGA-3(* PLFURSDUWLFOHV DQG µ ǋP¶ 3/*$
microspheres suspended in 3% (w/v)medium viscosity 
CMC at a 1.5:1 (v:w) ratio of solid to aqueous carrier.  
The ratio of microparticles to microspheres was 3:1 
(w:w). 
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Figure 5.9 Confocal microscopy image of four phase bioplotted 
construct shown in Figure 5.8 with magnified images of 
individual phases. 
 
187 
Figure 5.10 Yield stresses for bioplotted PLGA-PEG microparticulate 
scaffolds as assessed by unconstrained compression 
testing.  PLGA-PEG microparticles were suspended in a 
variety of aqueous carriers at a variety of carrier:solid 
(v:w) ratios for bioplotting into cylindrical PTFE moulds.  
Samples were tested after 24 hours sintering. 
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Figure 5.11 <RXQJ¶VPRGXOLIRUELRSORWWHG3/*$-PEG microparticulate 
scaffolds as assessed by unconstrained compression 
testing.  PLGA-PEG microparticles were suspended in a 
variety of aqueous carriers at a variety of carrier:solid 
(v:w) ratios for bioplotting into cylindrical PTFE moulds.  
Samples were tested after 24 hours sintering. 
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Figure 5.12 Porosities of bioplotted PLGA-PEG microparticulate 
VFDIIROGV DV DVVHVVHG E\ ǋ&7 LPDging and analysis.  
PLGA-PEG microparticles were suspended in a variety of 
aqueous carriers at different carrier:solid (v:w) ratios for 
bioplotting into cylindrical PTFE moulds.  Samples were 
tested after 24 hours sintering. 
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Figure 5.13 Mean pore sizes of bioplotted PLGA-PEG microparticulate 
scaffolds as assessed by ǋ&7 LPDJLQJ DQG DQDO\VLV.  
PLGA-PEG microparticles were suspended in a variety of 
aqueous carriers at different carrier:solid (v:w) ratios for 
bioplotting into cylindrical PTFE moulds.  Samples were 
tested after 24 hours sintering. 
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Figure 5.14 ǋ&7WUDQVPLVVLRQLPDJHVIURPHDUO\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stages of the acquisition process.  Shrinking can be seen 
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acquisition process.  PLGA-PEG microparticles were 
suspended in 3% (w/v) medium viscosity CMC at a 1.4:1 
(v:w) ratio of liquid:solid for bioplotting into cylindrical 
PTFE moulds.  Samples were tested after 24 hours 
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Figure 5.15 Representative SEM images of fracture surfaces of 
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1. General Introduction 
Many tissue engineering strategies involve the production of biomaterial scaffolds 
which have largely uniform three-dimensional architectures.  These scaffolds may 
also deliver drugs or therapeutic proteins, though usually with spatially-homogenous 
profiles.  They can then be directly implanted in vivo or uniformly pre-seeded with 
appropriate cell types to form tissue-engineered constructs.  The homogeneity of 
constructs produced in this way does not reflect the complexity of the tissues they 
are designed to emulate which may limit their ability to produce fully-functional tissue 
regeneration. 
Heterogeneity exists in vivo on a wide range of length scales, arguably most 
obviously in the fact that a tissue may contain several cell types and a whole organ 
may then contain multiple tissues with distinct cell populations.  Extracellular matrix 
(ECM) differences may also exist between different locations, in terms of mechanical 
properties and/or biochemical composition.  Recreating these variations in tissue 
composition will be important to achieve truly effective, functional repair of large 
areas of defective or missing tissue.  Another important consideration is the need for 
neo-tissue to become rapidly and effectively vascularised after implantation.  This 
may necessitate the pre-vascularisation of constructs prior to delivery to the clinic.  
For these reasons there is a clear need for construct fabrication techniques which are 
capable of macro-VFDOHµVXE-PLOOLPHWUH¶WKUHH-dimensional patterning. 
Tissues also have functional heterogeneity on a finer scale due to the arrangement 
and alignment of cells and ECM molecules and the presence of gradients of proteins 
and other signalling molecules1-6.  These environmeQWV IRUP WKH ORFDO µQLFKHV¶ WKDW
play a pivotal role in the regulation of cell and tissue function.  The replication of 
such niches in vitro would allow a more detailed understanding of the cell and 
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molecular biology of these microenvironments.  Knowledge gained in this way can 
then support the development of more effective tissue engineering constructs. 
Cell and scaffold patterning techniques can be broadly divided into three categories.  
Firstly there are those techniques that produce three-dimensional scaffolds but only 
allow the production of a restricted set of simple patterns.  This category covers 
approaches such as electrospinning7,8, layered moulding strategies9 or gradient 
mixing10-13.  Techniques that allow the production of complex patterns but only in two 
dimensions form the second category and those that facilitate the production of 
complex three-dimensional patterns are the third category of techniques.  The 
complexity offered by the latter two categories is essential for the replication of tissue 
architectures and these techniques will be discussed further below. 
For the purpose of this thesis a technique is considered to be three-dimensional if it 
is capable of generating macro-scale constructs suitable for tissue engineering or can 
exert patterning effects at any point within macro-scale constructs.  In this context a 
macro-scale construct is taken to be a centimetre or more in size.  Two-dimensional 
techniques such as photolithography, soft lithography, microfluidics, laser-induced 
forward transfer and inkjet printing have informed the development of three-
dimensional techniques.  However their utility is limited when it comes to the 
production of macro-scale tissue engineering constructs or the deduction of 
fundamental microenvironmental biology by dimensionality and resolution 
respectively.  These techniques have been comprehensively reviewed elsewhere14-23 
and only three-dimensional techniques will be considered further. 
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1.1 Patterning of Individual Objects: Recreating Cellular Microenvironments 
1.1.1 Microinjection and Micromanipulation 
Microinjection involves the delivery of sub-millilitre volumes of (partially) fluid 
material into a substrate via the application of pressure.  The pressure may be 
pneumatically, hydraulically or directly applied either manually or automatically.  
Microinjection is typically used in combination with either manual or automated 
micromanipulation to precisely control the site of delivery.  Drugs, signalling 
molecules and viral vectors have been injected into both embryonic and adult tissue 
for the study of the mechanisms of development and disease progression24-29. 
More recently, and more relevantly for tissue engineering, 
microinjection/micromanipulation (MM) techniques have also been used to deliver 
cells30-32 and synthetic polymer microspheres31-34 into adult tissues.  The delivery of 
cells and microspheres into scaffold materials could allow the creation of tissue and 
developmental models in vitro, with the microspheres responsible for controlled 
delivery of biological signals.  These environments may permit the study of 
fundamental cell biology and the screening of potential tissue engineering therapies. 
Automated MM platforms have recently been developed which improve the precision 
and repeatability of delivery35-39.  Many of these aim to automate the manipulation of 
the cells, cell clusters or embryos into which the injection is to be performed.  One 
study demonstrated a platform for automated control of injection position within a 
bulk collagen hydrogel39.  Though the platform was only used to produce simple 
arrays of cell clusters suspended in poly(vinyl pyrollidone) the technology could allow 
the production of complex environments with greater speed and precision than is 
possible manually.  Though the resolution achieved in this study compares well with 
many other three-dimensional patterning techniques it may not provide high enough 
resolution for the recreation of early developmental environments or the study of cell 
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biology at a single cell level.  A key challenge for the future may thus be to utilise MM 
techniques to manipulate and deliver cells and microspheres individually. 
1.1.2 (Holographic) Optical Tweezers 
An optical tweezer (OT) system creates µRSWLFDO WUDSV¶ by focusing a laser beam 
through a microscope objective with a high numerical aperture.  Two distinct types of 
force act within the optical traps and they interact to constrain objects within the 
traps.  The scattering force is produced by photons from the laser beam striking the 
object within a trap and the gradient force by a gradient in field intensity.  Dielectric 
objects such as cells or small particles composed of silica or synthetic polymers can 
be optically trapped, and this enables OT systems to arrange micron-scale objects 
individually with high resolution (Figure 1.1)40-43. 
The science underpinning OT systems was pioneered by Arthur Ashkin and 
colleagues44 and further developed in collaboration with J.M. Dziedzic45.  The authors 
speculated that OT systems could be utilised in trapping and manipulating biological 
materials.  This breakthrough was first achieved by the use of infrared lasers to 
effectively trap bacteria and viruses46,47.  The low absorbance of near infrared light 
(wavelengths around 750 ± 1500 nm) by the majority of biological materials enables 
their safe and effective manipulation.  This development of the technique has 
ultimately led to the successful trapping of mammalian cells48,49. 
To allow OT systems to generate complex patterns in three dimensions they must be 
capable of generating multiple traps from a single laser source.  Systems have now 
been developed which are capable of generating multiple traps in two dimensions50-
53.  Furthermore, holographic optical tweezer (HOT) systems with the ability to 
generate multiple traps in three dimensions have also been devised54-61.  These 
systems have been used to stably trap and manipulate both eukaryotic and 
prokaryotic cells62 and this has been extensively utilised in cell sorting63-77.   
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Figure 1.1 ± Schematic depicting the principles of operation of a holographic 
optical tweezer system.  i) A computer-controlled spatial light modulator (SLM) 
acts in combination with telescopic optics and a microscope objective to generate 
optical traps in 3D.  ii) These traps can stably hold objects such as cells or 
microscopic synthetic particles in precisely defined positions. 
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OT systems have the ability to position trapped objects with precision on the cellular 
level.  This high resolution manipulation has been combined with microfluidic devices 
to study the responses of prokaryotes to different environmental conditions70,78.  
However, effective utilisation of OT-based manipulation to perform three-dimensional 
patterning of mammalian cells has to date been very limited.  A small number of 
early studies do demonstrate, at least in two dimensions, the potential of HOT 
systems in the study of cell-cell interactions on a single cell level42,43,79. 
In one study a single rod cell was placed next to groups of cells containing a cone 
cell and a multipolar neuron and it was found that prominent growth of the neuron 
was inhibited by the presence of the rod cell43.  Other studies have demonstrated the 
3D patterning potential of HOT systems by positioning synthetic particles into 
complex 3D structures with spacing of a few microns40,68.   
The practical limitations of fabrication one cell at a time may limit the use of OT 
systems in the production of tissue engineering constructs directly.  However their 
high resolution offers valuable opportunities for use in in vitro tissue and disease 
modelling.  OT systems could allow the study and replication of microenvironmental 
features at a resolution higher than that possible with any other three-dimensional 
patterning technique. 
1.2 Production of Patterned Constructs: Recreating Macro-Scale Tissue 
Heterogeneity 
The level of interest in the three-dimensional patterning techniques discussed below, 
referred to collectively as solid freeform fabrication or rapid prototyping (RP) 
techniques has grown rapidly in recent years.  RP technologies have found significant 
application in tissue engineering due to their capability to produce bespoke scaffold 
architectures that replicate clinical defect sites.  More recent research has also 
addressed their capacity to produce constructs which contain patterns in various 
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features and properties.  A number of RP techniques have been utilised including 
stereolithography, multiphoton lithography, selective laser sintering, 3D printing, 
fused filament fabrication, bioplotting and bioprinting. 
1.2.1 Stereolithography 
Stereolithography (STL) is a maskless optical lithography technique in which a laser 
light is scanned across the surface of a liquid precursor bath to solidify a thin layer of 
the material in the desired two-dimensional pattern on a support table.  Vertical 
motion of the table allows the generation of successive layers, each created at the 
liquid surface and bound to the underlying layer (Figure 1.2).  STL was developed 
and patented by Charles Hull for high-fidelity reproduction of synthetic polymer 
components in industrial manufacturing80.  Further developments of the technique 
have demonstrated its potential for the fabrication of biological constructs for tissue 
engineering and modelling81.  STL has the potential to be used for patterning 
construct constituents and properties by dividing the fabrication of each layer into a 
series of successive steps utilising different precursor mixtures.  Different mixtures 
may then form different final materials, encapsulate different cell types or different 
biological signals.  
Scaffolds used in tissue engineering are typically designed to degrade or be resorbed 
in vivo, supporting and encouraging tissue repair.  The compatibility of STL 
techniques with biodegradable/resorbable materials therefore further supports its use 
within the field of tissue engineering.  A number of biodegradable synthetic polymers 
have been used successfully in STL-based scaffold fabrication, including 
polypropylene fumarate (PPF)82-86, poly(D,L-lactide)87,88 and polycaprolactone 
(PCL)88,89.
  
  
Figure 1.2 ± Schematic depicting the principles of operation of a stereolithography device.  A laser scans the surface of a photocurable liquid precursor to 
selectively solidify a thin layer close to the surface (1).  The sample support table then moves down to allow a new layer to be scanned and solidified, 
which is bound to the first layer (2).  By repetition of these steps a three-dimensional structure is built. 
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Photocurable forms of natural polymers including chitosan90 have also been 
developed which are suitable for use in STL.  Scaffolds formed from these materials 
have inherent bioactivity and may aid the reconstitution of natural cell-matrix 
interactions and the integration of the scaffold with surrounding native tissue.  Wang 
and colleagues demonstrated that scaffolds could be produced via STL from 
engineered peptides containing photosensitive non-canonical amino acids91. 
STL has also been applied to a number of ceramic materials such as alumina92-95 and 
ǃ-WULFDOFLXP SKRVSKDWH ǃ-TCP)96.  Scaffolds are made by suspending ceramic 
SDUWLFOHVLQDV\QWKHWLFSRO\PHUSUHFXUVRUWRSURGXFHWKHLQLWLDOµJUHHQ¶VFDIIROGZKLFK
is then subjected to heat treatment to remove the polymer and sinter the ceramic.  
Scaffolds produced in this way can have compressive strengths of up to 23.54 MPa, 
making them suitable for the repair of load-bearing bones96. 
To increase the potential patterning complexity that can be achieved via STL, 
particularly for multi-tissue constructs, the incorporation of cells in the fabrication 
process is an important step.  Whilst this is not usually possible with the materials 
described above, viable cells can be incorporated in scaffolds formed from hydrogels 
such as poly(ethylene glycol) dimethacrylate (PEGDMA)97,98 or poly(ethylene glycol) 
diacrylate (PEGDA)99.  Short-term cell survival has been demonstrated in PEGDMA, 
with one study showing 87% viability of human dermal fibroblasts 24 hours post-
fabrication98.  Longer term studies that demonstrate functional biological structure 
formation within the resulting constructs have yet to be performed.  The full 
effectiveness of this technique for cell patterning therefore remains to be established. 
Incorporation of biological proteins into the scaffold structure introduces an additional 
level of functionality that could further increase the efficacy of STL based construct 
formation100,101.  Such incorporation has been demonstrated by a study showing the 
successful incorporation of the growth factor bone morphogenetic protein-2 (BMP-2).  
Post-fabrication bioactivity, both in vitro and in vivo, was achieved by encapsulating 
the protein in poly(lactic-co-glycolic acid) (PLGA) microspheres101.  As well as 
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potentially protecting the protein during construct fabrication, encapsulation in 
polymer microspheres allowed the temporal presentation of the protein to be 
controlled.  This is in addition to the spatial control exerted by the STL process itself. 
It has been shown that STL can offer high resolution morphological control and 
feature sizes DVVPDOODVǋPKDYHEHHQDFKLHYHG86.  A number of recent studies 
have also shown that varying simple morphological parameters such as pore size can 
have a significant effect on the adhesion and proliferation of cells on STL-derived 
scaffolds102-104.  However these studies have largely focused on the generation of 
scaffolds with uniform properties. 
STL can be used to pattern constructs both between and within individual layers, with 
the latter being more difficult to achieve but providing a greater level of functional 
complexity.  A small number of recent studies have utilised STL to achieve both types 
of patterning in a variety of construct constituents100,105-107.  Two of these have 
demonstrated patterning of polysaccharides and peptide-modified poly(ethylene 
glycol) (PEG) within hydrogel scaffolds for control of protein binding and cell 
adhesion respectively100,106.  In the latter study it was qualitatively shown that human 
dermal fibroblasts preferentially attached to and proliferated in regions of the 
scaffolds which contained peptide-modified PEG106. Whilst these examples illustrate 
the potential of STL, patterns of sufficient complexity to replicate tissue macro-
architectures were not generated and functionality has not been demonstrated. 
Recently, a study by Chan and colleagues generated hydrogels able to support 
proliferation of encapsulated NIH/3T3 fibroblasts with differently-labelled cell 
populations able to be included in different layers of the same construct105.  This 
direct approach provided constructs containing multiple cell types, which may be key 
to replicating tissue architecture.  Similarly Zorlutuna and colleagues synthesised 
constructs composed of PEG and a modified photocurable alginate107.  Some 
encapsulated cell types were viable and proliferative whilst others showed significant 
cell death, suggesting that different materials may be required to support different 
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cell types.  The authors were subsequently able to show that cells and materials 
could be independently patterned and produced constructs that contained C2C12 
myoblasts, hippocampal neurons and adipose-derived stem cells. 
Whilst the studies discussed thus far serve to illustrate the potential of STL for the 
production of complex scaffold constructs, there are a number of practical limitations 
that must be considered for future applications of this technology.  The resolution 
limits of STL are yet to be fully characterised.  Simple applications have demonstrated 
the production of structures less than 10 ǋP LQ VL]H86 but intra-scaffold patterning 
has only been performed with coarser resolutions of the order RI  ǋP or 
more105,106 
A further limitation of STL for three-dimensional patterning is the requirement for 
extensive washing steps whenever the precursor materials are changed.  This 
prevents blurring between neighbouring regions but can make the production of 
complex scaffolds very time-consuming.  This may be particularly problematic when 
cells are to be incorporated since components of the photosensitive precursor mixes 
used for STL can be cytotoxic97,106,107.   
STL variants have been developed which utilise dynamic masking to speed up the 
fabrication process.  Rather than a point source scanning a surface to form each two-
dimensional layer, a whole layer is simultaneously illuminated as defined by a 
dynamic mask.  The most commonly used masks are digital micromirror devices 
consisting of arrays RIPLUURUVZKLFKFDQEHVZLWFKHGEHWZHHQµRQ¶DQGµRII¶VWDWHVLQ
which they do and do not reflect light108-110.   
Studies utilising digital micromirror device projection photolithography (DMDPP) in 
tissue engineering are far fewer in number than those using conventional STL and 
the development of the technique is at an earlier stage.  The materials used have 
predominantly been synthetic polymers such as PPF111 and a mixture of PLGA and 
poly(ethylene glycol) hydroxyethylmethacrylate112.  In a small number of cases 
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scaffolds have also been produced from hydrogels such as PEGDA, which could be 
surface modified with laminin113 or fibronectin114 in order to promote cell attachment.  
Although biologically-relevant patterning has not been demonstrated with DMDPP, a 
study published by Choi and coworkers did show the development of a multi-material 
system which was utilised for patterning commercially available STL resins both 
within and between layers115.  The advantages that DMDPP has over the more 
established STL technique make this a promising method for future biological 
patterning applications. 
STL has been used to produce constructs for tissue engineering and in vitro 
modelling from a wide variety of materials, encapsulating a range of different cell 
types and biological signals.  The ability of the technique to offer high-resolution 
morphological patterning of constructs is well-established81 and more complex 
patterning of cell populations, materials and proteins has also been 
demonstrated100,105-107.  The patterning resolution so far demonstrated may not be 
sufficient to reproduce the microenvironmental characteristics of the cell niche but 
significant potential still exists for the generation of macro-scale patterns. 
1.2.2 Multiphoton Lithographic Techniques 
Multiphoton lithography (MPL) is an adaptation of STL in which the intended effect of 
the illumination is produced only when two (or more) photons arrive at a point 
simultaneously116-118.  This happens very precisely at the focal point of the laser 
optical system and it is this property that gives MPL superior spatial resolution 
compared to STL.  The use of MPL techniques in tissue engineering and modelling is 
less widespread than that of conventional STL but reports published so far 
demonstrate the potential of the technique119,120. 
Materials utilised for freeform fabrication applications of MPL include hyaluronic acid 
121, proteins such as bovine serum albumin and fibrinogen122-125, the 
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organic/inorganic hybrid polymer ORMOCER® 126-128 and protein/polymer hybrids 
which offer the mechanical strength of polymers alongside the bioactivity of 
proteins129.  As with STL, some of these techniques use digital micromirror devices to 
speed up construct fabrication122,124.  The data in these publications illustrate that 
MPL techniques have resolutions which are at least an order of magnitude finer than 
those seen in conventional STL, with sub-micron features often achievable.  The wide 
range of materials studied shows that this approach can potentially produce scaffolds 
suitable for application in many different tissues. 
MPL techniques have also been developed to generate three-dimensional patterns 
within pre-existing hydrogels130.  A series of publications by Shoichet and colleagues 
has focused on the development of agarose based hydrogels which can be modified 
by the induction of crosslinking and/or exposure of photocaged reactive moieties for 
protein immobilisation131-142.  Three different routes to protein immobilisation have 
been demonstrated and it has been shown that all three systems are capable of 
producing different protein concentrations by varying the number of times an area is 
scanned132-134.  The results in these studies show that the patterning resolution is 5 
ǋPLQWKHSODQHSHUSHQGLFXODUWRWKHLQFLGHQWOLJKWǋPLQWKHGLUHFWLRQSDUDOOHO
that immobilised protein patterns are stable for at least 8 days and that two proteins 
can be patterned simultaneously. 
A number of studies have demonstrated the functional effects of immobilised proteins 
in terms of the ability to regulate biological activities133,136-139,141.  One study showed 
that murine endothelial cells would migrate significant distances into hydrogel 
scaffolds in response to vascular endothelial growth factor and that step gradients 
produced greater migration than uniform concentrations135. 
Anseth and colleagues have used a similar approach to pattern PEG-based 
hydrogels143-151.  The mechanical properties of these gels can be controlled using 
MPL, with dynamic control possible via photocleavable crosslinks143,145,147,150.  
Modification of gel stiffness during stem cell culture has been shown to dramatically 
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alter the differentiation pathway of the cells145.  Concomitant protein immobilisation 
via chemical conjugation can also be achieved using this method.  The simultaneous 
photoconjugation of multiple proteins has been demonstrated with a resolution of 1 
ǋPDFKLHYHG LQ WKH SODQH SHUSHQGLFXODU WR LQFLGHQW OLJKW aǋP LQ WKH GLUHFWLRQ
parallel)143. The ability of MPL to dynamically manipulate different gel properties 
simultaneously suggests that it has enhanced capability for the production of complex 
constructs relative to other techniques. 
The MPL techniques discussed above, and others similar152-154, can pattern protein 
signals and mechanical properties in cytocompatible hydrogels with resolutions which 
are better than most three-dimensional fabrication techniques.  Coupled with 
hydrogel fabrication via MPL, this could potentially allow for the production of 
scaffolds containing an initial set of patterns which could then be dynamically altered 
during an in vitro culture period.  The secondary stage of this approach does have a 
significant limitation in that the patterning can only extend as far into the scaffold as 
its optical properties will allow, which is typically no more than a few millimetres. 
1.2.3 Selective Laser Sintering 
In selective laser sintering (SLS) laser illumination is used to bind selected regions of 
sequentially deposited layers of powder in order to build three-dimensional structures 
in a layer-by-layer fashion (Figure 1.3).  Since the technique was patented by Carl 
Deckard155 a significant body of work has demonstrated that SLS can be used to 
produce tissue engineering scaffolds with precise control of morphology156.  However, 
the range of patterning which can be performed within SLS derived constructs is 
inherently limited by the use of powders as starting materials into which live cells 
cannot be incorporated.  Additionally, the difficulties that would be associated with 
removing unsintered powder from scaffolds during fabrication means that it is difficult 
to envisage individual layers containing multiple materials or biological signals.
  
 
  
Figure 1.3 ± Schematic depicting the principles of operation of a selective laser sintering device.  A feed stage is raised so that a thin layer of powder 
precursor material stands proud (1).  This layer is then spread across the sample stage by a roller (2) and the powder particles selectively bound to one 
another by laser irradiation-mediated melting (3).  The sample stage then moves down to allow a new layer of powder to be spread across the first layer 
(4).  By repetition of these steps, a three-dimensional structure is built. 
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Published work utilising SLS for tissue engineering scaffold fabrication has almost 
exclusively focused on synthetic polymers as scaffold materials.  A wide range have 
been used including PCL157-161, poly(vinyl alcohol)162, poly(ethylene)163, poly(L-lactic 
acid) (PLLA)164, PLGA165 and poly(hydroxybutyrate-co-hydroxyvalerate)166,167. To 
demonstrate the potential for SLS scaffold fabrication in bone applications, a number 
of studies have demonstrated the inclusion of ceramic micro- or nanoparticles in 
polymer/ceramic composite scaffolds.  Ceramic materials which have been 
incorporated in this way include: hydroxyapatite (HA)162-165,168,169 ǃ-TCP165, calcium 
phosphate166,167 and apatite-wollastonite glass170, though in the final case high 
temperature post-fabrication sintering was used to remove the polymer phase.  Pure 
ceramic scaffolds have also been directly fabricated from HA171,172.  These ceramic 
containing materials have been used to produce scaffolds with mechanical strengths 
as high as 12.06 MPa165 which show good compatibility with bone-relevant cell 
types168,170. 
SLS can be used to produce scaffolds which directly incorporate biological signalling 
molecules159.  A recent study demonstrated the fabrication of scaffolds from 
nanoparticles of (poly-3-hydroxy butyrate co-valerate) which were loaded with bovine 
serum albumin167.  If the incorporation of such agents into precise positions within 
the bulk structure could be achieved this would enable more complex spatio-temporal 
patterning via SLS, but this capacity has not yet been demonstrated. 
Currently there are no published reports of the use of SLS for patterning of construct 
constituents within the gross shape.  The scaffolds that have been produced have 
IHDWXUHV GRZQ WR  ǋP LQ VL]H ZLWKLQ LQGLYLGXDO OD\HUV161 but in this sense finer 
resolution can be achieved with other patterning techniques.  The other major 
limiting factor to the applicability of SLS in tissue engineering and modelling is the 
lack of ability to incorporate cells within the bulk structure as it is formed.  This would 
seem to be a prerequisite if effective reproduction of tissue architecture is to be 
achieved. 
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1.2.4 3D Printing 
3D printing (3DP) is conceptually similar to SLS in that layers of a powdered starting 
material are sequentially and selectively solidified to form three-dimensional 
structures.  The practical difference is in the use of liquid chemical binders rather 
than laser light to solidify the material (Figure 1.4)173.  3DP was originally patented by 
Emanuel Sachs and colleagues174,175 but has since been applied to the production of 
tissue engineering scaffolds176.  Extensive post-processing steps are required to 
remove unsintered powder from 3DP-produced scaffolds and consequently, as with 
SLS, multi-material patterning is likely to be restricted to simple layered geometries. 
A small number of studies have used synthetic polymers such as PLGA177,178 and 
poly(lactic acid)177,179 in 3DP scaffolds for in vitro cell culture and tissue production.  
However the majority of publications have focused on the production of ceramic 
scaffolds for applications in bone tissue engineering176,180,181.  Many of the studies 
published thus far have utilised some form of calcium phosphate for scaffold 
fabrication.  The most commonly used are HA182-190 DQG ǃ-TCP187,188,191-194, though 
others include tetracalcium phosphate191, brushite195,196 and calcium aluminate197.  
7KHVH FHUDPLF VFDIIROGV FDQ FRQWDLQ IHDWXUHV DV VPDOO DV  ǋP197 and have 
compressive strengths of over 30 MPa whilst still maintaining at least 30% 
porosity184,198 or at least 5 MPa where porosities of over 60% are needed184. 
Since ceramic scaffolds typically require post-fabrication sintering at very high 
temperatures, cells and biological signalling molecules cannot usually be incorporated 
in the fabrication process185,186,188,198.  There are some studies that have attempted to 
solve this problem.  In a 2010 study by Vorndran and co-workers BMP-2 was printed 
in the aqueous binder used to produce brushite ceramic scaffolds with retention of 
bioactivity196.  However the post-fabrication processing steps required to fully develop 
the scaffolds were not applied in this case.  Another publication detailed a system  
 
  
 
  
Figure 1.4 ± Schematic depicting the principles of operation of a 3D printing device.  A feed stage is raised so that a thin layer of powder precursor 
material stands proud (1).  This layer is then spread across the sample stage by a roller (2) and the powder particles bound to one another by selective 
deposition of a liquid binder, typically by an inkjet printhead (3).  The sample stage then moves down to allow a new layer of powder to be spread 
across the first layer (4).  By repetition of these steps, a three-dimensional structure is built. 
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that forms patterned implants which can delay and control the presentation profile of 
multiple drugs179. Theoretically the 3DP process could be used to produce complex 
independent three-dimensional patterns of multiple construct constituents and 
properties.  However for the reasons stated above and other practical limitations, the 
predominant use for 3DP in tissue engineering is for accurate defect shape replication 
and the production of defect-matched scaffolds.  As with SLS, the control of 
macroscopic features may increase the rate of tissue in-growth in 
vivo183,184,186,187,191,193,198 but the technique is currently unable to incorporate cells and 
biological signals. 
1.2.5 Fused Filament Fabrication 
Fused filament fabrication (FFF) (also called fused deposition modelling) involves the 
extrusion of synthetic polymer melts as fibres or filaments.  These filaments are 
deposited layer-by-layer in two dimensional patterns to build three-dimensional 
structures (Figure 1.5).  As with many other RP techniques FFF was developed as a 
commercial process for the fabrication of plastic parts199.  The requirement for 
heating to melt the synthetic polymers renders the process incompatible with cells 
and in many cases biological signalling molecules.  As with SLS and 3DP the 
technique does allow the generation of complex macro-architectural features within 
the bulk scaffold. 
The use of FFF in tissue engineering was pioneered by Dietmar Hutmacher and 
colleagues200-205, who demonstrated the potential for PCL-based scaffolds produced 
by FFF to be used for bone tissue engineering.  The majority of scaffolds made by 
FFF for tissue engineering have continued to be made from PCL206-211 with calcium 
phosphate incorporation in some cases to act as a cue for increased proliferation of 
osteogenic cells200,206,211. 
  
 
  
Figure 1.5 ± Schematic depicting the principles of operation of a fused filament fabrication or bioplotting device.  These techniques involve the extrusion 
of polymer melts and hydrogels respectively.  In both cases, the material is extruded as a series of continuous filaments to form a single structure layer 
(1), and then relative motion of the deposition stage and the extrusion nozzle allows a second layer to be produced (2).  By repetition of these steps, a 
three-dimensional structure is built. 
Chapter 1 - General Introduction 
21 
 
Other synthetic polymers used include PLLA207, PEG derivatives212, poly(butylene 
tetrephthalate)213, poly(hydroxymethylglycolide-co-İ-caprolactone)209, polyurethane214 
and a PEG-PCL-poly(D,L-lactic acid) block copolymer215.  Minimum scaffold feature 
VL]HVDVVPDOODVǋPKDYHEHHQDFKLHYHG204, and compressive strengths as high 
as 3.1 MPa whilst maintaining 61% porosity201. 
FFF techniques have recently been combined with electrospinning to produce 
multilayer, multifunctional scaffolds216-218.  One study aimed to produce a hybrid 
scaffold for osteochondral defect repair by electrospinning collagen onto an FFF 
scaffold which was subsequently seeded with bone marrow stromal cells217.  While 
this does add a level of complexity to the bulk structure, patterning is limited to 
morphological features and cells cannot be placed at precise positions nor biological 
signalling agents incorporated. 
Although FFF has the potential to produce tissue engineering scaffolds which contain 
complex patterns of material properties, this use of the technique has not been 
explored in the literature.  Instead the focus has been on control of overall scaffold 
morphology and macropore structure to match defects and for optimisation of 
mechanical properties with retention of porosity respectively.  Such applications have 
been demonstrated both in vitro200,201,206,212,219 and in vivo202,210,212. 
1.2.6 Bioplotting 
Conceptually bioplotting is similar to FFF in that it involves the extrusion of scaffold 
materials as fibres or filaments to build three-dimensional structures in a layer-by-
layer fashion (Figure 1.5)220,221.  In contrast to FFF bioplotting is performed at 
temperatures which are suitable for the incorporation of cells and biological signalling 
molecules.  This has limited the choice of materials which have been utilised for 
construct fabrication to hydrogels and hydrogel precursors of both natural and 
synthetic origins222-224.  Due to this restriction in choice of material, truly functional 
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patterning is more likely to come via the incorporation of multiple cell types or 
multiple signalling molecules rather than the use of different materials. 
Many of the natural polymer hydrogels have the advantage of being inherently 
biocompatible and biofunctional.  However their relatively slow gelation kinetics can 
be challenging to accommodate in bioplotting approaches, since the deposited 
material must have sufficient solidity to prevent significant flow after deposition.  
Nonetheless, the use of these materials in bioplotting based scaffold fabrication is 
widespread, with alginate being the most common225-232.  Other materials utilised 
include: collagen233-236, gelatin237-240, fibrinogen238, chitosan239,240, MatrigelTM 226 and 
methylcellulose226.   
To overcome the problematic gelation kinetics of some of these biological hydrogels, 
recent studies from two groups of researchers have outlined modifications designed 
to induce rapid solidification after extrusion241-243.  One approach utilised deposition 
at low temperatures for bioplotting chitosan241, whilst the other sought to produce 
large collagen constructs by alternating deposition of a collagen solution with spray 
coating of nebulised sodium bicarbonate242,243.  The minimum extruded filament 
diameter achieved across the studies discussed so far, which defines the potential 
SDWWHUQLQJUHVROXWLRQLVDURXQGǋP244,245.  This is broadly comparable with those 
achieved via other 3D fabrication techniques244,245. 
Incorporation of cells in bioplotting processes has been widely demonstrated with the 
majority of studies assessing cell viability in vitro.  A wide variety of mammalian cell 
types have been used including liver225,235,237-240, cartilage230, heart229,232, bone235 and  
vascular cells236.  Where quantitative evaluation was performed the measured 
viabilities immediately after production were all greater than 80%.  Quantification of 
viability in post-fabrication culture is less commonly performed.  One study did show 
that hepatocytes which were 98% viable immediately post-plot maintained 93% 
YLDELOLW\ DIWHU RQHPRQWK¶V FXOWXUH237.  In a smaller number of cases the post-plot 
functionality of cells has also been demonstrated to be retained, as illustrated by 
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matrix synthesis230, protein secretion237 and expression of cell lineage markers232.  
The diversity of cell types used in these studies highlights the wide range of 
applications for which bioplotting may be applicable. 
The use of synthetic polymers for bioplotting applications in tissue engineering and 
modelling is far less widespread than the use of natural polymers.  A small number of 
recent studies have used Pluronic F-127236, peptide-modified PEG246, partially-
polymerised acrylamide247,248, poly(N-(2-hydroxypropyl)methacrylamide lactate-PEG-
PHPMAm-lactate)249 or methacrylated derivatives of gelatin and hyaluronic acid 
crosslinked with multi-arm PEG derivatives250-252.  The majority of these studies have 
demonstrated the inclusion of viable cells in the fabrication process236,246,249-251.  
Qualitative assessment has shown that in some cases these cells can maintain high 
levels of viability for several weeks250,251.  
The major advantage of using synthetic polymers is that they can be tailored for 
optimal flow behaviour and gelation kinetics.  They can also be rendered stimulus 
responsive to allow post-print induction of gelation, potentially enabling greater 
pattering resolution.  However these filaments are often not inherently biocompatible 
and may require chemical modification, by peptide conjugation for instance246. The 
filament diameters achieved are broadly the same as those of natural polymers 
except in the case of partially polymerised acrylamide which could be deposited as a 
ǋPILODPHQW247. 
In the studies discussed above the overall morphology of the scaffold could be 
accurately controlled, but there are only a few published studies in which bioplotted 
constructs have been patterned within the bulk shape.  Materials230,253, cell 
populations226,242,253 and/or proteins253 have been heterogeneously incorporated into 
constructs in distinct locations.  However in most cases the features produced were 
several millimetres or more in size.  One study was able to demonstrate patterning 
on a finer scale than this, incorporating two different fluorescent dyes into distinct 
UHJLRQV ZKLFK ZHUH DURXQG  ǋP LQ VL]H249.  This resolution is somewhat lower 
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than those associated with other patterning techniques such as STL.  Despite this 
limitation, the wide variety of cell types that can be used with bioplotting gives the 
technique considerable advantage over many other patterning methods. 
As with other patterning techniques discussed a key limitation is the current lack of 
assessment of pattern functionality.  Two recent publications have detailed the 
results of the in vivo assessment of very simply patterned two-phase scaffolds.  In 
the first study two-phase constructs were produced containing mesenchymal stem 
cells in an alginate hydrogel and endothelial progenitor cells within MatrigelTM 245.  
The second study generated constructs with mesenchymal stem cells and articular 
chondrocytes both contained in alginate244.  Histological staining showed distinct 
tissue formation and cell behaviour in the discrete phases of the scaffolds and these 
studies can be taken as the first successful demonstration of the capacity for 
functional construct patterning via bioplotting. 
The inherent compatibility of the bioplotting process with the incorporation of cells 
and biological signalling molecules potentially allows very complex construct 
patterning to be performed.  Cells, materials and biological signals can be 
independently patterned in three dimensions at the same time as controlling overall 
scaffold shape and morphology.  However the realisation of this potential and the 
conversion of these patterns into heterogeneous functionality has not yet been widely 
demonstrated. 
1.2.7 Bioprinting 
Bioprinting is a fundamentally different approach to the production of tissue 
engineering constructs which involves three-dimensional fabrication using scaffold-
free cell aggregates as a printing ink (Figure 1.6)254,255.  Higher level aggregation and 
self-assembly processes then drive the conversion of bioprinted constructs into 
continuous tissues254-257.  To produce uniformly sized aggregates for printing cells are 
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cultured in microcapillary tubes to allow them to form cell-cell junctions and deposit 
matrix.  Once they have acquired sufficient mechanical strength they are then 
removed from the tubes and sub-divided257.   
In the bioprinting approach to construct production the smallest structures which can 
be produced consist of a single aggregate, and the patterning resolution is thus 
defined by the aggregate size258.  Early studies using this technique deposited 500 
ǋPFHOODJJUHJDWHVLQWRVLPSOHJHRPHWULHVVXFKDVULQJVDQGVKRUWWXEHV259,260.  Later 
studies showed significantly increased pattern complexity, with scaffolds produced 
from multiple cell types and in more complex geometries designed, for instance, to 
replicate branching sections of vascular systems261.  More recently still, published 
results have shown an improvement iQ SDWWHUQ UHVROXWLRQV E\ WKH XVH RI  ǋP
aggregates as the printing ink258.  Ultimately this work has culminated in the launch 
of the NovoGen MMX BioprinterTM which is the first commercial rapid prototyping 
device to be specifically designed for biological fabrication262-264. 
In generating more complex construct morphologies, a combined 
bioprinting/bioplotting technique can be used to deposit both cell aggregates and 
size-matched hydrogels.  The hydrogels used in studies referred to above act as 
temporary support structures during fabrication, but are designed to degrade away 
once aggregates are sufficiently adhered to one another258,262,263. 
Since bioprinting is an approach which does not utilise biomaterials for construct 
fabrication, the potential complexity of patterning which can be performed is much 
reduced in comparison with other technologies.  However, in some respects the 
formation of a construct without materials simplifies its optimisation and removes 
some of the obstacles to its success in vivo.  There is no need to tailor the 
degradation rate of the construct to maximise host tissue ingrowth, since this will be 
managed by the natural processes of extracellular matrix remodelling, and any 
potential side effects from the presence of synthetic materials are 
removed254,255,261,265. 
  
 
  
Figure 1.6 ± Schematic depicting the principles of a bioprinting process.  First cells are cultured at high density in capillary tubes to allow for the 
production of extracellular matrix and the formation of coherent structures.  These cultures are then expelled, subdivided and briefly incubated to allow 
them to round up and form spheroid aggregates (1).  These aggregates are then individually positioned layer-by-layer to form neo-tissue constructs (2). 
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1.3 Current and Future Directions 
The more accurate replication of tissue architectures is undoubtedly an important 
consideration for future tissue engineering applications.  MM and OT systems have 
great potential in the formation of in vitro tissue models for the reproduction and 
study of niche micro-architectural characteristics.  Practical considerations limit their 
current application to macro-scale construct production but they could potentially be 
combined with macro-scale techniques in future applications. 
The remaining patterning technologies considered have the potential to replicate 
macro-scale tissue features.  Techniques such as STL, MPL and bioplotting are able 
to incorporate cellular and biological signal components to produce complex tissue 
engineering constructs.  This gives them significant advantages over other techniques 
such as SLS, FFF and 3DP that are often limited to morphological patterning of 
scaffold materials.  The maximum patterning resolution in bioplotting-based 
approaches is typically coarser than that achievable with STL and MPL, but the 
heterogeneous incorporation of cells and biological signal molecules is more easily 
achieved with this than with any of the other techniques discussed.   
A key challenge for the field is ensuring that patterned constructs are stable in 
longer-term in vitro culture, in order that they can be used to model tissues and the 
progression of disease and repair.  It will also become important in the future to 
assess pattern maintenance after in vivo implantation, in order that the constructs 
can be deemed suitable clinical therapies.  Additionally more exhaustive and longer-
term studies will be needed to assess post-production cell viability and demonstrate 
that patterns generated in tissue engineering constructs ultimately lead to the 
formation of heterogeneous tissues. 
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1.4 Thesis Aims 
The overall aim of the work contained within this thesis is to explore and extend the 
potential of three-dimensional patterning techniques for the fabrication and 
modification of biological constructs for tissue engineering and modelling.  More 
specifics aims are as follows: 
x To develop synthetic polymer microsphere formulations for temporally-
controlled release of growth factors. 
x To produce extracellular matrix-derived biomaterials which can be used in 
bulk construct fabrication or as alternative microsphere formulations for 
controlled growth factor presentation. 
x To evaluate the use of microinjection and micromanipulation techniques for 
the precise patterning of growth factor-releasing microspheres in in vitro 
culture environments to create functional signal gradients. 
x To evaluate the use of a bioplotting platform for the production of tissue 
engineering constructs composed of novel scaffold materials. 
x To evaluate the same platform for the production of constructs containing 
three-dimensional patterns of cell populations, materials and/or growth 
factor-releasing microspheres. 
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2. Materials & Methods 
2.1 General Consumables & Reagents 
Agar ± catalogue number BP1423-500, Fisher Scientific (Loughborough, UK) 
Agarose ± catalogue number A2576, Sigma-Aldrich (Poole, UK) 
Alginic Acid Sodium Salt (Sodium Alginate) ± catalogue number 177775000, Acros 
Organics (Geel, Belgium) or Protanal® LF10/60, FMC BioPolymer (Philadelphia, PA, 
USA) 
Alpha Minimum Essential Medium (ĮMEM) ± catalogue number A10490-01, Life 
Technologies (Carlsbad, CA, USA) 
Antibiotic/Antimycotic (AB/AM) ± catalogue number 30-004-CI, Mediatech (Manassas, 
VA, USA) 
Bone Morphogenetic Protein-2 (BMP-2) ± recombinant human BMP-2 was purchased 
from Prof. Walter Sebald (University of Wurzburg, Germany) 
Calcium Sulphate ± catalogue number 237132, Sigma-Aldrich (Poole, UK) or 
catalogue number 40144, Alfa Aesar (Karlsruhe, Germany) 
Carboxymethyl Cellulose (CMC) ± catalogue number 12M8P (medium viscosity) or 
12M31P (high viscosity), Ashland Speciality Ingredients (Poole, UK) 
Collagen ± rat tail collagen type I, catalogue number 354249, BD Biosciences 
(Oxford, UK) 
Collagenase Type 2 ± catalogue number LS004177, Worthington Biochemical 
Corporation (Lakewood, NJ, USA) 
D,L-lactide ± catalogue number L09026, Alfa Aesar (Karlsruhe, Germany)
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'XOEHFFR¶V 0RGLILHG (DJOH 0HGLXP '0(0 ± catalogue number 10-017-CV, 
Mediatech (Manassas, VA, USA) or catalogue number 42430-025, Life Technologies 
(Paisley, UK) 
(DJOH¶V 0LQLPXP (VVHQWLDO 0HGLXP (0(0 ± catalogue number M2279, Sigma-
Aldrich (Poole, UK) 
Foetal Bovine Serum (FBS) ± catalogue number 900-108, Gemini Bio-Products (West 
Sacramento, CA, USA) or catalogue number F9665, Sigma-Aldrich (Poole, UK) 
Ethylenediaminetetraacetic acid (EDTA) ± catalogue number ED2SS, Sigma-Aldrich 
(Poole, UK) 
Gelatin ± porcine type A, catalogue number G1890, Sigma-Aldrich (Poole, UK) 
Glycolide ± Purasorb G, Purac (Gorinchem, The Netherlands) 
Human Serum Albumin (HSA) ± catalogue number A9511, Sigma-Aldrich (Poole, UK) 
Hydroxyproline ± catalogue number H1637, Sigma-Aldrich (Poole, UK) 
L-Glutamine ± catalogue number G7513, Sigma-Aldrich (Poole, UK) 
Live/Dead Viability/Cytotoxicity Kit ± catalogue number L-3224, Life Technologies 
(Paisley, UK) 
MEM Non-Essential Amino Acid Solution ± catalogue number M7145, Sigma-Aldrich 
(Poole, UK) 
Micro BCA Protein Assay Kit ± catalogue number 23235, Fisher Scientific 
(Loughborough, UK) 
Penicillin/Streptomycin (Pen/Strep) ± catalogue number 15070-063, Life Technologies 
(Paisley, UK) 
Pepsin ± catalogue number P7012, Sigma-Aldrich (Poole, UK) 
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Phenol/Chloroform/Isoamyl Alcohol ± catalogue number 77617, Sigma-Aldrich (Poole, 
UK) 
Pluronic® F-127 ± catalogue number P2443, Sigma-Aldrich (Poole, UK) 
Poly(ethylene glycol) (PEG) ± Polyglykol 400, Clariant (Leeds, UK) or catalogue 
number 81210, Sigma-Aldrich (Poole, UK) 
Poly(lactic-co-glycolic acid) (PLGA) ± various products sourced from Evonik 
Biomaterials (Birmingham, AL, USA) 
PrestoBlue® Cell Viability Reagent ± catalogue number A-13262, Life Technologies 
(Paisley, UK) 
Quant-iTTM PicoGreen® dsDNA Assay Kit ± catalogue number P11496, Life 
Technologies (Paisley, UK) 
Trypan Blue ± catalogue number SV3008401, Fisher Scientific (Loughborough, UK) 
Trypsin ± catalogue number T4549, Sigma-Aldrich (Poole, UK) 
Trypsin/EDTA ± catalogue number 25-053-CI, Mediatech (Manassas, VA, USA) or 
mixture of Sigma-Aldrich trypsin and EDTA products to final concentrations of 0.25% 
(w/v) trypsin and 0.02% (w/v) EDTA 
Unless otherwise specified all other reagents are of analytical reagent grade or higher 
and purchased from Sigma-Aldrich (Poole, UK). 
2.2 General Cell Culture 
2.2.1 Murine Primary Calvarial (mPC) Cells 
mPC cells were a kind gift of Laura Sidney and Adam Taylor (University of 
Nottingham).  Cells were isolated from the calvariae of 1 to 3 day-old neonatal CD1 
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mice by sequential enzymatic digestion.  Briefly ± serial digestions were performed 
using collagenase type IA (1.4 mg mL-1) and trypsin II S (0.5 mg mL-1) and cells 
released during the first two digestions were discarded.  Cells released during the 
subsequent three digestions were combined and seeded on tissue culture treated 
polystyrene at 6,600 cells cm-2. 
P3&FHOOVZHUHFXOWXUHGLQĮ0(0VXSSOHPHQWHGZLWKYY)%66LJPD-Aldrich), 
1% (v/v) L-glutamine and 1%(v/v) pen/strep.  Cultures were maintained at 37oC and 
5% (v/v) CO2 as monolayers on tissue culture treated polystyrene.  At 80% 
confluency, cells were passaged by trypsinisation and reseeded at between 1/3rd and 
1/6th of this density.  Passage procedure for a T75 flask was as follows (with all 
volumes scaled accordingly for smaller culture vessels) ± culture medium was 
aspirated from the flask and the cell monolayer washed with 10 mL phosphate-
buffered saline (PBS).  After aspiration of the PBS, 3 mL of trypsin/EDTA (Sigma-
Aldrich) was added to the flask, which was incubated at 37oC until all cells had 
detached, resulting in a single cell suspension.  The trypsin was deactivated by the 
addition of 7 mL of culture medium and the resulting suspension was centrifuged at 
200 g for 5 minutes.  The supernatant was aspirated and the cell pellet resuspended 
in fresh culture medium for seeding into the desired culture vessel(s). 
2.2.2 Human Osteosarcoma Cell Line 
HOS cells (catalogue number ATCC-CRL-1543, LGC Standards, Teddington, UK) were 
cultured in DMEM (Life Technologies) supplemented with 10% (v/v) FBS (Sigma-
Aldrich), 1% (v/v) L-glutamine, 1%(v/v) pen/strep and 1% (v/v) non-essential amino 
acids.  Cultures were maintained at 37oC and 5% (v/v) CO2 as monolayers on tissue 
culture treated polystyrene.  At 80% confluency, cells were passaged by 
trypsinisation and reseeded at between 1/5th and 1/8th of this density.  Passage 
procedure for a T175 flask was as follows (with all volumes scaled accordingly for 
smaller culture vessels) ± culture medium was aspirated from the flask and the cell 
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monolayer washed with 20 mL PBS.  After aspiration of the PBS, 6 mL of 
trypsin/EDTA (Sigma-Aldrich) was added to the flask, which was incubated at 37oC 
until all cells had detached, resulting in a single cell suspension.  The trypsin was 
deactivated by the addition of 9 mL of culture medium and the resulting suspension 
was centrifuged at 220 g for 5 minutes.  The supernatant was aspirated and the cell 
pellet resuspended in fresh culture medium for seeding into the desired culture 
vessel(s). 
2.2.3 Immortalised Human Mesenchymal Stem Cells 
Immortalised human mesenchymal stem cells (ihMSCs) were kindly donated by Dr. 
Hassan Rashidi and Dr. James Dixon (University of Nottingham).  Primary hMSCs 
(bone marrow-derived, catalogue number SC-7500, TCS Cellworks, Buckingham, UK) 
were immortalised using a previously published protocol266.  This involved retrovirus-
mediated transduction of the cells with human telomerase reverse transcriptase and 
the human papillomavirus E6 and E7 genes.  The effect is to activate telomerase and 
inactivate the Rb/p16 pathway, circumventing the senescence normally seen in 
hMSCs after only a relatively short time in culture.  Histological staining showed the 
ihMSCs had retained their ability to differentiate down the osteogenic, chondrogenic 
and adipogenic lineages in response to the appropriate chemical cues (data not 
shown). 
ihMSCs were cultured in DMEM (Life Technologies) supplemented with 10% (v/v) 
FBS (Sigma-Aldrich), 1% (v/v) L-glutamine, 1%(v/v) pen/strep and 1% (v/v) non-
essential amino acids.  Cultures were maintained at 37oC and 5% (v/v) CO2 as 
monolayers on tissue culture treated polystyrene.  At 80% confluency, cells were 
passaged by trypsinisation and reseeded at between 1/5th and 1/8th of this density.  
Passage procedure for a T175 flask was as follows (with all volumes scaled 
accordingly for smaller culture vessels) ± culture medium was aspirated from the 
flask and the cell monolayer washed with 20 mL PBS.  After aspiration of the PBS, 6 
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mL of trypsin/EDTA (Sigma-Aldrich) was added to the flask, which was incubated at 
37oC until all cells had detached, resulting in a single cell suspension.  The trypsin 
was deactivated by the addition of 9 mL of culture medium and the resulting 
suspension was centrifuged at 220 g for 5 minutes.  The supernatant was aspirated 
and the cell pellet resuspended in fresh culture medium for seeding into the desired 
culture vessel(s). 
2.2.4 MC3T3-E1 Murine Pre-Osteoblast Cell Line 
MC3T3-E1 cells (a kind gift from Dr. Claudia Fischbach-Teschl, Cornell University) 
ZHUHFXOWXUHGLQĮ0(0VXSSOHPHQWHGZLWKYY)%6*HPLQL%LR-Products), 1% 
(v/v) L-glutamine and 1%(v/v) AB/AM.  Cultures were maintained at 37oC and 5% 
(v/v) CO2 as monolayers on tissue culture treated polystyrene.  At 80% confluency, 
cells were passaged by trypsinisation and reseeded at between 1/3rd and 1/6th of this 
density.  Passage procedure for a T150 flask was as follows (with all volumes scaled 
accordingly for smaller culture vessels) ± culture medium was aspirated from the 
flask and the cell monolayer washed with 20 mL PBS.  After aspiration of the PBS, 5 
mL of trypsin/EDTA (Mediatech) was added to the flask, which was incubated at 37oC 
until all cells had detached, resulting in a single cell suspension.  The trypsin was 
deactivated by the addition of 10 mL of culture medium and the resulting suspension 
was centrifuged at 200 g for 5 minutes.  The supernatant was aspirated and the cell 
pellet resuspended in fresh culture medium for seeding into the desired culture 
vessel(s). 
2.2.5 Bovine Primary Articular Chondrocytes 
The articular cartilage surfaces were removed from the femero-patellar groove of one 
to three day-old animals using a scalpel and placed into PBS (60 mL per joint) 
supplemented with 2% (v/v) AB/AM.  After one hour the PBS was replaced and the 
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cartilage left for a further hour, after which a scalpel was used to dissect the tissue 
down to pieces of no more than 2 mm in any dimension.  The pieces were then 
soaked in fresh supplemented PBS for one more hour before being transferred to 
DMEM (Mediatech) supplemented with 2% (v/v) AB/AM and 0.2% (v/v) collagenase 
type 2 (150 mL per joint).  The suspension was incubated for 24 hours, stirred, at 
37oC, 5% CO2.  7KHUHVXOWLQJVROXWLRQZDVSDVVHGWKURXJKDǋPFHOOVWUDLQHUDQG
centrifuged at 500 g for 3 minutes, followed by resuspension in 50 mL supplemented 
PBS.  Centrifugation and resuspension steps were repeated twice, replacing the PBS 
in the second iteration with DMEM supplemented with 2% (v/v) AB/AM and 10% 
(v/v) FBS (Gemini Bio-Products).  Cells were counted and then transferred to T150 
culture flasks, at 10 million cells per flask for use within 24 ± 48 hours, or as few as 1 
million cells per flask for longer term culture.  Medium was completely refreshed 
three times per week but cells were not passaged prior to use. 
2.2.6 NIH 3T3 Murine Fibroblast Cell Line 
3T3s (catalogue number ATCC-CRL-1658, LGC Standards, Teddington, UK) were 
cultured in DMEM (Life Technologies) supplemented with 10% (v/v) FBS (Sigma-
Aldrich), 1% (v/v) L-glutamine and 1%(v/v) pen/strep.  Cultures were maintained at 
37oC and 5% (v/v) CO2 as monolayers on tissue culture treated polystyrene.  At 80 - 
90% confluency, cells were passaged by trypsinisation and reseeded at between 1/8th 
and 1/10th of this density.  Passage procedure for a T175 flask was as follows (with 
all volumes scaled accordingly for smaller culture vessels) ± culture medium was 
aspirated from the flask and the cell monolayer washed with 20 mL PBS.  After 
aspiration of the PBS, 6 mL of trypsin/EDTA (Sigma-Aldrich) was added to the flask, 
which was incubated at 37oC until all cells had detached, resulting in a single cell 
suspension.  The trypsin was deactivated by the addition of 9 mL of culture medium 
and the resulting suspension was centrifuged at 200 g for 5 minutes.  The 
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supernatant was aspirated and the cell pellet resuspended in fresh culture medium 
for seeding into the desired culture vessel(s). 
2.2.7 C2C12 Murine Myoblast Cell Line 
C2C12s (catalogue number ATCC-CRL-1772, LGC Standards, Teddington, UK) were 
cultured in DMEM (Life Technologies) supplemented with 10% (v/v) FBS (Sigma-
Aldrich), 1% (v/v) L-glutamine and 1%(v/v) pen/strep.  Cultures were maintained at 
37oC and 5% (v/v) CO2 as monolayers on tissue culture treated polystyrene.  At 80% 
confluency, cells were passaged by trypsinisation and reseeded at 1/5th of this 
density.  Passage procedure for a T175 flask was as follows (with all volumes scaled 
accordingly for smaller culture vessels) ± culture medium was aspirated from the 
flask and the cell monolayer washed with 20 mL PBS.  After aspiration of the PBS, 6 
mL of trypsin/EDTA (Sigma-Aldrich) was added to the flask, which was incubated at 
37oC until all cells had detached, resulting in a single cell suspension.  The trypsin 
was deactivated by the addition of 9 mL of culture medium and the resulting 
suspension was centrifuged at 200 g for 5 minutes.  The supernatant was aspirated 
and the cell pellet resuspended in fresh culture medium for seeding into the desired 
culture vessel(s). 
2.2.8 Cryopreservation of Cells 
In order to retain cells for later use and prevent the need for unnecessarily extended 
culture and the associated risk of phenotypic changes they were stored in the vapour 
phase of liquid nitrogen.  The cryopreservation medium used for this was foetal 
bovine serum (as appropriate to each cell type) supplemented with 10% (v/v) 
dimethyl sulphoxide (DMSO) as a cryoprotectant.  To prepare cells for 
cryopreservation they were trypsinised as for normal passage, centrifuged as 
appropriate to the cell type and resuspended in cryopreservation medium.  A single 
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T75 flask was suspended in 1 to 2 mL of medium and a single T150 or T175 in 2 to 3 
mL.  These cell suspensions in cryopreservation medium were transferred into a 
1DOJHQHµ0U)URVW\¶)LVKHU6FLHQWLILF/RXJKERURXJK8.ILOOHGZLWKLVRSURSDQRODQG
placed in a -80oC freezer for 48 hours.  This step was designed to produce a cooling 
rate of approximately 1oC min-1.  After this they were transferred to the vapour phase 
of liquid nitrogen for long-term storage. 
To retrieve cells from liquid nitrogen for further culture cryovials containing frozen 
cell suspension were first thawed by placing them into a water bath set to 37oC.  
These suspensions of cells in cryopreservation were then diluted by a factor of ten 
using pre-warmed complete culture medium and centrifuged as appropriate to the 
cell type.  Finally the cell pellets were resuspended in pre-warmed complete culture 
medium and seeded into appropriate culture vessels. 
2.2.9 Trypan Blue Counting & Viability Assessment 
Trypan blue is a coloured dye which cannot cross the intact membrane of a viable 
cell.  It can, however, cross the compromised membrane of a dead cell, and can 
therefore be used to quantitatively assess cell viability.  For pre-bioplotting cell 
counting and viability assessment 100 ǋL of cell suspension was mixed with 100 ǋL of 
trypan blue.  10 ǋL of this mixture was then added to the counting chamber of an 
improved Neubauer haemocytometer and five cell counts performed, each covering 
one of the nine major square divisions of the chamber.  These counts were then 
averaged and converted to cell numbers per mL by multiplication by a factor of 2 x 
104. 
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2.3 PLGA-PEG-PLGA Triblock Copolymer Synthesis & Characterisation 
2.3.1 Polymer Synthesis 
PLGA-PEG-PLGA triblock copolymer was a kind gift of Giles Kirby (University of 
Nottingham)267.  The PEG content of this copolymer means that its addition to PLGA-
based microspheres increases the hydrophilicity of the microspheres.  The additional 
water ingress into the microspheres that this encourages leads to acceleration of the 
release of protein encapsulated within them.  This effect is both because the 
additional water content encourages swelling of the polymer matrix and thus greater 
protein diffusion through it and also because it accelerates degradation of the 
polymer through ester hydrolysis. 
To prepare the polymer 5.5575 g PEG (Sigma-Aldrich) was heated to 120oC under 
vacuum to achieve melting of the polymer.  Under a nitrogen atmosphere the 
temperature was further raised to 150oC and 7.5 g D,L-lactide and 2.5 g glycolide 
added.  After 30 minutes of the reaction, 0.075 g of stannous octoate was added and 
the reaction maintained for a further 8 hours.  After completion of the reaction and 
cooling of the vessel back to room temperature, the product and remaining 
monomers were dissolved in cold water (4oC).  Heating to 80oC precipitated the 
polymer whilst leaving unreacted monomers in solution.  The supernatant was 
decanted and the process repeated a second time.  Following this the solid product 
was snap frozen and lyophilised for 48 hours before being stored at -20oC until 
further use. 
2.3.2 Gel Permeation Chromotography 
Gel permeation chromatography measurements of the synthesised triblock copolymer 
using a PL-GPC 120 (Polymer Labs) indicated a molecular weight of 4590 Da and a 
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polydispersity index of 1.60 (analysis performed by Natasha Birkin (University of 
Nottingham). 
2.3.3 Nuclear Magnetic Resonance 
Nuclear magnetic resonance analysis of the triblock copolymer was performed by 
Natasha Birkin (University of Nottingham) using a DPX-300 instrument (Bruker, 
Coventry, UK).  The solvent was deuterated chloroform and measurements at 300 
MHz confirmed the purity and composition of the product. 
2.4 PLGA-Based Microsphere Fabrication 
For the purposes of this thesis, microparticles prepared via emulsion-based 
techniques will be referred to as microspheres.  These techniques typically produce 
microparticles which are broadly spherical in nature, but it is not claimed that they 
are perfect spheres.  To fabricate microspheres an oil phase comprising a solution of 
synthetic polymer in volatile organic solvent is emulsified in an aqueous phase.  This 
aqueous phase contains an emulsifier which acts to stabilise the interfaces between 
the two phases and prevent oil droplets from coalescing.  To minimise interfacial 
energy spherical oil droplets are formed, and subsequent evaporation of the organic 
solvent leads to the formation of solid polymer microspheres.  Encapsulation of drugs 
and proteins into these microspheres can be by dispersion of a solid in the oil phase 
(solid-in-oil-in-water single emulsion), by co-dissolution in the oil phase (oil-in-water 
single emulsion) or by dissolution in an aqueous phase which is emulsified within the 
oil phase (water-in-oil-in-water double emulsion). 
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2.4.1 Single Emulsion Technique 
PLGA (lactide-to-glycolide ratio 85:15 or 50:50, molecular weight 53 kDa or 59 kDa 
respectively) was dissolved in dichloromethane (DCM) (Fisher Scientific, 
Loughborough, UK) at 2% (w/v) with a total polymer mass of 1 g.  This solution was 
then added to an aqueous solution of 0.3% (w/v) poly(vinyl alcohol) (PVA) 
(catalogue number 363170, Sigma-Aldrich, Poole, UK), with a volume of 500 mL in a 
600 mL beaker.  The mixture was then emulsified using a high-speed homogeniser at 
the desired speed (Silverson L5M, Silverson Machines Ltd., Chesham, UK at 9,000 
rpm, or Ultra Turrax T25 Basic, IKA Werke GmbH, Staufen, Germany in the range 
11,000 ± 24,000 rpm).  Homogenisation was for two minutes, and the resulting 
emulsion was stirred for 24 hours at 300 rpm, to allow for complete DCM evaporation 
and hardening of the microspheres.  The resulting microsphere suspension was 
SDVVHGWKURXJKDǋPFHOOXORVHDFHWDWHILOWHU)LVKHU6FLHQWLILF/RXJKERURXJK8.
under vacuum and washed with 1 L of deionised water (dH2O).  Small amounts of 
dH2O ejected from a disposable Pasteur pipette were used to wash the microspheres 
off the filter and into suspension.  The suspension was then transferred into a 
suitable container, plunge frozen in liquid nitrogen and freeze dried for at least 48 
hours (Free Drier Modulyo, IMA Edwards, Alcester, UK or ModulyoD, Thermo Fisher 
Scientific, Waltham, MA, USA). 
For the production of fluorescent microspheres via single emulsion, fluorescein (Acros 
Organics, Geel, Belgium) was co-dissolved with PLGA in DCM prior to 
homogenisation.  A number of different concentrations were used, in the range 0.1 ± 
20% (w/w) relative to PLGA. 
2.4.2 Double Emulsion Technique 
PLGA was dissolved in DCM at the desired concentration.  In some cases a portion of 
the PLGA was replaced with PLGA-PEG-PLGA triblock but the total polymer mass was 
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always maintained at 1 g.  A small amount of water (2% (v/v) relative to the organic 
phase) was added to the polymer solution and this combination was homogenised for 
two minutes to form a primary emulsion using a Silverson L5M homogeniser 
(Silverson Machines Ltd., Chesham, UK, speed in the range 2,000 ± 9,000 rpm).  For 
polymer concentrations of 5% (w/v) and below the primary emulsification step was 
carried out in a 100 mL beaker, and for higher concentrations it was carried out in a 
25 mL beaker.  The primary emulsion was then added to an aqueous solution of 
0.3% (w/v) PVA and this mixture homogenised to form a secondary emulsion.  For 
polymer concentrations of 5% (w/v) and below the secondary emulsification was 
carried out in a 600 mL beaker using 500 mL of PVA and for higher concentrations 
the process utilised 200 mL of PVA and a 250 mL beaker.  The secondary emulsion 
was stirred for 24 hours, filtered and freeze dried, as described above for 
microspheres produced by single emulsion. 
Fluorophores and proteins could be incorporated into microspheres by dissolving 
them in the water which was added to the organic polymer solution to form the 
primary emulsion. 
2.4.3 Refined Double Emulsion Technique 
The refined double emulsion technique differed from the standard technique in the 
vessels used for the primary emulsification step.  This protocol step was carried out 
in 30 mL poly(tetrafluoroethylene) (PTFE) beakers (catalogue number 216-0165, 
VWR International, Lutterworth, UK).  The refined technique also utilised a shortened 
stirring time for microsphere hardening of only 4 hours. 
2.5 Microsphere Size Distribution Analysis via Laser Diffraction 
Laser diffraction-based size analysis works by laser illuminating a suspension of 
objects in order to generate a pattern of diffracted light which is detected under 
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conditions where the Fraunhofer diffraction equation applies.  This allows the 
intensity of light at various angles from the straight-through beam to be related to 
the size of the objects causing the diffraction. 
The size distributions of microspheres produced using the emulsion techniques 
described above were measured using a laser diffraction particle sizing instrument 
(Coulter LS230, Beckman Coulter (UK) Ltd., High Wycombe, UK).  The micro volume 
sample module was loaded with 18 mL of dH2O for background and calibration 
measurements.  Following this, 1 mL was removed and a suspension of the 
PLFURVSKHUHVWREHVL]HGDGGHGǋ/DWDWLPHXQWLOWKHRSWLPDOREVcuration for the 
PDFKLQH¶VRSHUDWLRQZDVUHDFKHG7KHPRGXOHZDVWKHQWRSSHGXSWRP/RQFH
again, and readings taken over 120 s. 
2.6 Scanning Electron Microscopy 
In scanning electron microscopy (SEM) the sample to be imaged is bombarded by an 
electron beam, leading to the emission of secondary electrons by inelastic scattering 
from the sample surface.  The relative intensity of emission of secondary electrons 
from different points on the sample surface then gives height information, and the 
topography of the surface can be deduced.  In order to prevent charge build-up, 
which causes imaging artefacts, sample surfaces must be rendered conductive prior 
to imaging.  This is achieved by sputter coating a very fine layer of metal (typically 
gold or platinum) onto samples.  Furthermore, since the imaging process is  
conducted under vacuum, samples must be completely dry, necessitating the use of 
a dehydration protocol for many biological samples.  Since air drying, which involves 
the boiling of liquids, can cause damage to samples, drying is usually achieved via 
gradual replacement of water with ethanol in chemically-fixed samples.  To remove 
the ethanol, samples are subjected to critical point drying, which replaces the ethanol 
with supercritical carbon dioxide in which there is no distinction between gas and 
liquid and thus no chance of boiling. 
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To prepare for SEM samples were either gold coated (SC030, Balzers, Liechtenstein 
or EM SCD005, Leica Microsystems (UK) Ltd, Milton Keynes, UK) or platinum coated 
(Polaron SC7640, Quorum Technologies, East Grinford, UK).  SEM was then 
performed using a JSM 6060LV (JEOL, Welwyn Garden City, UK) or an XL30 (Philips 
5HVHDUFK&DPEULGJH8.DQGWKHDVVRFLDWHGPDQXIDFWXUHU¶VVRIWZDUH,PDJHVZHUH
taken at a minimum of three different magnifications and in three different quadrants 
of each sample where possible. 
Prior to sputter coating, hydrogel samples were fixed for one hour in 3% (w/v) 
glutaraldehyde in PBS, washed twice in PBS and then dehydrated by soaking in 
increasing concentrations of ethanol.  Two 15 minute soaks were performed at each 
of the following concentrations ± 0, 30, 50, 70, 90 and 100% (v/v) and samples were 
then stored in 100% ethanol until they were dried in a Samdri® PVT-3 critical point 
dryer (tousimis, Rockville, MD, USA) and platinum coated.  
2.7 Measurement of Protein Release Rate from Microspheres 
In alkaline environments Cu2+ ions which are chelated with peptides or proteins can 
be reduced to Cu+ 268.  The subsequent chelation of these Cu+ ions with bicinchoninic 
acid (BCA) will then form a purple-coloured product which has an absorbance at 562 
nm which is proportional to the protein concentration. 
This reaction is utilised in the Micro BCA Protein Assay Kit, which was used to 
quantify the protein content of release medium in which protein-loaded microspheres 
KDGEHHQ LQFXEDWHG $VSHUPDQXIDFWXUHU¶V LQVWUXFWLRQV ǋL of each sample or 
standard was mixed in a 96-well plate well in triplicate with 100 ǋL of complete 
working reagent.  After 2 hours incubation at 37oC, the absorbance of the mixture in 
each well was measured at 562 nm. 
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2.8 Borosilicate Glass Needle Manufacture 
A P-97 Flaming/Brown micropipette puller (Sutter Instrument Company, Novato, CA, 
USA) was used to produce closed-tip needles from borosilicate glass capillaries (1 
mm outer diameter, 0.58 mm inner diameter, catalogue number 640766, Harvard 
Apparatus, Edenbridge, UK).  The closed, drawn ends of these capillaries were then 
broken by hand and those with relatively smooth ends were used for semi-automated 
MM-based microsphere patterning. 
2.9 Microinjection and Micromanipulation of PLGA Microspheres 
2.9.1 Manual Microinjection/Micromanipulation System 
A manual micromanipulator (catalogue number M3301R, World Precision 
Instruments, Hitchin, UK) was used to position the manual delivery of injection 
volumes of 0.1 ǋL or more of microsphere suspension (see Figure 2.1).  These were 
delivered either into dH2O for microsphere counting or into 0.75% (w/v) agar 
hydrogels for assessment of positional accuracy and patterning capability.  Delivery 
was either via 701 RN syringes (catalogue number 7635-01, Hamilton Bonaduz AG, 
Bonaduz, Switzerland) fitted with needles of various gauges (point style 3, Hamilton 
Bonaduz AG, Bonaduz, Switzerland) or via plunger-in-needle syringes (catalogue 
numbers 00570 and 00802, SGE Europe, Milton Keynes, UK).  
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Figure 2.1 ± Manual microinjection/micromanipulation system consisting of a 
microlitre syringe attached to a manual micromanipulator.  Maximum positional 
accuracy of the micromanipulator is ±50 ǋm in the two horizontal dimensions and 
ǋPLQWKHYHUWLFDOGLUHFWLRQ 
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2.9.2 Semi-Automated Microinjection/Micromanipulation System 
A CellTram vario manual microinjector (catalogue number 5176 000.033, Eppendorf 
UK, Stevenage, UK) was used in conjunction with a TransferMan NK 2 semi-
automated programmable micromanipulator (catalogue number 5188 000.012, 
Eppendorf UK, Stevenage, UK) to deliver microsphere individually or in small numbers 
(see Figure 2.2).  Delivery was into 1% (w/v) agarose solutions as they cooled from 
80oC to room temperature and formed gels.  A second micromanipulator was used to 
make small adjustments to the positions of microspheres which were disturbed by 
fluid movements during cooling and manipulation. 
 
  
 
 
  
Figure 2.2 ± Semi-automated microinjection/micromanipulation system comprising a pair of programmable micromanipulators and a manual 
microinjector.  The system is mounted on an inverted microscope to allow real-time visualisation of cells and microspheres during positioning. 
Programmable 
Micromanipulator 
Manual 
Microinjector 
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2.10 PLGA Microsphere Counting 
2.10.1 Counting Using a Haemocytometer 
Microsphere suspension ejected from Hamilton syringes was diluted with dH2O 
according to the following formula: 
Final Volume = 2 mL x (Ejected Volume/ ǋ/) x (Suspension Density/ 25% (w/v)) 
Each resulting, lower density suspension was loaded into both counting chambers of 
an improved Neubauer haemocytometer (10 ǋ/ in each chamber).  Two microsphere 
counts were then performed on the central 5x5 square of each chamber (see Figure 
2.3) in order to determine the microsphere density in the suspension, and thus the 
total microsphere number ejected. 
2.10.2 Counting via Light Blocking 
When particles are flowed in sufficiently dilute suspension that they pass individually 
through a region of uniform laser illumination they will block and/or scatter light 
depending on their size.  The length of blocking and extent of scattering can be used 
to derive particle size distributions and the number of such events gives particle 
counts. 
An AccuSizer 780 AD instrument (Particle Sizing Systems Europe, Dordrecht, The 
Netherlands) was used to count microspheres in ejected suspension volumes (see 
Section 2.9.1).  Samples were added to the sample chamber and the chamber then 
drained through the detector until all liquid was gone.  Microsphere counts were 
derived from blocking events only, to eliminate the effects of noise from very fine 
contaminants. 
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Count 1 
Count 2 
 
Counts converted to microsphere numbers per mL by multiplication by a factor of 
5x104 
 
Figure 2.3 ± Schematic showing counting procedure performed on microspheres 
using improved Neubauer haemocytometer. 
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2.11 Demineralisation of Bovine Bone 
Fresh bovine tibias were harvested from 12 ± 24 month-old animals which were 
slaughtered by an EU certified butcher (J Broomhall Ltd., Gloucestershire, UK).  
Cancellous bone segments were cleaned of residual soft tissue and washed for one 
hour at 37oC with PBS containing 0.1% (w/v) gentamicin (catalogue number 15750, 
Life Technologies, Paisley, UK).  The bone fragments were then washed with dH2O 
(five times the gentamicin solution volume) and finally dried under vacuum filtration 
ILOWHUSDSHUZLWKǋPSRUHV7KHSLHFHVZHUHWKHQEULHIO\ LPmersed in liquid N2, 
before being wrapped in protective cotton sheet and broken up with a hammer until 
they were no more than 4 mm in any dimension.  The resulting fragments were 
rinsed in a large volume of dH2O to remove debris and dried with absorbent material.  
A Krups F203 mill was used to grind the pieces to a powder after they had been 
cooled again in liquid N2. 
The powdered bone was placed into a 0.5 M hydrochloric acid solution (25 mL per g 
of bone) and stirred at 300 rpm for up to 24 hours at room temperature to remove 
mineral from the matrix.  The HCl was removed, the powder washed in dH2O (five 
times the HCl volume) and then dried, all under vacuum filtration.  The dried, 
demineralised powder was transferred into a 1:1 mix of chloroform and methanol (30 
mL per g of powder, Fisher Scientific, Loughborough, UK) and incubated for 1 hour at 
room temperature to remove remaining lipids.  Under vacuum filtration, the liquid 
was removed, and the powder washed in methanol (60 mL per g of demineralised 
bone powder) and PBS (150 mL per g of demineralised bone powder), before being 
dried.  The resulting demineralised bone matrix (DBM) was lyophilised for 48 hours 
and stored at -20oC until further use. 
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2.12 Decellularisation of Demineralised Bone Matrix 
Demineralised bone powder was stirred for 24 hours at 37oC in a 0.05% (w/v)/0.02% 
(w/v) trypsin/EDTA solution (Sigma-Aldrich) (enough to completely cover the 
powder) to cleave cell-matrix protein linkages.  Under vacuum filtration, the liquid 
was removed, the powder washed in a volume of PBS equal to the volume of 
trypsin/EDTA solution and then placed in an equal volume of fresh PBS.  The 
suspension was stirred at room temperature for 24 hours, followed by washing with a 
volume of dH2O equal to the PBS volume, drying, and lyophilising for 48 hours.  The 
resulting decellularised extracellular matrix (DECM) was stored at -20oC until further 
use. 
2.13 Hydrogel Formation from Demineralised and Decellularised Bovine Bone 
Solubilisation of extracellular matrix-derived powders (ECM powders) was achieved 
by pepsin digestion of the constituent proteins, producing a solution which was 
capable of undergoing gelation.  ECM was added to a 0.01 N HCl solution at the 
desired digest concentration (which was higher than the final concentration of ECM in 
gels to be used in future experiments).  Pepsin was added at 10% (w/w) relative to 
the ECM, and the resulting suspension was stirred at room temperature for 4 days or 
until all traces of solid had disappeared.  Once this process was complete, ECM 
solution was stored at -20oC until further use. 
To form a hydrogel ECM digest was mixed with sufficient 0.1 M sodium hydroxide to 
neutralise the solution and with 10x PBS (one ninth of the digest volume).  Finally 1x 
PBS was used to dilute to the desired final ECM concentration.  All mixing was 
performed at 4oC to prevent early gelation, which could be induced by raising the 
temperature of the pre-gel mixture to 37oC. 
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2.14 Haemotoxylin and Eosin Staining of Demineralised and Decellularised 
Bovine Bone 
DBM and DECM powders were fixed overnight in 10% (v/v) neutral-buffered formalin 
before being embedded in 3% (w/v) agarose gel overnight.  Samples were then 
paraffin embedded and divided into 5 ± 7 ǋm thick sections before staining with 
haemotoxylin and eosin (these processing steps were performed by the 
+LVWRSDWKRORJ\ 'HSDUWPHQW RI WKH 4XHHQ¶V 0HGLFDO &HQWUH 1RWWLQJKDP
Haemotoxylin stained cell nuclei in these sections blue-black and eosin was used as a 
counterstain to label ECM constituents with a pink colour. 
2.15 Purification & Extraction Protocol for PicoGreen® Assay to Quantify DNA 
Phenol/chloroform extraction can be used to isolate and purify nucleic acids from 
samples also containing large amounts of protein which may interfere with the results 
of quantitative DNA assays.  The essence of the technique is that when a mixture of 
phenol and chloroform (sometimes containing isoamyl alcohol to reduce foaming) is 
centrifuged with an aqueous sample the proteins will partition into the organic phase 
and the nucleic acids into the aqueous phase.  The latter can then be precipitated out 
by addition of alcohol and collected by centrifugation. 
To quantify the double-stranded DNA (dsDNA) content of ECM-derived digests, they 
were first mixed 1:1 (v:v) with 25:24:1 (v:v:v) phenol/chloroform/isoamyl alcohol 
and centrifuged at 10000 g for 10 minutes at 4oC.  The aqueous phases were 
carefully removed and transferred to fresh tubes.  The phenol/chloroform/isoamyl 
alcohol addition and centrifugation steps were repeated until no white precipitate was 
seen at the aqueous-organic interface.  At this point the aqueous phase was mixed 
10:1:10 (v:v:v) with 3 M sodium acetate and ethanol and frozen on dry ice.  Whilst 
frozen, this mixture was placed into centrifugation at 10000 g for 10 minutes at 4oC 
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and the supernatant carefully poured off.  Four times the original digest volume of 
70% (v/v) ethanol was added, centrifugation repeated and the supernatant carefully 
removed.  Finally the samples were air dried at room temperature for 20 minutes 
prior to resuspension in tris-EDTA buffer as detailed below. 
DNA quantification for purified samples was performed using the Quant-iTTM 
PicoGreen® dsDNA Assay Kit which utilises a proprietary reagent to selectively bind 
dsDNA and fluoresce thereafter.  dsDNA standards, samples and the PicoGreen® 
reagent were diluted for assay in 10 mM Tris-HCl/1 mM EDTA buffer at pH 7.5.  
Standards and three samples of each type of digest were assayed in triplicate by 
mixing them with assay reagent in equal parts to a total volume of 200 ǋL in the 
wells of black 96-well plates.  Fluorescence intensity was then measured at 480 nm 
excitation and 520 nm emission. 
2.16 Micro-Computed Tomography Imaging and Three-Dimensional Analysis 
In micro-computed tomography (ǋCT) a sample is illuminated by an x-ray source and 
transmission images taken at regular intervals as the sample is rotated.  This 
produces a set of projection images which can be used to reconstruct images of the 
sample cross-section in a set of planes perpendicular to those of the projection 
images.  Each cross-sectional image in fact represents the average sample density 
over a thin three-dimensional slice of the sample whose thickness is equal to the 
resolution of the instrument.  These slices can then be stacked to reconstruct the 
three-dimensional architecture of the sample.  To ensure that different materials or 
phases are distinguishable in the sample, they must have significantly different 
opacities to x-ray radiation.  This typically means that they must have different 
physical densities. 
ǋCT imaging of samples was undertaken using a Skyscan 1174 (Bruker microCT, 
Kontich, Belgium) and associated control software.  Images were taken at either 6.7 
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or 14.5 ǋm resolution every 0.4o of rotation from 0 to 180o and at each rotation step 
a total of 6 frames were averaged to produce the final image.  The NRecon software 
provided by the manufacturer was used to reconstruct cross-sectional slices with ring 
artefact reduction set to 20, beam hardening to 20% and consistent thresholding 
across all samples.  Finally CTAn was used to produce three-dimensional models of 
scanned samples and to perform analyses such as measurements of total porosity 
and pore size distribution.  As with reconstruction in NRecon, consistent thresholding 
was applied across all samples to be compared and despeckling was also performed 
to remove objects of 100 voxels or less from reconstructed images prior to analysis 
and modelling. 
2.17 Hydroxyproline Assay for Collagen Quantification 
The collagen content of both native tissues and in vitro engineered neo-tissues can 
be deduced from measurements of the hydroxyproline level, since this non-
proteinogenic amino acid accounts for 14.3% by mass of naturally-occurring 
collagen269.  Acid-hydrolysed samples can be oxidised by chloramine T and the 
hydroxyproline component subsequently reacted with p-dimethylaminobenzaldehyde 
(pDAB) to form a coloured product, the concentration of which is linearly related to 
sample absorbance at 540 nm.  
First a 0.25 M sodium phosphate buffer was prepared at pH 6.5 using dibasic sodium 
phosphate.  Next, the hydroxyproline assay stock solution was prepared, starting 
from a 0.24 M/2.05 M citric acid/sodium acetate solution and a 0.85 M sodium 
hydroxide solution.  These solutions were mixed in a 13:5 ratio and glacial acetic acid 
was then added in a 1:75 ratio with this mixture.  The solution was supplemented 
with the addition of dH2O in an 11:114 ratio, and finally by the addition of toluene at 
a 1:2000 ratio. 
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The hydroxyproline assay working solution was prepared from the stock solution by 
mixing it with isopropanol in a 10:3 ratio, adjusting the pH to 6.0, and then 
supplementing with dH2O to bring the total volume to 15/13
th of the pre-pH adjusted 
volume.  The working solution was then used to prepare a 0.07 M solution of 
chloramine T, with the solvent being an 8:1 mixture of working solution and 
isopropanol. 
The final solution to be prepared was a 1.16 M solution of p-
dimethylaminobenzaldehyde (pDAB) in a 30:13 mixture of isopropanol and 60% 
perchloric acid. 
The first step in preparing samples and standards for assay was acid hydrolysis.  This 
was achieved through a 40 hour incubation, at 120oC, of a 1:1 mix of 10 M 
hydrochloric acid with either the sample to be assayed, or a blank solution of the 
enzyme used to digest the samples.  After hydrolysis, the samples were dried by 
incubation at 90oC, and resuspended in 0.25 M sodium phosphate buffer (pH 6.5) at 
four times the volume originally hydrolysed. 
Into a 96-well flat-ERWWRPHG SODWH ZDV SODFHG  ǋ/ RI HDFK VWDQGDUG DQG HDFK
sample in triplicate.  To each well ǋ/RIchloramine T solution was added and the 
mixture was incubated at room temperature for 20 minutes.  This was followed by 
WKHDGGLWLRQRIǋ/RIS'$%VROXWLRQDQGLQFXEDWLRQIRUPLQXWHVDWoC.  The 
plate was cooled back to room temperature, and the absorbance of each well read at 
540 nm between 10 and 30 minutes after removal from the water bath.  The collagen 
content of each sample was then calculated as follows: 
&ROODJHQ&RQWHQW  ሾ+\GUR[\SUROLQHሿǋJP/[ሺ'LOXWLRQ)DFWRUሻ'U\:HLJKWRI6DPSOHJ[[ [ 
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2.18 Spectrophotometric Analysis of Gelation Kinetics 
Pre-gel mixtures (see Section 2.10) at 4oC were pipetted into 96-well plates (100 ǋL 
per well, n = 6) and loaded into a pre-warmed spectrophotometer at 37oC (Infinite 
200, Tecan, Reading, UK).  Sample absorbances were then measured every 3 
minutes for 90 minutes at 405 nm.  This wavelength falls within a band which has 
been used to track collagen fibril and fibre formation and thus gelation. 
2.19 Rheological Analysis of Hydrogel Gelation and Mechanical Properties 
Rheology is the study of the (often non-Newtonian) viscoelastic behaviour of 
materials such as hydrogels and amorphous polymers which neither behave 
completely as solids nor completely as liquids.  Measurements are performed on thin 
samples between narrowly-separated plates in order to prevent significant edge 
effects or variation of mechanical properties through the sample thickness.  Primarily 
rheological measurements involve the application of (oscillatory) strain in order to 
deduce the amount of energy stored by elastic behaviour and lost by viscous (flow) 
behaviour.  Other parameters such as the strain experienced by the sample or the 
sample viscosity can also be measured or calculated. 
ECM-derived hydrogels were subjected to rheological testing using a Physica MCR 
301 rheometer (Anton Paar, Hertford, UK).  Oscillatory strains were applied to 
deduce the rate of change of gel properties during gelation and also to assess the 
final mechanical properties of the fully-formed gels.  Pre-gel solutions (see Section 
2.10) at 4oC were loaded between 50 mm parallel plates with a 0.2 mm measuring 
gap which were also pre-cooled to 4oC in a humidified chamber.  Samples were then 
subjected to a 1% oscillatory strain at 1 rad s-1 for 60 minutes to allow for complete 
gelation.  During the first 75 s of measurements the plates and sample were warmed 
to 37oC to induce gelation. 
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Immediately following this, the now-gelled samples were subjected to a strain 
amplitude sweep from 0.1 ± 200% strain at a constant strain rate of 1 rad s-1.  This 
was designed to assess whether the ECM-derived hydrogels would exhibit the strain 
stiffening expected of collagen hydrogels and also to define the failure strain for 
these gels. 
2.20 Bead Formation from Alginate and ECM-Derived Hydrogels 
Alginic acid is a block copolymer polysaccharide of mannuronic and guluronic acids.  
It is typically derived from seaweed and can be induced to form hydrogels by ion 
exchange.  The sodium salt (sodium alginate) shows good water solubility at ambient 
conditions, but if the sodium ions are exchanged for divalent calcium ions they can 
act to crosslink the individual alginate chains and form a hydrogel.  This provides a 
simple method for the formation of alginate hydrogel beads in which sodium alginate 
solutions are simply dripped into aqueous baths containing high concentrations of 
calcium salts, leading to almost instantaneous gelation. 
This approach was used to produce beads containing or composed of ECM-derived 
hydrogels.  1% (w/v) sodium alginate (Acros Organics) solutions in PBS were mixed 
with DECM digest in varying ratios such that the DECM concentration in the final 
mixture was always 6 mg mL-1 and the total volume was always 10 mL.  These 
mixtures were then dripped through 22G tapered dispense tips (catalogue number 
TTN22, Adhesive Dispensing, Milton Keynes, UK) into 100 mL baths of 5% (w/v) 
calcium chloride which were pre-warmed to 37o&$IWHUKRXU¶VLQFXEDWLRQWRDOORZ
DECM-derived gel formation the beads could be collected and either imaged or dried 
at 65oC for 24 hours for dry weight measurement.  Alternatively the beads could be 
transferred to 0.25 M sodium citrate for 10 minutes to cause the alginate to revert to 
a liquid state and leaving the beads composed entirely of DECM-derived hydrogel. 
Chapter 2 - Materials & Methods 
58 
 
2.21 Production and Sintering of PLGA-PEG Microparticles 
Previously published work has described the production of a microparticulate 
synthetic polymer material which undergoes thermoresponsive liquid sintering to 
form a porous solid with mechanical properties suitable for bone repair270-273.  The 
microparticles consist of a blend of PLGA and PEG which has a glass transition 
temperature higher than room temperature but lower than 37oC.  This means that 
when the microparticles are heated to 37oC in an aqueous environment they soften 
and form adhesion bridges between one another.  The PEG component subsequently 
leaches into the aqueous carrier fluid leading to an increase in the glass transition 
temperature and hardening of the material.  As a result a solid is formed from the 
microparticle network which defines an interconnected pore structure. 
In particular in this work, PLGA (85:15 lactide:glycolide, 53 ± 56 kDa) was melt 
blended at 90oC with PEG in a 93.5:6.5 ratio.  This melt blend was then milled in a 
Krups F203 mill which had been pre-cooled with liquid nitrogen.  The resulting 
powder was manually sieved using analytical test sieves (Retsch (UK), Castleford, 
UK) to select the 50 ± 100 ǋm size fraction. 
To produce microparticle-based constructs these PLGA-PEG microparticles were 
suspended in CMC to form dense pastes which were formed into the desired 
construct shape via bioplotting.  These constructs were incubated in a humidified 
environment at 37oC for two hours.  Following this the constructs were submerged in 
0.9% (w/v) sodium chloride in the same environment for a further 22 hours 
2.22 Use of Fab@Home Bioplotting Platform 
The Fab@Home solid freeform fabrication platform (Model 1)274 was used to produce 
three-dimensional constructs in a layer-by-layer fashion by extrusion of scaffold 
materials through tapered dispense tips (catalogue number 7005006 or 7018097, 
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Nordson EFD, Westlake, OH, USA).  Materials were loaded into 10 mL Luer lock 
syringes (catalogue number 26265, Exel International, Saint Petersburg, FL, USA).  
The pistons of these syringes were then depressed to deposit material at a computer-
controlled rate utilising the FabStudio (v0.23a) software designed for the Fab@Home 
platform.  This software also controlled the motion of the syringe tips in two 
dimensions and of the build stage in the third dimension in order to achieve 
positional control of deposition (see Figure 2.4). 
In other cases the Fab@Home solid freeform fabrication platform (Model 2) was used 
in conjunction with alternative tapered dispense tips (catalogue number TTNx where 
x is the tip gauge, Adhesive Dispensing, Milton Keynes, UK).  Materials were sealed 
into 10 mL Luer lock syringe barrels (catalogue number 7100LL1NPK, Adhesive 
Dispensing, Milton Keynes, UK) by the use of SmoothFlowTM pistons (catalogue 
number 5111PE-B, Nordson EFD, Westlake, OH, USA).  These pistons were then 
depressed to deposit material at a computer-controlled rate utilising the FabStudio 
(v2.0.1) and FabInterpreter software suite designed for the Fab@Home platform.  
This software package also controlled the motion of the syringe tips in two 
dimensions and of the build stage in the third dimension in order to achieve 
positional control of deposition (see Figure 2.5). 
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Figure 2.4 ± Fab@Home Model 1 bioplotting platform.  Associated software drives 
motion of syringe carriage in two dimensions, motion of build tray in the third 
dimension and rate of depression of syringe plungers to give complete control 
over rate and location of material deposition.  Three-dimensional positioning 
accuracy is ±25 ǋm. 
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Figure 2.5 ± Fab@Home Model 2 bioplotting platform.  Associated software drives 
motion of syringe carriage in two dimensions, motion of build tray in the third 
dimension and rate of depression of syringe plungers to give complete control 
over rate and location of material deposition.  Three-dimensional positioning 
accuracy is ±25 ǋm. 
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2.22.1 Bioplotting of Alginate Hydrogels 
To achieve a consistency which was liquid enough to allow flow for deposition but 
solid enough to prevent significant flow after deposition sodium alginate solutions 
were partially calcium-crosslinked prior to bioplotting.  This was achieved by mixing 
them with the poorly-water soluble salt calcium sulphate.  In order to optimise the 
material for deposition a variety of alginate concentrations, calcium sulphate 
concentrations and ratios of the two components were tested.  These were in the 
ranges 1 ± 4% (w/v), 0.5 ± 4% (w/v) and 1:1 ± 3:1 (v:v, alginate:calcium sulphate) 
respectively. 
The process of sample preparation involved drawing up the two components into 
separate 10 mL Luer lock syringes (catalogue number 300912, BD, Oxford, UK or 
catalogue number 26265, Exel International, Saint Petersburg, FL, USA) and mixing 
them back and forth via Luer-to-Luer connectors (catalogue number 13136, Qosina, 
Edgewood, NY, USA) 100 times.  The post-mixing crosslinking of the alginate takes 
an appreciable time to reach completion, and various post-mix wait times were also 
assessed from 0 ± 60 minutes.  All deposition of alginate hydrogels was performed 
using 20G tapered tips and a material flow rate of 5.82 ǋL s-1. 
In cases where cells were to be incorporated into bioplotted alginate constructs they 
were either suspended directly in the uncrosslinked sodium alginate solution prior to 
mixing with calcium sulphate or indirectly via suspension in PBS.  In this latter case 
the cell suspension in PBS and the uncrosslinked alginate solution were first mixed 10 
times prior to the mixing of this cell-laden alginate with the calcium sulphate a 
further 90 times.  In all cases, the pre-plotting viability of the cells to be included was 
assessed via trypan blue staining and the final density of cells in bioplotted constructs 
was always 5 x 105 mL-1. 
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2.22.2 Bioplotting of PLGA-PEG Microparticle Pastes 
To prevent early sintering of PLGA-PEG microparticles all materials used for sample 
preparation were pre-cooled to 4oC and wherever possible all preparation was carried 
out at this temperature as well.  PLGA-PEG microparticles with or without a 
proportion of PLGA-based microspheres were mixed with a variety of aqueous 
carriers (medium viscosity CMC, high viscosity CMC or Pluronic® F-127 at 
concentrations of 0.1 ± 4% (w/v)) at the desired v:w ratio (1:1 ± 1.7:1).  The 
resulting pastes were loaded into syringe barrels for deposition which was carried out 
using 16G tapered tips.  Material flow rates were in the range 5.82 ± 38.8 ǋL s-1. 
2.23 Unconstrained Compression Testing 
Compression testing involves the application of steadily increasing strain to material 
samples coupled with measurements of the force being exerted to achieve these 
strains.  This allows the deduction of properties such as the yield stress (the stress at 
WKH RQVHW RI SODVWLF GHIRUPDWLRQ DQG WKH <RXQJ¶V PRGXOXV WKH ratio of stress to 
strain during elastic deformation).  Constrained testing involves constriction of the 
samples being tested so that they cannot expand in any direction perpendicular to 
the axis of loading.  Unconstrained testing is conducted without this restriction. 
PLGA-PEG microparticulate scaffolds were subjected to unconstrained compression 
testing using a TA.HDplus texture analyser (Stable Micro Systems, Godalming, UK).  
Samples were tested at 37oC immediately at the end of 24 hours sintering.  The 
probe movement rate was 0.04 mm s-1 (which equates to a 0.333% s-1 strain rate) 
and the test was continued to 50% strain.   
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2.24 Live/Dead Staining of Cells in Alginate Hydrogels 
7KHµOLYH¶FRPSRQHQWRIWKH/LYH'HDG9LDELOLW\&\WRWR[LFLW\.LWFRQVLVWVRIa solution 
of calcein AM (an acetomethoxy (AM) derivative of the fluorescent molecule calcein).  
The AM group which prevents fluorescence of the molecule is only cleaved by the 
esterases contained within living cells and the molecule is therefore only fluorescent 
ZKHQ WUDSSHG LQ YLDEOH FHOOV 7KH µGHDG¶ FRPSRQHQWRI WKH VWDLQLQJNLW LV HWKLGLXP
homodimer-1 (EH-1) which can only cross cell membranes once those cells are 
membrane compromised (dead or dying).  Upon crossing these membranes, EH-1 is 
then able WRELQGWKHFHOOV¶'1$DWZKLFKSRLQWLWEHFRPHVIOXRUHVFHQW 
In order to stain cells contained within bioplotted alginate hydrogels, small samples 
of the gels were submerged in a 2 ǋM/2 ǋM calcein AM/EH-1 solution for 30 minutes.  
For each bioplotted gel three samples were stained and three fields of view imaged 
for each sample to assess cell viability.  Imaging was undertaken by removing 
samples from their stain solutions, pressing them between glass slides and glass 
coverslips and then viewing them using a Leica DM IRB inverted microscope (Leica 
Microsystems (UK), Milton Keynes, UK) and QCapture Pro software (QImaging, 
Surrey, Canada). 
2.25 MTS Assay for Cell Proliferation 
MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium) and a number of closely-related tetrazolium dyes are reduced by 
enzymes contained within viable, metabolising cells to produce formazan products.  
This results in a colour change which can be measured spectrophotometrically to 
allow quantification of cell populations. 
Here an MTS assay kit (catalogue number G3581, Promega UK, Southampton, UK) 
was used to assess cell proliferation in the wells of 96-well tissue culture plates.  To 
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the 100 ǋL of culture medium within each well was added 20 ǋL of MTS reagent (n = 
6, cell-free controls evaluated for each culture condition).  The resulting mixture was 
incubated at 37oC for 3 hours before the absorbance of each well was read at 490 
nm using an Infinite 200 spectrophotometer (Tecan, Reading, UK). 
2.26 Statistical Analysis 
The homogeneity of variances across different experimental groups to be compared 
ZDV GHWHUPLQHG E\ /HYHQH¶V WHVW  &RPSDULVRQV RI WZR H[SHULPHQWDO JURXSV ZHUH
then made using the VWXGHQW¶V W-test whilst comparisons of more than two groups 
ZHUHPDGHE\RQHZD\DQDO\VLVRIYDULDQFH$129$XVLQJ:HOFK¶V)VWDWLVWLFZKHQ
group variances were found to be unequal.  Appropriate post hoc procedures were 
used after ANOVA to perform pairwise comparisons between experimental groups.  
,Q FDVHV RI HTXDO JURXS VL]H DQG HTXDO YDULDQFHV 7XNH\¶V SURFHGXUH ZDV DSSOLHG
ZKLOVW*DEULHO¶VZDVXWLOLVHG IRUJURXSVRIXQHYHQVL]HZLWKHTXDOYDULDQFHVDQGWKH
Games-Howell procedure for cases of unequal variance.  All statistical tests were 
performed at the 5% significance level. 
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3. Production and Patterning of PLGA-Based 
Microspheres 
3.1 Introduction 
3.1.1 Poly(lactic-co-glycolic acid) 
Poly(lactic-co-glycolic acid) (PLGA) has a long and extensive history of use in 
biomedical science275,276 and is approved by the Food and Drug Administration in the 
USA and by similar organisations around the world for a number of uses277,278.  PLGA 
has excellent biocompatibility, with low-toxicity degradation products and relatively 
little immune response upon implantation279-283.  PLGA is commonly-used in the fields 
of drug delivery and tissue engineering, where it allows the release profile of drugs or 
proteins encapsulated within it to be extensively tailored276,279,284. 
Well-established methodologies allow control of the morphology of PLGA scaffolds via 
the use of porogens285-287 and production techniques such as supercritical fluid 
foaming288.  Porous scaffolds can also be produced via microparticle sintering in 
which case the structural properties of the scaffolds can be controlled by varying 
parameters including the microparticle size and size range, sintering temperature and 
time and the loading regime applied during formation289,290.  Control of scaffold 
structure brings the potential for control over protein release, cell growth and 
differentiation and also in vivo tissue ingrowth and architecture291-293. 
3.1.2 PLGA Microparticles 
Particular attention has fallen on forming PLGA into microparticles and 
microparticulate scaffolds.  Roughly spherical polymer microparticles can be obtained 
in a very broad range of sizes with well controlled protein encapsulation and release 
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via solvent evaporation techniques (also known as emulsion techniques)294,295.  In 
single emulsion manufacture an organic polymer solution, with or without protein, is 
emulsified in an external aqueous phase.  This external phase usually contains a 
surfactant or other emulsifier to stabilise the liquid organic droplets whilst the volatile 
solvent evaporates to leave behind solid microparticles296-298.  The double emulsion 
technique is an extension of this in which an internal aqueous phase containing the 
protein to be encapsulated is pre-emulsified in the organic oil phase before this 
primary emulsion is then itself emulsified in the external aqueous phase299-301.  A third 
alternative for solvent evaporation microparticle manufacture is to disperse the 
protein to be encapsulated in the organic polymer solution as a solid before 
emulsification302-306.  The above techniques are amongst the most well-established 
and widely-used for microparticle manufacture but others include spray drying, 
electrospraying, microfluidics, ultrasonic atomisation and supercritical fluid 
processing284,307-316. 
3.1.3 Use of PLGA Microparticles for Controlled Delivery of Proteins 
The therapeutic delivery of proteins is not a new concept, with a range of products 
having been in the clinic for many years317,318.  However many potentially effective 
proteins are limited in their practical application by their short in vivo half-lives.  
Additionally, systemic delivery tends to lead to poor bioavailability at the desired site 
of action and undesirable side effects at other locations318-320.  One solution to both 
of these problems is to encapsulate the protein into a synthetic polymer scaffold for 
controlled release over time.  This methodology provides protection from degradation 
for the protein and significantly lengthens its half-life317,318,321.  It also ensures that 
the therapeutic is available in a sustained dose form and allows the entirety of the 
protein load delivered to be located in or near the target organ or tissue. 
Protein release from PLGA is known to follow a tri-phasic release pattern, starting 
with an initial burst release during the first 24 hours (quite often of a significant 
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proportion of the total encapsulated protein).  This is followed by a lag phase during 
which very little protein is released and finally there is a period of sustained release 
of any remaining protein (Figure 3.1)294,308. 
The proportion of protein released in the initial burst is broadly dictated by the 
proportion that is either adsorbed to the polymer surface or encapsulated very close 
to it.  The size of the burst can thus be altered by modification of the total scaffold 
surface area.  This in turn can be achieved by altering the porosity and pore or 
structure size of the scaffold.  The burst release can also be affected by modification 
or coating of the surface of the scaffold in a variety of ways284,285,292,322-324. 
After the release of this surface-located protein the release profile of PLGA enters a 
lag phase during which the polymer has yet to significantly degrade so that very little 
further protein is released.  The final phase of release then begins at around the 
same time as significant polymer degradation i.e. the point at which significant mass 
starts to be lost from the scaffold.  The degradation properties of the polymer thus 
define the timepoint for onset of the third phase of release.  They also set the rate of 
release during this phase and they can be tailored by altering both the lactide-to-
glycolide monomer ratio and the molecular weight of the PLGA used276,277,325. 
A significant body of work has addressed the addition of release modifiers such as 
poly(ethylene glycol) (PEG) and Pluronic® (a triblock copolymer of poly(ethylene 
oxide) and poly(propylene oxide)) to the PLGA used to make controlled-release 
scaffolds277,303,305,308,326-328.  This addition may be with the aim of adjusting the rates 
and timescales for a typical tri-phasic release or of altering the shape of the release 
curve entirely.  In the latter case a zero order release profile is often of particular 
interest since it assures a steady rate of protein delivery throughout the period of 
release and thus a constant level of biological activity294.  Alternatively it is sometimes 
desired simply to minimise the burst release such that a steady release of active 
factor is achieved albeit after an initial delay284,327,329.  
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Figure 3.1 ± Schematic representing typical tri-phasic protein release from 
PLGA scaffold. 
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For microparticulate scaffolds protein release can be controlled simply via size 
modification of microparticle size294,298,330-333.  A number of process parameters can 
be altered to affect the size distribution of the resulting microparticles.  The resulting 
change in surface area will alter both the size of the burst release and the rate of 
degradation of the microparticles.  Coatings and material layering can easily be 
applied to microparticles and used to affect the release profile and/or the cellular 
response to PLGA-based microparticles32,292,303,329,334-344. 
Perhaps most importantly microparticles can constitute (part of) injectable scaffold 
formulations for tissue engineering therapies.  This in turn offers the promise of 
minimally-invasive treatments which can be delivered into tissues or defect spaces 
without the need for open surgery32.  This ultimately leads to less pain and 
discomfort for patients, shorter recovery times and lower infection risks. 
Of particular relevance to the work presented in this thesis is the fact that the 
injectability of these microparticle formulations also renders them compatible with a 
number of patterning technologies.  These include microinjection/micromanipulation 
and bioplotting and can be used to pattern protein-loaded microparticles within tissue 
engineering constructs for spatially-controlled delivery of these therapeutic agents. 
3.1.4 Microinjection and Micromanipulation Techniques in Tissue Engineering 
As described earlier (see Section 1.1.1) there are some examples of the use of 
microinjection and micromanipulation (MM) techniques in tissue engineering.  These 
early examples have typically involved a single precisely-positioned delivery of cells 
and/or synthetic polymer microspheres into adult tissues30-34.  Obstacles still remain 
to the application of MM techniques for three-dimensional patterning.   
In order to fully utilise the positional resolution of micromanipulation systems and 
produce very fine scale patterns a key challenge is to achieve the delivery of very 
small volumes of very densely-suspended cells or microspheres.  Dense suspension is 
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LPSRUWDQWLQRUGHUWRPLQLPLVHWKHµGHDGYROXPH¶RIVXVSHQVLRQIOXLGGHOLYHUHGDQGWR
prevent excessive cell or microsphere movement after delivery.  The ultimate aim in 
this regard is to achieve precise delivery of individual objects which has been little 
demonstrated for rigid objects such as synthetic polymer microspheres. 
3.1.5 Aims & Objectives 
The first major aim of the work presented in this chapter is to generate robust 
protocols for the fabrication of PLGA-based microspheres demonstrating low degrees 
of batch-to-batch size variability.  More specifically three protocols will be devised for 
the production of microspheres whose mean sizes vary across around two orders of 
magnitude.  The ability to precisely define and choose the microsphere size will allow 
significant variation of the release profile of encapsulated proteins to tailor the 
presentation of each to match its native production during the biological process to 
be replicated.  Additional modification of protein release profiles via the addition of 
PLGA-PEG-3/*$WULEORFNFRSRO\PHUµ7ULEORFN¶ZLOODOVREHHYDOXDWHG 
A further task will be the production of fluorescent versions of all microsphere sizes 
to allow microsphere patterns in bulk scaffold materials to be imaged via fluorescence 
microscopy.  This will be achieved via direct incorporation of fluorophores into the 
polymer matrix during microsphere fabrication. 
The second major aim of this work is to evaluate MM techniques for their potential to 
pattern synthetic polymer microspheres into in vitro cell culture environments.  
Microsphere patterning would allow proteins encapsulated within them to be 
presented to cells in a spatially-controlled manner.  This could create complex 
heterogeneous signal environments which would allow developmental and repair 
mechanisms to be modelled.  The modification of these mechanisms by potential 
tissue engineering therapies could also be evaluated. 
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Initial efforts will focus on finding conditions which result in the consistent delivery of 
sub-microlitre volumes of microsphere suspension.  Consistency will be assessed on 
the basis of microsphere numbers and this will involve the development of an 
accurate and reliable method of counting.  Further to this the ability of MM 
techniques to precisely position these small volume deliveries within hydrogels will be 
evaluated.  Work will progress to consider the delivery and patterning of individual 
microspheres and the smallest length scales on which this is possible.  Finally, an 
important consideration will be the definition of a material environment which is 
suitable for both microsphere patterning and also cell adhesion and proliferation (see 
Appendix). 
3.2 Materials and Methods 
3.2.1 Microsphere Fabrication via Single Emulsion Technique 
See Section 2.4.1. 
3.2.2 Microsphere Fabrication via Double Emulsion Technique 
See Section 2.4.2. 
3.2.3 Microsphere Fabrication via Refined Double Emulsion Technique 
See Section 2.4.3 for general methodology.  Bone morphogenetic protein-2-loaded 
(BMP-2-loaded) microspheres were fabricated by utilisation of a 99:1 (w:w) mix of 
HSA and BMP-2 dissolved in PBS at 100 mg mL-1 as the aqueous phase at primary 
emulsification. 
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3.2.4 Microsphere Size Distribution Analysis via Laser Diffraction 
See Section 2.5. 
3.2.5 Scanning Electron Microscopy (SEM) Imaging of Microspheres 
See Section 2.6. 
3.2.6 PLGA-PEG-PLGA Triblock Copolymer Synthesis & Characterisation 
See Section 2.3. 
3.2.7 Measurement of Protein Release Rate from Microspheres 
To assess the rate of release of protein from BMP-2-loaded microspheres, 100 mg 
samples of microspheres were incubated at 37oC in 3 mL phosphate-buffered saline 
(PBS, pH 7.4) under gentle agitation for a total of 28 days.  During this time the 
liquid was regularly removed to be assayed for protein content and replaced with 
fresh PBS.  See section 2.7 for details of protein quantification assay which was run 
in triplicate on three separate samples from each microsphere formulation to be 
assessed.  Blank (protein-free) microspheres were used as controls for each 
formulation. 
3.2.8 Borosilicate Glass Needle Manufacture 
See Section 2.8. 
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3.2.9 Microinjection and Micromanipulation of PLGA Microspheres 
See Section 2.9 for general protocols for microinjection and micromanipulation 
utilising a fully manual system (see Section 2.9.1) and a semi-automated system (see 
Section 2.9.2). 
3.2.10 PLGA Microsphere Counting 
See Section 2.10 for general protocols for microsphere counting utilising a 
haemocytometer (see Section 2.10.1) or a light blocking-based particle sizing and 
counting system (see Section 2.10.2). 
3.3 Results 
Previous unpublished work on PLGA microsphere fabrication gave significant 
indications as to the correct choice of conditions for the production of microspheres 
with mean sizes of around 100 ǋm.  This size was therefore chosen as a starting 
point for the work presented in this thesis and the production of smaller 
microspheres evaluated for the provision of the desired two order of magnitude 
variation (see Section 3.1.5). 
3.3.1 Production of Microspheres with Size Distributions Centred on Around 
100 ǋPµǋP¶0LFURVSKHUHV 
As a result of the previous work referred to above, a 20% (w/v) PLGA (50:50, 59 
kDa) concentration was chosen for fabrication targeted at this largest microsphere 
size.  A double emulsion protocol was chosen as it had been found previously 
(unpublished work) to give higher encapsulation efficiency for proteins.  A range of 
homogenisation speeds were then tested to determine that which was optimal for 
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production of the correct size of microspheres (1000 ± 9000 rpm using Silverson L5M, 
identical at primary and secondary emulsification steps, Figure 3.2).  Laser 
diffraction-based size analysis demonstrated that 2000 rpm was the correct choice of 
speed for future work, resulting in a mean microsphere size of 98.6 ǋm. 
An assessment of the batch-to-batch variability of the process at this homogenisation 
speed was then undertaken based on size distribution consistency (n = 6, Figure 
3.3).  The coefficient of variance of mean microsphere size for this process was found 
to be 18.5% and the mean of the mean sizes to be 84.8 ǋm.  SEM imaging (JEOL 
JSM 6060LV) was also undertaken (representative images shown in Figure 3.4).  
Microspheres were found to be predominantly spherical and smooth-surfaced with 
sizes that reflected the distribution seen via laser diffraction. 
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Figure 3.2 - Laser diffraction-derived size distributions demonstrating the effect 
on PLGA microsphere size of altering the homogenisation speeds used during 
double emulsion microsphere manufacture.  Speeds at primary and secondary 
emulsification the same in all cases, polymer concentration fixed at 20% (w/v). 
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Figure 3.3 ± Laser diffraction-derived size distributions showing degree of batch-
to-EDWFK YDULDELOLW\ GXULQJ µ ǋP¶ 3/*$ PLFURVSKHUH SURGXFWLRQ YLD GRXEOH
emulsion using homogenisation speeds of 2000 rpm at both emulsification steps 
and a polymer concentration of 20% (w/v). 
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Figure 3.4 ± 5HSUHVHQWDWLYH6(0LPDJHVRIµǋP¶3/*$PLFURVSKHUHVSURGXFHG
via double emulsion with a polymer concentration of 20% (w/v) and 
homogenisation speeds of 2000 rpm at both emulsification steps. 
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Fluorescent microspheres were produced by replacing the water normally used as the 
inner aqueous phase with 0.1 mg mL-1 acridine orange.  The microspheres produced 
were highly fluorescent and could easily be visualised via fluorescence microscopy.  
As with blank microspheres, an assessment of the batch-to-batch variability of the 
process was undertaken based on size distribution consistency (n = 6, Figure 3.5).  
The coefficient of variance of mean microsphere size for this process was found to be 
9.1%.  The mean of the mean microsphere sizes was found to be 91.0 ǋm indicating 
that the addition of fluorophore had caused a slight shift in the microsphere size 
distribution.  SEM imaging (JEOL JSM 6060LV) was also undertaken (representative 
images shown in Figure 3.6).  The addition of fluorophore to the microsphere 
formulation did not appear to have altered the predominantly spherical nature of the 
microspheres.  However there did appear to have been an increase in the amount of 
surface imperfections and pores on the microspheres. 
Volume-EDVHG VL]H GLVWULEXWLRQV IRU µ ǋP¶ PLFURVSKHUHV VKRZHG UHODWLYHO\ IHZ
microspheres with sizes lower than 50 ǋm.  However, number-based distributions 
highlighted the presence of a very significant number of microspheres with sizes 
below 10 ǋm (Figure 3.7(a)).  To allow microspheres to flow over one another more 
effectively when in aqueous suspension for both microinjection (see Sections 3.3.4, 
3.3.5 and 3.3.6) and bioplotting (see Chapter 5) it was necessary to remove this 
small size fraction.  This was achieved by manual sieving using an analytical test 
sieve (Retsch (UK), Castleford, UK) with a 40 ǋm mesh.  After sieving the volume-
based size distribution showed little change (Figure 3.7 (b)), but the number-based 
distribution demonstrated the complete removal of the small microsphere fraction 
(Figure 3.7 (a)). 
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Figure 3.5 ± Laser diffraction-derived size distributions showing degree of batch-
to-EDWFKYDULDELOLW\GXULQJ IOXRUHVFHQW µ ǋP¶3/*$PLFrosphere production via 
double emulsion.  Homogenisation speeds used were 2000 rpm at both 
emulsification steps, polymer concentration was 20% (w/v) and a solution of 0.1 
mg mL-1 acridine orange was the inner aqueous phase. 
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Figure 3.6 ± Representative SEM LPDJHV RI IOXRUHVFHQW µ ǋP¶ 3/*$
microspheres produced via double emulsion with a polymer concentration of 20% 
(w/v), homogenisation speeds of 2000 rpm at both emulsification steps and an 
inner aqueous phase consisting of 0.1 mg mL-1 acridine orange. 
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Figure 3.7 ± Laser diffraction-derived size distributions, based on number fraction 
DDQGYROXPHIUDFWLRQEWRVKRZDOWHUDWLRQVDFKLHYHGYLDVLHYLQJRIµǋP¶
PLGA microspheres (where the sub-ǋP IUDFWLRQ LV GLVFDUGHG 0LFURVSKHUHV
were produced via double emulsion with a polymer concentration of 20% (w/v) 
and homogenisation speeds of 2000 rpm at both emulsification steps. 
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3.3.2 Production of Microspheres with Mean Sizes Covering Two Orders of 
Magnitude Below 100 ǋm 
It was clear from the work described above that mean microsphere sizes of 10 ǋm or 
less (i.e. at least one order of magnitude lower than those produced by the existing 
protocol) could not be produced using a polymer concentration of 20% (w/v).  A 
range of lower PLGA (50:50, 59 kDa) concentrations (2 ± 17% (w/v)) were evaluated 
using 9000 rpm homogenisation speeds (Silverson L5M) at both emulsification steps.  
The aim in this study was to produce microspheres with size distributions centred 
close to 1 and 10 ǋm without showing significant overlap with one another.  Laser 
diffraction-based size analysis demonstrated that 2 and 17% (w/v) concentrations 
may be suitable for this purpose, producing size distributions centred on 1.94 and 
14.4 ǋm respectively (Figure 3.8).  To assess whether the smaller of the distributions 
could be shifted to further reduced size faster homogenisation speeds were tested 
using an alternative homogeniser (Ultra Turrax T25 Basic).  No further reduction in 
size was observed (Figure 3.9) and the 9000 rpm homogenisation speed was carried 
forward for further work. 
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Figure 3.8 - Laser diffraction-derived size distributions demonstrating the effect on 
PLGA microsphere size of altering the polymer concentration used during double 
emulsion microsphere manufacture.  Homogenisation speeds at primary and 
secondary emulsification are 9000 rpm in all cases. 
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Figure 3.9 - Laser diffraction-derived size distributions demonstrating the effect 
on PLGA microsphere size of altering the homogenisation speeds used during 
double emulsion microsphere manufacture.  Homogenisation speeds at primary 
and secondary emulsification the same in all cases, polymer concentration fixed at 
2% (w/v). 
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7KHODUJHURIWKHVHWZRPLFURVSKHUHVL]HV¶ǋP¶PLFURVSKHUHVZDVIXUWKHUVWXGLHG
to assess batch-to-batch variability based on size distribution consistency (n = 6, 
Figure 3.10).  The coefficient of variance of mean microsphere size for this process 
was found to be 9.3% and the mean of the mean sizes to be 13.6 ǋP6(0LPDJLQJ
(JEOL JSM 6060LV) was also undertaken (representative images shown in Figure 
3.11) and demonstrated that microspheres were predominantly spherical with 
smooth surfaces lacking pores.  The microsphere sizes seen reflected the distribution 
seen via laser diffraction. 
Similar analyses were performed for fluorescent versions of these microspheres which 
were produced utilising 0.1 mg mL-1 acridine orange as the aqueous phase at primary 
emulsification (Figures 3.12 & 3.13).  The coefficient of variance of mean 
microsphere size for this process was found to be 4.9% and the mean of the mean 
sizes to be 14.4 ǋP  7KLV LQGLFDWHG WKDW DV ZLWK µ ǋP¶PLFURVSKHUHV 6HFWLRQ
3.3.1) the addition of fluorophore had slightly increased the mean microsphere size.  
SEM imaging (JEOL JSM 6060LV) again showed the maintenance of predominantly 
spherical, smooth-surfaced microsphere morphology. 
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Figure 3.10 ± Laser diffraction-derived size distributions showing degree of batch-
to-EDWFK YDULDELOLW\ GXULQJ ¶ ǋP¶ 3/*$ PLFURVSKHUH SURGXFWLRQ YLD GRXEOH
emulsion.  Homogenisation speeds used were 9000 rpm at both emulsification 
steps and polymer concentration was 17% (w/v). 
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Figure 3.11 ± 5HSUHVHQWDWLYH6(0LPDJHVRI¶ǋP¶3/*$PLFURVSKHUHVSURGXFHG
via double emulsion with a polymer concentration of 17% (w/v) and 
homogenisation speeds of 9000 rpm at primary and secondary emulsifications. 
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Figure 3.12 ± Laser diffraction-derived size distributions showing degree of batch-
to-EDWFK YDULDELOLW\ GXULQJ IOXRUHVFHQW ¶5 ǋP¶ 3/*$PLFURVSKHUH SURGXFWLRQ YLD
double emulsion.  Homogenisation speeds used were 9000 rpm at both 
emulsification steps, polymer concentration was 17% (w/v) and 0.1 mg mL-1 
acridine orange was the inner aqueous phase. 
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Figure 3.13 ± Representative SEM LPDJHV RI IOXRUHVFHQW ¶ ǋP¶ 3/*$
microspheres produced via double emulsion with a polymer concentration of 17% 
(w/v), homogenisation speeds of 9000 rpm at primary and secondary 
emulsifications and an inner aqueous phase of 0.1 mg mL-1 acridine orange. 
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A batch-to-EDWFKYDULDELOLW\VWXG\ZDVDWWHPSWHGIRUWKHVPDOOHVWPLFURVSKHUHVL]Hµ
ǋP¶ PLFURVSKHUHV  7KH ILUVW WKUHH EDWFKHV SURGXFHG VKRZHG D JRRG GHJUHH RI
consistency (Figure 3.14 (a)) and similar predominantly spherical, smooth-surfaced 
morphology to that seen in other microsphere sizes (SEM imaging, Philips XL30, 
Figure 3.15).  However subsequent batches showed very high variability and 
significant populations of much larger than intended microspheres (Figure 3.14 (b)).   
6LPLODUSUREOHPVZHUHVHHQZKHQWKHSURGXFWLRQRIIOXRUHVFHQWµǋP¶PLFURVSKHUHV
was attempted, either by co-dissolution of fluorescein with the polymer (single 
emulsion, see Figure 3.16) or by the use of acridine orange solutions as the aqueous 
phases at primary emulsification (double emulsion, see Figure 3.17). 
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Figure 3.14 ± Laser diffraction-derived size distributions for first three batches (a) 
DQGVXEVHTXHQWVL[EDWFKHVERIµǋP¶3/*$PLFURVSKHUHVSURGXFHGYLDGRXEOH
emulsion technique using homogenisation speeds of 9000 rpm at both 
emulsification steps and a polymer concentration of 2% (w/v). 
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Figure 3.15 ± 5HSUHVHQWDWLYH 6(0 LPDJHV RI µ ǋP¶ 3/*$PLFURVSKHUHV HDUO\
batches, see Figure 3.14 (a)) produced via double emulsion with a polymer 
concentration of 2% (w/v) and homogenisation speeds of 9000 rpm at primary 
and secondary emulsifications. 
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Figure 3.16 - Laser diffraction-derived size distributions demonstrating the effect 
RQ IOXRUHVFHQW µ ǋP¶ 3/*$ PLFURVSKHUH VL]H RI DOWHULQJ WKH IOXRUHVFHLQ
concentration co-dissolved with the polymer during single emulsion microsphere 
manufacture.  Speed at emulsification fixed at 24,000 rpm and polymer 
concentration at 2% (w/v). 
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Figure 3.17 - Laser diffraction-derived size distributions demonstrating the effect 
RQ IOXRUHVFHQW µ ǋP¶ 3/*$ PLFURVSKHUH VL]H of altering the acridine orange 
concentration used during double emulsion microsphere manufacture.  Speeds at 
primary and secondary emulsification steps fixed at 9000 rpm and polymer 
concentration at 2% (w/v). 
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3.3.3 The Effect of PLGA-PEG-PLGA Triblock Copolymer on Protein Release 
from Microspheres 
The refined double emulsion technique utilised here (see Section 2.4.3) was found to 
produce greater yields of microspheres and to result in higher protein encapsulation 
efficiencies than the original double emulsion technique.  The former is 
predominantly due to the use of PTFE containers for conducting the primary 
emulsification procedure and the latter due to the decreased organic solvent 
evaporation time.  An additional result of these alterations was an improvement in 
the batch-to-batch consistency of the microsphere fabrication process.  Figure 3.18 
shows laser diffraction-derived si]HGLVWULEXWLRQVIRUµ100 ǋP¶PLFURVSKHUHVSURGXFHG
via the refined protocol using a PLGA (85:15, 56 kDa) concentration of 20% (w/v) 
and homogenisation speeds of 4000 and 2000 rpm at primary and secondary 
emulsifications respectively (Silverson L5M).  The coefficient of variance of the mean 
microsphere sizes was found to be 9.1% and the mean of the mean sizes to be 74.3 
ǋm.  SEM imaging (JEOL JSM 6060LV) showed that the changes to the protocol had 
not changed the predominantly spherical, smooth-surfaced nature of the 
microspheres (representative images shown in Figure 3.19). 
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Figure 3.18 - Laser diffraction-derived size distributions showing degree of batch-
to-EDWFK YDULDELOLW\ GXULQJ µ ǋP¶ 3/*$ PLFURVSKHUH SURGXFWLRQ YLD UHILQHG
double emulsion technique.  Homogenisation speeds used were 4000 and 2000 
rpm at primary and secondary emulsifications respectively and polymer 
concentration was 20% (w/v). 
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Figure 3.19 ± Representative SEM imageV RI µ ǋP¶ 3/*$ PLFURVSKHUHV
produced via refined double emulsion technique with a polymer concentration of 
20% (w/v) and homogenisation speeds of 4000 and 2000 rpm at primary and 
secondary emulsifications respectively. 
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As per the method detailed in Section 3.2.7 the release of protein from BMP-2-loaded 
PLGA-based (85:15, 56 kDa) microspheres produced using the protocol above was 
measured over 28 days using the MicroBCA Assay Kit.  Release was assessed from 
microspheres containing 0, 10 and 30% (w/w) Triblock (Figure 3.20).  Clear 
differences were seen between the release profiles produced by the different 
microsphere formulations. 
The protein released during the first KRXUVIURPSRO\PHUPLFURVSKHUHVWKHµEXUVW
UHOHDVH¶ LVEHOLHYHGWREHSUHGRPLQDQWO\WKDWZKLFKLVDGVRUEHGWRWKHPLFURVSKHUH
surfaces308.  As a result the amount released in this period is typically not related to 
the polymer composition of the microspheres.  In Figure 3.18 (b) this burst release 
has effectively been subtracted from the release profiles which are shown as the 
cumulative release of protein from 24 hours after the initiation of incubation.  Once 
this composition-independent but variable burst is subtracted a clearer trend of more 
rapid release with increasing Triblock content emerges. 
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Figure 3.20 ± Cumulative mass release profiles of 99:1 (w:w) HSA:BMP-2 mixture 
IURPµǋP¶3/*$-based microspheres containing varying amounts of Triblock.  
Profiles are shown from beginning of incubation (a) or from 24 hours after start of 
incubation (b) i.e. with the burst release subtracted. 
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3.3.4 Consistency of Delivery of Microspheres via Microlitre Syringes 
Initial evaluation of the ability of microinjection to deliver PLGA microspheres was 
performed using microlitre Hamilton syringes and plunger-in-needle syringes.  The 
DELOLW\ WR UHSHDWHGO\ GUDZ XS DQG FRPSOHWHO\ HMHFW YDULRXV GHQVLWLHV RI µ ǋP¶
microsphere suspension in water through needles of various sizes was assessed 
(Table 3.1). 
Subsequently the ability of these syringe types to deliver microspheres consistently 
was assessed.  The ultimate aim of the microsphere delivery and patterning work 
presented in this chapter was to achieve heterogeneity of protein signals.  In order to 
produce consistent signal environments it was important that the protein load 
delivered under a given set of conditions was reproducible.  It was on this basis that 
consistency was evaluated.  Since the delivered protein load could not be accurately 
measured for small volume deliveries a surrogate measure was needed.  The 
microsphere mass was expected to be proportional to the protein load, but this could 
not be accurately measured either.  The number of microspheres in a delivery was 
considered a potential surrogate output but would only be proportional to protein 
load if the microsphere size distribution was found to be consistent between different 
deliveries. 
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  Suspension Density/ %(w/v) 
Needle Type 
Needle Inner 
'LDPHWHUǋP 10 20 50 75 
P-i-N 340 9 9 9 9 
P-i-N 260 9 9 9 8 
33G 110 9 9 9 8 
 
 
 
  
Table 3.1 - Summary of feasibility (9) or unfeasibilty (8) of repeatedly drawing 
XS DQG FRPSOHWHO\ HMHFWLQJ µ ǋP¶PLFURVSKHUH VXVSHQVLRQV HDUO\ EDWFKHV VHH
Figure 3.14 (a)) of various densities (i.e. various proportions of solid content) 
through various needle sizes.  Note that P-i-N denotes the use of a positive 
displacement, plunger-in-needle syringe. 
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,Q WKLV DQG VXEVHTXHQW ZRUN HMHFWLRQV ZHUH FRQVLGHUHG WR EH HLWKHU µUHSHDWHG¶ RU
µFRQVHFXWLYH¶7KHIRUPHUFRQVLVWHGRIUHSHDWHGO\GUDZLQJ up and ejecting a volume 
in its entirety whilst the latter consisted of drawing up a volume and then ejecting it 
sequentially in equally-sized parts.  Practical considerations dictate that the latter 
would be preferred for the production of microsphere patterns involving a large 
number of individual injections. 
The similarity of size distributions resulting from different microsphere deliveries was 
considered to be true by definition for repeated ejections in which the complete 
suspension volume was delivered on each occasion.  However an assessment was 
necessary to evaluate whether it was also true for consecutive ejections.  This 
evaluation was performed under conditions that were considered to be the most 
likely to result in differences (the smallest usable needle size at the highest usable 
suspension density for this needle size).  Three series of ejections were performed, 
each consisting of five consecutive 1 ǋ/HMHFWLRQVRIZY µǋP¶PLFURVSKHUH
suspension through a 33 G needle.  The mean results from these three series are 
shown in Figure 3.21 (with error bars omitted for clarity).  The distributions were 
visually very similar and within experimental error of one another.  The mean sizes 
for the five ejections were (from first to last) 1.80, 1.84, 1.79, 1.85 and 1.82 ǋm.  
Microsphere number was therefore considered an appropriate surrogate measure for 
SURWHLQORDGZKHQGHOLYHULQJµǋP¶PLFURVSKHUHV 
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Figure 3.21 ± Mean laser diffraction-derived size distributions resulting from series 
RI ILYH FRQVHFXWLYH HMHFWLRQV RI  ǋO RI  ZY VXVSHQVLRQ RI µ ǋP¶
PLFURVSKHUHV HDUO\ EDWFKHV VHH )LJXUH  D IURP D WRWDO YROXPH RI  ǋO
(microlitre syringe, 33 G needle, n =3, error bars omitted for clarity). 
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)RU µ ǋP¶ PLFURVSKHUHV FRXQWLQJ ZDV SHUIRUPHG XVLQJ DQ LPSURYHG 1HXEDXHU
haemocytometer.  Figure 3.22 shows exemplar microsphere counts resulting from 
repeated and consecutive ejections of the same volume of suspension of the same 
density.  In this case, as was observed across many conditions, the repeated 
ejections contained microsphere numbers which were within experimental error of 
one another.  On the other hand, the microsphere numbers resulting from three 
series of consecutive ejections showed very wide variability.  This suggested that 
water may not be an adequate suspension fluid for achieving consistent delivery of 
microsphere suspensions.  It was postulated that this may be due to insufficient 
viscosity of the fluid.  This could have led both to settling of the microspheres out of 
suspension and also to preferential ejection of the fluid in the early ejections. 
7KHXQUHOLDELOLW\RIµǋP¶PLFURVSKHUHSURGXFWLRQVHH6HFWLRQDQG)LJXUH
meant that this hypothesis could not be tested on the smallest microsphere size.  
Instead VXEVHTXHQW HYDOXDWLRQ ZDV SHUIRUPHG XVLQJ WKH ¶ ǋP¶ DQG µ ǋP¶
microsphere sizes only.  In order to try to reduce the impact of the issues discussed 
above carboxymethyl cellulose (CMC) was considered as a viscosity modifier for use 
in the delivery of microspheres. 
)LJXUHV  DQG  VKRZ SKRWRJUDSKV RI VXVSHQVLRQV RI ¶ ǋP¶ DQG µ ǋP¶
microspheres in various concentrations of CMC at various intervals of time after they 
were homogenously suspended in those fluids.  CMC Concentrations higher than 1% 
(w/v) were not considered as they were found to be too viscous to be drawn up 
through the needle sizes under investigation.  Microsphere batches of both sizes were 
found to contain subpopulations which were porous enough to float in all suspension 
fluids.  This meant that they never reached a point at which all microspheres had 
VHWWOHG WR WKH ERWWRP RI WKH FRQWDLQHUV  7KH WLPHV WR µFRPSOHWH VHWWOLQJ¶ ZHUH
therefore considered to be the times beyond which no further change was observed 
(Table 3.2).  Increasing the concentration of CMC was found to result in large 
increases in the times to complete settling for both microsphere sizes. 
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Figure 3.22 ± 0LFURVSKHUH QXPEHUV UHVXOWLQJ IURP  ǋ/ HMHFWLRQV RI  ZY 
VXVSHQVLRQRIµǋP¶PLFURVSKHUHVHDUO\EDWFKHVVHH)LJXUHDWKURXJKD
G needle.  Counting performed using an improved Neubauer haemocytometer.  Error 
bars are one standard deviation.  Shown are five repeated ejections (A) and three 
series of WHQHMHFWLRQVSHUIRUPHGFRQVHFXWLYHO\IURPWRWDOYROXPHVRIǋ/%ZLWK
each series normalised to its own first ejection to allow direct comparison. 
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(A) Water 0.5% CMC 1% CMC 
0.5% CMC 1% CMC (B) 
(C) 1% CMC 
Figures 3.23 ± Representative images RI  ZY VXVSHQVLRQV RI µ ǋP¶
microspheres in various concentrations of CMC and at various times after they 
were homogenously suspended in those fluids ± 5 minutes (A), forty minutes (B) 
and 90 minutes (C). 
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Water 0.5% CMC 1% CMC (A) 
0.5% CMC 1% CMC (B) 
1% CMC (C) 
Figures 3.24 ± 5HSUHVHQWDWLYH LPDJHV RI  ZY VXVSHQVLRQV RI µ ǋP¶
microspheres in various concentrations of CMC and at various times after they 
were homogenously suspended in those fluids ± 5 minutes (A), 20 minutes (B), 
40 minutes (C) and 120 minutes (D). 
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Time to Complete Settling/ min 
CMC Concentration/ 
% (w/v) 
ǋP0LFURVSKHUHV ǋP0LFURVSKHUHV 
0 5 5 
0.5 40 20 
1.0 90 40 
 
 
  
Table 3.2 - Times taken for PLGA microspheres to completely settle out of 
suspension in various concentrations of CMC as assessed visually. 
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Following this various combinations of CMC concentration, microsphere suspension 
density and needle size were assessed for their ability to allow repeated drawing up 
and ejection of suspension (Tables 3.3 and 3.4).  For both microsphere sizes 
suspensions in water of up to 75% (w/v) could be drawn up and ejected with 
appropriate choice of needle size.  It was also found in all cases that increasing the 
concentration of CMC used in the suspension fluid resulted in a decrease in the 
maximum usable suspension density for a given needle size.  It also resulted in an 
increase in the minimum usable needle size. 
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Suspension Density/ % 
(w/v) 
[CMC]/ 
% (w/v) 
Needle Type 
Needle Inner 
DiameteUǋP 10 20 50 75 
0 P-i-N 340 9 9 9 8 
0 24G 310 9 9 9 9 
0 26G 260 9 9 9 9 
0 P-i-N 260 9 9 9 8 
0 30G 160 8 8 8 8 
0.5 P-i-N 340 9 9 8 8 
0.5 24G 310 9 9 9 8 
0.5 26G 260 9 9 8 8 
0.5 P-i-N 260 9 9 8 8 
0.5 30G 160 8 8 8 8 
1.0 P-i-N 340 9 9 8 8 
1.0 24G 310 9 9 8 8 
1.0 26G 260 8 8 8 8 
1.0 P-i-N 260 8 8 8 8 
1.0 30G 160 8 8 8 8 
 
 
Table 3.3 - Summary of feasibility (9) or unfeasibility (8) of repeatedly drawing 
XSDQGFRPSOHWHO\HMHFWLQJ¶ǋP¶3/*$PLFURVSKHUHVXVSHQVLRQWKURXJKYDULRXV
needle sizes at various suspension densities (i.e. various proportions of solid 
content).  Note that P-i-N denotes the use of a positive displacement, plunger-in-
needle syringe. 
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Suspension Density/ % 
(w/v) 
[CMC]/ 
% (w/v) 
Needle Type 
Needle Inner 
'LDPHWHUǋP 10 20 50 75 
0 20G 600 9 9 9 9 
0 22G 410 9 9 8 8 
0 P-i-N 340 9 8 8 8 
0 24G 310 9 8 8 8 
0 P-i-N 260 8 8 8 8 
0 26G 260 8 8 8 8 
0.5 20G 600 9 9 9 8 
0.5 22G 410 9 9 8 8 
0.5 P-i-N 340 9 8 8 8 
0.5 24G 310 8 8 8 8 
0.5 P-i-N 260 8 8 8 8 
0.5 26G 260 8 8 8 8 
1.0 20G 600 9 9 8 8 
1.0 22G 410 9 8 8 8 
1.0 P-i-N 340 9 8 8 8 
1.0 24G 310 8 8 8 8 
1.0 P-i-N 260 8 8 8 8 
1.0 26G 260 8 8 8 8 
 
 
Table 3.4 - Summary of feasibility (9) or unfeasibility (8) of repeatedly drawing 
XS DQG FRPSOHWHO\ HMHFWLQJ µ ǋP¶ 3/*$ PLFURVSKHUH VXVSHQVLRQ WKURXJK
various needle sizes at various suspension densities (i.e. various proportions of 
solid content).  Note that P-i-N denotes the use of a positive displacement, 
plunger-in-needle syringe. 
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Next a more comprehensive study of delivery consistency was undertaken.  The first 
step, as for the smallest microsphere size, was to assess whether different ejections 
resulted in microsphere populations with the same size distributions.  For both 
remaining microsphere sizes 5 ǋL volumes of suspension were ejected as series of 1 
ǋL volumes (n = 6).  In order to create sufficient obscuration to allow laser 
diffraction-based size analysis the ejections of the six series were combined prior to 
analysis.  For each microsphere size the analysis was performed using the smallest 
needle size through which suspension could be ejected and the maximum suspension 
density which was usable for this needle size.  Examination of the size distributions 
shown in Figures 3.25 and 3.26 show only very slight differences between those 
derived from different ejections within consecutive series.  Mean sizes for the five 
HMHFWLRQVRI¶ǋP¶PLFURVSKHUHVZHUHDQGǋm from first 
WR ODVWHMHFWLRQ 7KHHTXLYDOHQWYDOXHV IRU µ ǋP¶PLFURVSKHUHVZHUH
66.6, 78.9 and 77.1 ǋm.  As a result of these analyses, microsphere number was 
considered an appropriate surrogate measure for theoretical delivered protein load. 
The next analysis undertaken was to determine whether light blocking-based particle 
counting would provide an accurate means to determine the number of microspheres 
contained within ejection volumes.  A particle size and count standard (Count-Cal 
Particle Size Standard, catalogue no. CC70, Thermo Scientific, Loughborough, UK) 
was counted at various different nominal numbers and the coefficient of variance 
(the standard deviation as a proportion of the mean) derived at each point (n = 6, 
Figure 3.27).  This coefficient provided a lower limit to the level of ejection-to-
ejection variability that could reliably be measured.  For measured variabilities below 
this level the coefficient of variance for the standard was taken as an upper limit to 
the true variability instead.  In either case the larger of the two values was referred 
WRDVWKHµSURFHVVYDULDELOLW\¶ 
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Figure 3.25 ± Laser diffraction-derived size distributions resulting from series of 
ILYH FRQVHFXWLYH HMHFWLRQV RI  ǋO RI  ZY VXVSHQVLRQ RI µ ǋP¶
microspheres IURP D WRWDO YROXPH RI  ǋO SOXQJHU-in-QHHGOH V\ULQJH  ǋP
inner diameter needle).  Six series pooled for analysis to generate sufficient 
obscuration for accurate laser diffraction-based microsphere sizing. 
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Figure 3.26 ± Laser diffraction-derived size distributions resulting from series of 
ILYH FRQVHFXWLYH LQMHFWLRQV RI  ǋO RI  ZY VXVSHQVLRQ RI µ ǋP¶
PLFURVSKHUHV IURPD WRWDOYROXPHRIǋO PLFUROLWUHV\ULQJH*QHHGOH 6L[
series pooled for analysis to generate sufficient obscuration for accurate laser 
diffraction-based microsphere sizing. 
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Figure 3.27 ± Assessment of the reliability of light blocking as a method to count 
microspheres.  A 70 ǋm microsphere size and count standard was counted at a 
variety of nominal microsphere numbers (n = 6) and the coefficient of variance 
(the standard deviation as a proportion of the mean) of the counting process 
derived at all levels. 
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Figure 3.28 shows a comparison of the microsphere counts resulting from two sets of 
six series of six 1 ǋ/ UHSHDWHG HMHFWLRQV RI  ZY µ ǋP¶ PLFURVSKHUH
suspension through a 20 G needle.  One set of results utilised 0.5% and the other 
utilised 1% (w/v) CMC as the suspension fluid.  The stark difference between the two 
demonstrated the significant effect that an alteration in fluid viscosity could have on 
the consistency of delivery.  These results also demonstrated the ability of the light 
blocking-based counting technique to distinguish between consistent and inconsistent 
delivery conditions. 
Later results utilising microlitre and plunger-in-needle syringes for patterning of 
microspheres (see Section 3.3.5) demonstrated that these simple delivery systems 
were not capable of exerting control at the single microsphere level.  A more 
sophisticated system was pursued for the purpose of patterning (see Section 3.3.6) 
and therefore a full systematic screening study of syringe-based delivery conditions 
was not undertaken. 
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Figure 3.28 ± µǋP¶3/*$PLFURVSKHUHQXPEHUVDVPHDVXUHGE\OLJKWEORFNLQJ
for exemplar microinjection-based delivery conditions to illustrate the ability of the 
technique to distinguish between consistent and inconsistent delivery.  Six series 
RI VL[ UHSHDWHG HMHFWLRQV RI  ZY VXVSHQVLRQ  ǋ/ SHU HMHFWLRQ ZHUH
performed through a 20 G needle using either 0.5 or 1% (w/v) CMC as the 
VXVSHQVLRQ IOXLG  0HDQV DUH SORWWHG ZLWK HUURU EDUV VKRZLQJ WKH µSURFHVV
YDULDELOLW\¶ 
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3.3.5 Patterning of Microspheres via Manual Microinjection & 
Micromanipulation 
Initial patterning attempts were made using microlitre and plunger-in-needle syringes 
in conjunction with a manual micromanipulator.  Sub-microlitre volumes of 
microsphere suspension were delivered into 0.75% (w/v) agar as a simple-to-
produce, readily-available model hydrogel.  Microspheres were fluorescently-labelled 
with acridine orange to allow for successful visualisation.  Volumes as low as 0.1 ǋL 
could be delivered and these volumes could be separated by as little as 750 ǋm 
whilst still remaining distinct. 
Figures 3.29 and 3.30 show representative fluorescence microscopy images of grids 
formed from multiple consecutive sub-PLFUROLWUHGHOLYHULHVRIVXVSHQVLRQVRI¶ǋP¶
DQG µ ǋP¶ PLFURVSKHUHV UHVSHFWLYHO\  $V FDQ EH VHHQ Ln these images it was 
found that the number of microspheres contained within each injection site and the 
shape and size of the injection sites varied widely.  Additionally, and particularly for 
¶ǋP¶PLFURVSKHUHV WKHQXPEHUVRIPLFURVSKHUHV LQHDFKVLWHwere still relatively 
large even at the smallest deliverable volumes.  Although the grids appeared regular 
it was found that the separations between individual sites of delivery could vary by as 
much as 100 ǋm either side of the nominal spacing.  As a result of these 
observations patterning with this MM system was not pursued further.  
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Figure 3.29 - 5HSUHVHQWDWLYH IOXRUHVFHQFH PLFURVFRSH LPDJH VKRZLQJ  ǋO
YROXPHV RI  ZY VXVSHQVLRQ RI µǋP¶ IOXRUHVFHQW 3/*$PLFURVSKHUes in 
1% (w/v) CMC delivered into 0.75% (w/v) agar gel at nominal spacings of 1 mm 
using a manual micromanipulator in conjunction with a plunger-in-needle 
microlitre syringe. 
1 mm 
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Figure 3.30 - 5HSUHVHQWDWLYH LPDJH VKRZLQJ  ǋO YROXPHV RI  ZY
susSHQVLRQ RI µ ǋP¶ IOXRUHVFHQW 3/*$ PLFURVSKHUHV LQ  ZY &0&
delivered into 0.75% (w/v) agar gel at nominal spacings of 1 mm using a manual 
micromanipulator in conjunction with a plunger-in-needle microlitre syringe. 
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3.3.6 Patterning of Microspheres via Semi-Automated Microinjection & 
Micromanipulation 
To overcome the limitations of the fully manual MM system utilised above a manual 
microinjector was used in conjunction with programmable micromanipulators to 
pattern microspheres individually into cooling/setting agarose.  The exemplar images 
VKRZQLQ)LJXUHGHPRQVWUDWHWKDWSDWWHUQLQJRILQGLYLGXDOµǋP¶PLFURVSKHUHV
was achieved on length scales as small as around 100 ǋm. 
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Figure 3.31 - Representative imDJHV VKRZLQJ µ ǋP¶ 3/*$ PLFURVSKHUHV
positioned individually into 1% (w/v) agarose hydrogel using a manual 
microinjector in conjunction with a semi-automated, programmable 
micromanipulator. 
100 ǋm 
100 ǋm 
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3.4 Discussion 
3.4.1 Generating Protocols for the Production of Three Sizes of Microspheres 
Double emulsion microsphere fabrication protocols were generated which were 
capable of producing PLGA microspheres with three different mean sizes ± around 2, 
around 15 and around 100 ǋm.  This fulfilled the criterion outlined in Section 3.1.5 
that the protocols should be able to produce microspheres with mean sizes covering 
around two orders of magnitude.  Furthermore the three size distributions showed 
distinct separation with little or no overlap as determined by laser diffraction-based 
size analysis.  The availability of these microspheres of distinct sizes should allow for 
the generation of distinct release profiles to tailor the presentation of any given 
protein to match its natural expression pattern in the biological process to be 
replicated. 
A range of homogenisation speeds were tested in conjunction with a 20% (w/v) 
PLGA concentration in the oil phase for the production of microspheres with mean 
VL]HV RI DURXQG  ǋP  6XEVHTXHQWO\ D UDQJH RI SRO\PHU FRQFHQWUDWLRQV ZHUH
evaluated for use with the maximum 9000 rpm speed of the high speed homogeniser 
to generate microspheres with means around one and two orders of magnitude 
lower.  The resulting mean sizes and the final conditions for manufacture are shown 
in Table 3.5. 
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µǋP
µMicrospheres 
µ15 ǋPµ
Microspheres 
µ100 ǋP¶
Microspheres 
Actual Mean 
Microsphere Size/ 
ǋP 
2.02 13.6 84.4 
Polymer 
Concentration/ % 
(w/v) 
2 17 20 
Primary 
Homogenisation 
Speed/ rpm 
9000 9000 2000 
Internal Aqueous 
9ROXPHǋO 1000 118 100 
Beaker Size/ ml 100 25 25 
Secondary 
Homogenisation 
Speed/ rpm 
9000 9000 2000 
External Aqueous 
Volume/ ml 
500 200 200 
Beaker Size/ ml 600 250 250 
Table 3.5 ± Optimised production conditions for three different sizes of 
microsphere using double emulsion manufacture with external aqueous phases 
consisting of 0.3% (w/v) PVA and overnight stirring at 300 rpm for microsphere 
hardening. 
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7KHPHDQVL]HVKRZQLQ7DEOHIRU µǋP¶PLFURVSKHUHV LVGHULYHG IURPWKHILUVW
three batches produced which showed single-peaked size distributions and only 4% 
variation in mean.  However subsequent batches showed multiple peaks per size 
distribution indicating high degrees of oil droplet aggregation in the secondary 
emulsion prior to microsphere hardening.  Additionally, very high batch-to-batch 
variation showed that this process was not sufficiently robust. 
All nine batches of this smallest microsphere size showed a main peak around 2 ǋm 
and there are a number of examples in the literature of the use of double emulsion 
techniques to produce microspheres of this size and smaller329,345-349.  Many of these 
protocols utilise sonication for at least one emulsification step in the place of 
homogenisation.  It may be that the high speed homogenisers used here do not 
produce a powerful enough emulsification effect to act on the whole of the relatively 
large volumes of liquid involved in small microsphere manufacture.  If this is the case 
then it is likely to also be true that the stirring used during microsphere hardening 
was insufficient to ensure maintenance of separation of the original oil droplets.  A 
reduction in the total batch mass may therefore help to overcome the problems 
experienced producing microspheres of around 2 ǋm mean size. 
)RU¶ǋP¶DQGµǋP¶PLFURVSKHUHVDOOVL]HGLVWUibutions were single-peaked and 
the distributions from multiple batches showed good visual overlap.  The coefficients 
of variance for the mean sizes of these two types of microspheres were found to be 
9.3 and 18.5% respectively.  It is difficult to give these figures a proper context since 
the issue of batch-to-batch variability is rarely explicitly addressed in published 
studies.  However significant batch-to-batch behavioural differences were not seen in 
the work presented in this thesis.  In other words different batches of microspheres 
prepared using the same conditions showed very similar flow behaviour and protein 
release. 
SEM imaging of both sizes of microspheres confirmed the size distributions seen by 
laser diffraction and showed them to be predominantly spherical with surfaces which 
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were smooth and almost completely lacking in pores.  This surface smoothness 
suggests that the microparticles should have a relatively low burst release for their 
size
350-352
, which is highly desirable in most protein release applications. 
3.4.2 Production of Fluorescent Microspheres 
7RDWWHPSW WRSURGXFH IOXRUHVFHQW µ ǋP¶PLFURVSKHUHVZKLFKFRXOGEHVXFFHVVIXOO\
imaged once delivered into tissue engineering scaffolds, the encapsulation of acridine 
orange via the double emulsion process was evaluated.  However significant 
aggregation was evidenced by the multi-peaked nature of the size distributions, 
which extended to sizes of up tR DURXQG  ǋP  7R HQVXUH WKDW IOXRUHVFHQW
microspheres could be used as accurate models for non-fluorescent microspheres in 
patterning studies it was important that their size distributions closely matched.  As a 
result none of the attempts undertaken could be considered successful.  Since the 
concentration of fluorophore used did not seem to affect the degree of aggregation 
seen in the microsphere production process, this approach was not pursued further. 
Encapsulation of fluorescein via a single emulsion technique was also evaluated but 
this tended to result in a greater degree of aggregation than was seen with double 
emulsion-based labelling.  As with acridine orange labelling the amount of 
fluorophore used did not appear to affect the degree of aggregation.  As a result this 
approach was also discontinued.  Due to the problems encountered with consistent 
SURGXFWLRQRIµǋP¶PLFURVSKHUHVIOXRUHVFHQWRURWKHUZLVHWKHHIIHFWLYHODEHOOLQJRI
this size of microsphere was no longer considered a priority. 
FOXRUHVFHQWYHUVLRQVRIWKHODUJHUWZRVL]HVRIPLFURSDUWLFOHVµǋP¶DQGµǋP¶
were successfully produced via double emulsion by utilisation of 0.1 mg mL-1 acridine 
orange as the inner aqueous phase.  Mean sizes of these two populations of 
fluorescent microspheres closely reflected those of the blank versions (14.4 and 91.0 
ǋm for fluorescent versions as compared to 13.6 and 84.4 ǋm for blank).  Batch-to-
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batch variabilities in both cases were low (4.9 and 9.1% coefficients of variance 
respectively) with good visual overlap of size distributions.  In both cases the addition 
of fluorophore actually appeared to reduce batch-to-batch variation, but the 
statistical significance of this result could not be assessed.  SEM imaging was 
performed on batches of both sizes and confirmed the size distributions seen via 
laser diffraction.  It also showed the spherical nature and almost entirely smooth and 
non-porous surfaces of the microspheres to have been maintained upon addition of 
the fluorophore. 
3.4.3 Effect of Triblock Incorporation on Protein Release Rate from 
Microspheres 
It was found that increasing the proportion of Triblock in the polymer mix used for 
microsphere manufacture led to more rapid release of encapsulated protein.  This 
trend was particularly clear once the first 24 hours of release (the burst release) was 
discounted.  Since a very large burst release of protein is often highly undesirable or 
even detrimental biologically, it is envisaged that many clinical applications of these 
microspheres would involve a pre-washing and incubation step designed to avoid the 
burst release protein being administered.  As a result the burst-subtracted release 
curves seen in Figure 3.20 (b) may actually be the more clinically-relevant. 
Previous work involving the addition of hydrophilic release modifiers to PLGA 
(microparticulate) scaffolds has shown similar trends of increasing rate of protein 
release with increasing hydrophilic content308,353-355.  As stated earlier it is believed 
that this acceleration is due to the encouragement of greater water ingress into the 
polymer matrix.  This results in more rapid diffusion of protein through the matrix as 
well as more rapid polymer degradation.  For instance, it has been explicitly 
demonstrated that a PLGA-PEG-PLGA copolymer exhibited greater water uptake than 
plain PLGA356.  In the work presented here a 30% (w/w) Triblock level led to 
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particularly accelerated release and a fundamentally-altered release profile which 
lacked the lag phase of a normal tri-phasic PLGA release profile.  This result has also 
been demonstrated using pure PLGA-PEG-PLGA copolymer microspheres353, 
suggesting that there is some critical threshold above which protein release occurs in 
a single phase.  This switch to a single phase profile is expected to be accompanied 
by a change to a release mechanism which is mediated only by diffusion and not by 
polymer degradation. 
It is well-established in the literature that variation of microsphere size can have a 
dramatic effect on the release rate of proteins encapsulated therein294,343,346.  
Together with the Triblock-based manipulation discussed above this means that the 
suite of protocols developed here should allow the development of complex 
controlled release formulations for the independent delivery of multiple proteins. 
3.4.4 Consistency of Delivery of Microspheres via Microlitre and Plunger-in-
Needle Syringes 
A major aim of the work undertaken in this chapter was to establish whether 
microlitre and plunger-in-needle syringes were viable delivery systems for PLGA 
microspheres.  It was found that with appropriate choice of needle size suspensions 
as dense as 75% (w/v) in water could be repeatedly drawn up and ejected from 
WKHVHV\ULQJHV7KHPLQLPXPQHHGOHLQQHUGLDPHWHUVZKLFKFRXOGEHXVHGZLWK¶
ǋP¶ DQG µ ǋP¶ PLFURVSKHUHV ZHUH IRXQG WR EH  DQG  ǋm respectively.  
These sizes were important as they provided a lower limit to the separation between 
injection sites which could be used for later patterning studies and thus the maximum 
patterning resolution which could theoretically be achieved. 
Another key consideration was the ability of these syringes to eject microsphere 
suspension in a way which would result in the delivery of a consistent mass of 
encapsulated protein.  Under challenging conditions the microsphere size 
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distributions resulting from different ejections were found to be consistent with one 
another for both microsphere sizes.  Under the assumption that microspheres had 
uniform density and that the mass of a microsphere determined its encapsulated 
protein load this meant that the number of microspheres in an ejection was a valid 
surrogate measure of the protein load. 
Initial studies using haemocytometer-based microsphere counting demonstrated that 
consecutive ejections could contain highly variable microsphere numbers when using 
water as the suspension fluid.  It was postulated that the low viscosity of the fluid 
may have led to rapid settling out of microspheres from suspension and/or 
preferential ejection of suspension fluid in early ejections.  CMC was assessed as a 
viscosity modifier for improving consistency of delivery.  It was found that the 
addition of 1% (w/v) CMC to suspension fluids could increase the time taken for 
microspheres to settle out of suspension by almost two orders of magnitude.  The 
downside to CMC addition was that it lowered the maximum suspension density of 
microspheres which could be used in conjunction with a given needle size.  It also 
increased the minimum needle size which could be used with each size of 
microsphere, thus decreasing any potential future patterning resolution. 
Based on repeated measurements of a count standard light blocking-based particle 
counting was found to be an effective method to quantify microspheres in sub-
microlitre ejection volumes.  Across the entire range studied coefficients of variance 
were found to be below 10%, with some as low as 3%.  This suggested that 
relatively small variabilities in ejected microsphere numbers could be reliably 
detected, though this ability was less effective at very low numbers. 
The utilisation of this technique allowed differentiation between delivery conditions 
which resulted in consistent microsphere numbers and those which did not.  Early 
results demonstrated that ensuring consistent delivery was more complex than simply 
increasing the viscosity of the suspension fluid.  In some cases increasing the 
viscosity by increasing the concentration of CMC led to increased variability.  
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Systematic assessment and optimisation of consistency was not conducted at this 
stage since delivery via microlitre and plunger-in-needle syringes was not found to be 
an effective route to fine-scale patterning.  These syringes may however provide a 
suitable route of delivery for microspheres into single precise tissue locations as part 
of tissue engineering therapies.  For these applications optimisation would be 
required for the specific microsphere population to be used.  The size distribution of 
the population would be expected to be the dominant factor in defining its flow 
properties. 
3.4.5 Patterning of Microspheres via Microinjection and Micromanipulation 
Initial studies examined the ability of a manual micromanipulator in conjunction with 
microlitre and plunger-in-needle syringes to pattern fluorescently-labelled 
microspheres within 0.75% (w/v) agar as a model hydrogel.  Test grids produced by 
multiple consecutive injections of microsphere suspension were visually regular in 
terms of their spacings.  However quantitative assessment of the spacings showed 
that they were subject to deviations of up to 100 ǋm from that which was intended.  
The morphology and size of individual delivery sites were found to vary widely, along 
with the number of microspheres contained within them. 
To resolve these issues a more sophisticated, semi-automated MM system was 
utilised which consisted of a manual microinjector combined with two programmable 
PLFURPDQLSXODWRUV  7KLV VHWXS DOORZHG µ ǋP¶ PLFrospheres to be individually 
positioned into cooling and setting agarose solutions with separations as low as 
around 100 ǋm.  This technique has excellent potential utility for the creation of fine-
scale complex protein environments such as interacting gradients.  However it was 
found to be strongly dependent on operator skill level due to the need for delicate 
corrections to microsphere motions caused by fluid flows created during injections.  
This dependence could be alleviated to an extent if the technique could be refined to 
allow microspheres to be delivered dry.  This may involve them being held on the 
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end of very narrow bore glass needles in the fashion of holding pipettes for 
intracytoplasmic sperm injection357. 
The relatively short times taken for agarose solutions to cool and set limited the 
number of microspheres which could be included in patterns.  In order to create 
larger patterns it may be necessary to consider alternative patterning protocols in 
future studies.  For instance, microspheres could be suspended in warm agarose and 
then transferred individually onto a patterning substrate in small volumes of solution 
which would set to secure the microspheres in place.  Once the pattern was 
SURGXFHGWKHK\GURJHO µLVODQGV¶FRXOGEHO\RSKLOLVHGDQGWKHSDWWHUQHGPLFURVSKHUHV
stored for future use.  Additionally and subsequently bulk hydrogels could be formed 
around the patterns with or without encapsulated cells, or indeed cells could be 
cultured on the original patterning substrate.  This protocol was developed during 
unpublished work conducted by Dr. Glen Kirkham at the University of Nottingham. 
Another limitation of this patterning approach is that agarose is known to be a poor 
substrate for in vitro cell growth due to its low capacity for cell adhesion358,359.  An 
adaptation of a previously-published protocol was used to modify the agarose used 
here via conjugation with gelatin in order to improve its cell compatibility (see 
Appendix).  Although further work remains to fully optimise this protocol and 
characterise the cell response to the resulting materials, they show promise as 
potential in vitro cell culture substrates. 
The studies outlined in this chapter demonstrate that MM techniques can be used to 
individually pattern PLGA microspheres with high resolution.  They can be patterned 
into hydrogel environments which can be rendered conducive to cell proliferation.  
This patterning is intended to allow the creation of complex protein signal 
environments which may replicate those seen in normal and perturbed 
developmental and repair processes.  These environments could then be used to 
study fundamental cell biology and to evaluate potential tissue engineering therapies 
in vitro. 
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The final steps in the development of MM techniques to this end are to demonstrate 
that the microsphere patterns created are converted into the expected protein signal 
patterns and that these are then translated into patterns of cellular behaviour.  
Proteins released from patterned microspheres in cell-free conditions would be 
expected to form gradients and other heterogeneous distributions only transiently.  It 
is believed that the presence of cells to act as a sink for the diffusing protein could 
stabilise these heterogeneous distributions for long enough to allow them to exert a 
biological effect.  Demonstrating and quantifying both stabilisation and biological 
efficacy will be a key step in the development of MM patterning techniques. 
It should also be noted that the patterning presented thus far is conducted in two 
dimensions for ease and effectiveness of imaging and assessment.  However the 
micromanipulators used in these studies function equally effectively in each of the 
three spatial dimensions.  The extension of patterning into the third dimension is 
therefore predominantly a practical and logistical challenge and mainly concerns the 
development of a patterning protocol allowing real-time positioning and visualisation 
across multiple focal planes. 
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4. Generation of Hydrogels from the Extracellular 
Matrix of Bovine Bone 
4.1 Introduction 
4.1.1 The Extracellular Matrix 
The extracellular matrix (ECM) surrounds the cells in every tissue in the body and is a 
complex mix of proteins, glycosaminoglycans (GAGs) and proteoglycans (PGs) which 
is vital to effective tissue function360-362.  Collagen in its many forms is the most 
abundant protein in the ECM363 but others which are common to many tissues include 
fibronectin364, laminin365 and elastin366.  GAGs are nitrogen-containing polysaccharides 
which bind as side-chains to core proteins to form PGs367.  PGs commonly found in 
the human body include aggrecan368, fibromodulin369, decorin370, biglycan370,371, 
perlecan372 and versican370,373. 
Perhaps the most basic function of the ECM is to provide overall structure to tissues 
and therefore to control and define their mechanical properties.  In connective 
tissues such as tendons and ligaments fibrillar proteins including collagen and elastin 
provide resistance to tensile loading374-376.  In contrast in tissues such as articular 
cartilage the high PG content ensures the maintenance of adequate tissue hydration 
for the even distribution of compressive load368,377. 
Another major function of the ECM is to provide anchorage for the cell types 
constituting each tissue in the complex arrangements which are necessary for correct 
function.  In this regard the ECM may be divided into the interstitial matrices which 
surrounds the cells in mesenchymal tissues and the basement membranes (BMs) on 
which various epithelial and endothelial cell layers sit.  BMs have specialised 
structures in which collagen, fibrillin and laminin are important constituent 
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proteins365,378.  Across both types of matrix much of the adhesion of cells to the ECM 
is mediated through the binding of integrins on the cell surface to arginine-glycine-
aspartic acid (RGD) peptide sequences379-382.  These are particularly common in 
fibronectin383 but are also found in other major ECM proteins384-386. 
It had been thought that the function of the fibrillar proteins of the ECM was 
restricted to those purposes discussed thus far i.e. providing mechanical strength and 
supporting the growth of adherent cells.  However it has subsequently been found 
WKDW WKHVH µVWUXFWXUDO¶ SURWHLQV FDQ KDYH ELRORJLFDO IXQFWLRQDOLW\ DQG FDQ DIIHFW FHOO
phenotype361,387,388 7KLVFUHDWHVDµG\QDPLFUHFLSURFLW\¶EHWZHHQDFHOODQG LWV ORFDO
ECM microenvironment in that cells can modulate their local matrix and vice versa.  
This process is further enhanced by the ability of GAGs in the matrix (especially 
heparin) to bind growth factors and other important signalling proteins389.  In this 
way signals can either be sequestered locally to protect them from degradation 
and/or more efficiently presented to cell surface receptors. 
4.1.2 Decellularised ECM as a Biomaterial 
The ultimate aim of any treatment developed in tissue engineering is to recreate the 
native architecture and function of the tissue being repaired or replaced390.  Much 
effort has gone into achieving this aim through the development and modification of 
synthetic biomaterials to reproduce some or all of the functions of the ECM391-393.  
However an alternative route has also been taken in which the native ECM is itself 
used as a biomaterial394,395.  With appropriate preparation ECM-derived materials can 
recapitulate the functions of the native ECM more completely than can stepwise-
modified synthetic materials. 
The first requirement for any biomaterial prepared from ECM is that it should be 
decellularised to ensure the removal of any material which may provoke immune 
response on implantation396.  Decellularisation may be achieved via a number of 
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approaches397,398 including the use of ionic399-402 or non-ionic detergents401-404, 
enzymatic treatments404-406, acid treatment407-409, induction of osmotic shock and 
lysis410,411, application of high hydrostatic pressures412-414 or combinations 
thereof405,415-422.  These different approaches have relative advantages and 
disadvantages but they all inevitably cause some alteration to both the structure and 
biological functionality of the matrices on which they are utilised.  The aim of any 
optimised decellularisation protocol is to minimise these alterations whilst still 
removing cellular and genetic material to an acceptable extent.  The approach taken 
to achieve this aim will depend on the biochemical composition, density and 
cellularity of the tissue to be processed. 
ECM materials have been extracted from several species and from a wide range of 
different tissues399-401,403,405,407,409-414,416-420,423-438.  Since ECMs derived from different 
tissues will often be composed of similar constituents it may be supposed that a 
VLQJOH WLVVXH FRXOG SURYLGH D µRQH VL]H ILWV DOO¶ (&0 PDWHULDO IRU XQLYHUVDO XVH
However recent results in the literature have shown tissue-specificity of the beneficial 
effects exerted by decellularised ECM materials420,425,439,440.  As a result ensuring the 
ability to successfully decellularise a wide range of tissues remains a priority if ECM-
derived scaffolds are to be broadly clinically-applicable. 
The results of in vivo pre-clinical studies utilising a number of these materials 
demonstrate their potential as therapies for the repair of tissue 
defects408,409,411,417,423,426,430,436,441,442.  The implantation of ECM scaffold materials is 
typically associated with an early inflammatory response which is indicative of 
constructive remodelling396,443-445.  Following this the scaffolds are typically resorbed 
within 3 months of implantation and completely replaced by new host tissue411,442,446-
448.  The precise mechanisms involved in this remodelling process are yet to be fully 
understood.  However the positive results obtained with these materials in pre-clinical 
studies have led to the launch of a number of products which have been successfully 
utilised in the clinic432,449. 
Chapter 4 ± Generation of ECM Hydrogels 
137 
 
Despite the successes achieved with ECM-derived scaffold materials in (pre-)clinical 
tissue engineering there has been little attempt to generate criteria for defining a 
material as decellularised.  A recent publication set three such criteria which were the 
absence of visible nuclei in appropriately-stained histological sections, a residual 
double-stranded DNA (dsDNA) level of less than 50 ng per mg of dry material and an 
absence of DNA fragments of more than 200 base pairs in length450.  However it is 
not clear what the scientific basis is for these particular figures and few of the 
materials used successfully in the studies referred to above had been explicitly 
assessed against these criteria. 
A recent development in the use of ECM scaffold materials has been the conversion 
of sheets and powders into hydrogels.  This has typically been achieved by the use of 
pepsin to digest and solubilise the materials, resulting in solutions which can be 
induced to form hydrogels by altering the pH and/or temperature to normal 
physiological levels421,439,451-457.  Homogenisation in high salt buffers has also been 
used and this too results in solutions which can be induced to gel by changes in pH 
or temperature458-461.  These hydrogels have been shown to be favourable in vitro 
culture environments for cells isolated from the tissues from which the gels are 
derived421,439,452,455,458,459. 
Pre-gel ECM-derived solutions constitute truly injectable scaffolds and are potentially 
compatible with a range of construct production and processing technologies 
including bioplotting (see Section 1.2.6).  It has been shown that when ECM scaffold 
materials are enzymatically degraded this results in the production of peptide 
fragments which can exhibit strong chemotactic and anti-microbial effects429,454,462-465.  
When these materials are implanted as sheets or powders then these bioactive 
peptides are not available immediately upon implantation, leading to delays in 
progenitor cell recruitment and bacterial infection suppression.  However hydrogels 
composed of peptide fragments produced by enzymatic digestion of decellularised 
ECM may exert these effects with only a minimal delay. 
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4.1.3 Bone Grafting and Demineralised Bone Matrix 
For the treatment of volumetric tissue loss in bone autograft is still considered the 
gold standard treatment since it provides patient-specific cells and matrix to achieve 
optimal repair466-468.  Nevertheless issues of donor site morbidity and lack of sufficient 
tissue availability have led to the desire for alternative treatments.  In this regard 
terminally-sterilised cadaveric allograft has found extensive use in orthopaedic 
surgery468,469.  However the mineralised nature of bone ECM results in sub-optimal 
availability of osteoinductive constituents which may limit the rate and extent of new 
bone formation470,471. 
To this end protocols have been developed to produce demineralised forms of 
allograft bone, known as demineralised bone matrix (DBM)472,473.  DBM is typically 
produced by acid demineralisation and organic solvent treatment for lipid 
extraction470,474-476.  Some studies have shown DBM formulations to be osteoinductive 
in vitro and potentially able to match the performance of autograft and/or allograft476-
480.  These positive in vitro results can be attributed at least in part to the retention of 
both osteogenic and angiogenic growth factors within DBM materials481-484. 
Some in vivo studies utilising DBM materials have shown them to have comparable or 
superior performance to autograft and/or allograft in ectopic implantation476, bone 
repair485-487 and spinal fusion481,488,489.  However not all studies show consistently 
beneficial effects474,490-492 and the efficacy of DBM formulations appears to be more 
variable in vivo than in vitro484,493.  Despite this a large number of DBM products are 
in current clinical use473. 
There are a number of suggested reasons why clinical results with DBM may be so 
variable including issues of batch-to-batch, process and donor 
variability473,479,483,484,494,495 and also the sterilisation method used472.  The preferred 
form of DBM for use in surgery is one in which the powder is suspended in a viscous 
liquid carrier to form a putty or paste which can be injected or moulded to fill cavities 
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and defects477,492,495-497.  The carriers used in these formulations have been suggested 
as another source of variation in outcome492,495,498,499.  Indeed significant 
nephrotoxicity has been demonstrated in rat models for one commonly-used carrier 
(glycerol)499,500. 
If DBM could be processed into a form which was capable of gelation then this would 
mean that it could be delivered minimally-invasively via injection.  Additionally it 
could be used to localise cells and exogenous growth factors to the defect site.  This 
material could also be used as a carrier for DBM powder in load-bearing areas where 
the gel alone may not be mechanically competent.  This carrier may have reduced 
toxicity as well as additional bioactivity relative to those currently utilised.  The 
generation of ECM-derived hydrogels has not yet been demonstrated in bone, 
perhaps due to concerns that the harsh processing used to demineralise the tissue 
may cause damage to the protein structure which would inhibit the ability of the 
material to undergo gelation. 
4.1.4 Aims & Objectives 
The overall aim of the work presented in this chapter is to generate hydrogels from 
the ECM of bovine bone.  These materials would have the direct clinical utility 
discussed above but in addition they would have the potential to be formed into 
microparticles for microinjection-based patterning (see Chapter 3) and to be used for 
bioplotting-based construct patterning (see Chapter 5).  An additional aim is to 
address the question of whether demineralisation alone is truly sufficient to 
adequately decellularise bone. 
More specific objectives include the demonstration of complete demineralisation and 
the assessment of the extent of decellularisation in both DBM and decellularised DBM 
(referred to as DECM).  Enzymatic digestion will be used to solubilise both DBM and 
DECM and the ability of these materials to gel will be assessed along with their 
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gelation kinetics.  The gel structures, mechanical properties and cell compatibilities in 
vitro will also be evaluated. 
The final objective of this work is to demonstrate that the ECM-derived materials can 
be formed into gel particles or beads.  This would allow exogenous growth factors 
and other proteins to be incorporated into the beads and potentially released at a 
cell-mediated rate. 
4.2 Materials and Methods 
4.2.1 Demineralisation of Bovine Bone 
See Section 2.11. 
4.2.2 Decellularisation of Demineralised Bone Matrix 
See Section 2.12. 
4.2.3 Micro-Computed Tomography (ǋCT) Imaging 
See Section 2.16. 
4.2.4 Haemotoxylin and Eosin (H & E) Staining of Demineralised and 
Decellularised Bovine Bone 
See Section 2.14. 
4.2.5 Purification & Extraction Protocol for Pico Green Assay to Quantify DNA 
See Section 2.15. 
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4.2.6 Hydroxyproline Assay for Collagen Quantification 
See Section 2.17. 
4.2.7 Hydrogel Formation from Demineralised and Decellularised Bovine Bone 
See Section 2.13. 
4.2.8 Spectrophotometric Analysis of Gelation Kinetics 
See Section 2.18. 
4.2.9 Rheological Analysis of Hydrogel Gelation and Mechanical Properties 
See Section 2.19. 
4.2.10 Scanning Electron Microscopy (SEM) Imaging 
See Section 2.6 for general methodology.  Imaging was performed using a Philips 
XL30 electron microscope and three samples were imaged for each condition 
examined. 
4.2.11 Assessment of Cell Proliferation on ECM-Derived Hydrogels 
Collagen, DBM and DECM pre-gel solutions at 3 and 6 mg mL-1 were plated into 96-
well plates (100 ǋL per well, n = 12) and allowed to gel for one hour at 37oC.  After 
this, human osteosarcoma (hOS) or murine primary calvarial (mPC) cells were added 
to each well in 100 ǋL of their respective media at a variety of seeding densities (5 ± 
20,000 cells per well).  At each of 48 and 72 hours post-seeding, six wells were 
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assessed for cellular proliferation with respect to unseeded gel controls and in 
comparison with tissue culture plastic (TCP).  Assessment of proliferation was via the 
MTS assay (see Section 2.25). 
4.2.12 Bead Formation from Alginate and ECM-Derived Hydrogels 
See Section 2.20. 
4.3 Results 
4.3.1 Demineralisation and Decellularisation of Bovine Bone 
As stated earlier the first aim of the work presented in this chapter was to 
demonstrate effective demineralisation of bovine bone.  A subsequent step was to 
assess whether a decellularisation step was necessary post-demineralisation to 
ensure adequate removal of cellular material.  The approach used to address these 
aims was developed by Dr. Lisa White, William Bowen, Paramjeet Dhadda and 
Hareklea Markides at the University of Nottingham based on previously-published 
protocols406,470,501.  Full details are in Sections 2.8 & 2.9 but in brief ± milled bovine 
bone was soaked in 0.5 M HCl for 5, 18 or 24 hours and this was followed by lipid 
extraction in chloroform/methanol.  After this came an optional 24 hour 
decellularisation step in trypsin/EDTA and finally lyophilisation for 48 hours.  The 
appearance of the bone-derived material at each stage can be seen in Figure 4.1.  It 
was found that only a 24 hour acid soak was sufficient to completely demineralise the 
bone tissue as assessed by ǋCT imaging (Figure 4.2).  This time span was used for 
all future production of both DBM and DECM. 
 
 
  
 
 
Figure 4.1 ± Representative images showing the appearance of bovine bone-derived materials at various stages of processing.  Left-to-right ± bone chips 
resulting from milling of cancellous bone (A), bone chips after demineralisation (B), hydrated DBM matrix post-lipid extraction (C), powder resulting from 
freeze drying of lipid extracted material with (DECM) or without (DBM) decellularisation step (D), pepsin-digested DBM/DECM-derived solution (E) and 
hydrogel formed from pepsin-digested material (F). 
(A) (B) (C) (D) (E) (F) 
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The next step was to assess the extent of decellularisation in both DBM and DECM, in 
order to deduce whether the enzymatic decellularisation step was necessary to 
sufficiently reduce cellular content.  Imaging of H & E stained histological sections 
showed that DBM contained intact cell nuclei whilst DECM contained no visible 
nuclear material (Figure 4.3).  Quantification of the dsDNA content of the materials 
was undertaken using the PicoGreen® assay.  Results showed that both materials had 
residual dsDNA levels which were significantly below the 50 ng per mg dry material 
which has been quoted in the literature as a criterion for effective decellularisation450 
(Figure 4.4).  Furthermore there was no statistically-significant difference between 
the dsDNA contents of the two materials when normalised to mass (1.96 ng mg-1 for 
DBM, 2.35 ng mg-1 for DECM).  However when the change in material mass pre- to 
post-decellularisation was taken into account it was found that approximately 40% of 
the total dsDNA content of DBM was removed by trypsin/EDTA treatment. 
The final characterisation technique performed on the DBM and DECM materials was 
the hydroxyproline assay for quantification of collagen.  The collagen contents of the 
two materials were found to be 93 and 92% by weight for DBM and DECM 
respectively (Figure 4.5).  There was no statistically-significant difference between 
these results and so based on this parameter at least it seems that the trypsin/EDTA 
decellularisation step may not significantly alter the biochemical composition of the 
material. 
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Figure 4.2 ± Representative transmission images from ǋCT analysis of milled bone 
chips (left) and DBM (right) to show qualitative loss of mineral (dark grey/black) 
during processing.  Images provided by Dr. Lisa White, Paramjeet Dhadda and 
Hareklea Markides. 
  
 
 
A B 
Figure 4.3 ± Representative bright field microscopy images of sections of DBM (A) and DECM (B) stained with haemotoxylin to show cell nuclei in 
blue/black and counterstained with eosin to show matrix constituents.  Insets show high magnification images and scale bars are 100 ǋm.  Images 
provided by Dr. Lisa White, Paramjeet Dhadda and Hareklea Markides. 
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Figure 4.4 ± Quantification of dsDNA for DBM and DECM via 
phenol/chloroform/isoamyl alcohol extraction and the PicoGreen® assay.  Also 
shown is a widely-used criterion for consideration of a material as successfully 
decellularised (50 ng dsDNA per mg dry material).  The inset graph shows more 
closely the values obtained for DBM and DECM.  Error bars show one standard 
deviation for three samples, each of which was assayed in triplicate. 
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Figure 4.5 ± Quantification of the collagen content (fraction of dry weight) of DBM 
and DECM powders via quantification of the non-proteinogenic amino acid 
hydroxyproline.  Error bars are one standard error resulting from assaying four 
samples of each material in triplicate. 
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4.3.2 Generation of Hydrogels from Demineralised and Decellularised Bovine 
Bone 
Both DBM and DECM could be successfully solubilised by room temperature 
incubation with pepsin at low pH, resulting in viscous cloudy liquids.  These liquids 
could be induced to form hydrogels by neutralisation and incubation at 37oC (see 
Figure 4.1 for appearance of the materials before and after gelation). 
Spectrophotometric analysis was used to assess the gelation kinetics of DBM and 
DECM-derived materials using collagen as a comparator since this was the major 
constituent of the pre-digestion ECM-derived powders.  Figure 4.6 (a) shows that 
DBM-derived hydrogels display very similar optical properties to collagen, whilst 
DECM-derived hydrogels are significantly more opaque.  Figure 4.6 (b) shows the 
normalised results of this analysis which more clearly illustrate the kinetics of gel 
formation.  As expected, 6 mg mL-1 gels form more quickly than 3 mg mL-1 for all 
materials, though this difference is largest for DECM-derived gels.  Collagen 
undergoes the most rapid gelation, followed by DECM-derived gels with DBM-derived 
gels being the slowest to completion (cessation of change of optical properties).  The 
majority of the change in absorbance for ECM-derived materials has occurred by 15 ± 
30 minutes after the initiation of incubation, but gelation is not complete until around 
30 minutes later. 
Rheological analysis was used to assess the evolution of the mechanical properties of 
the three materials during gelation (Figure 4.7).  As defined rheologically (storage 
modulus greater than loss modulus) all materials were considered to be gels almost 
immediately upon the temperature being raised to 37oC.  At both concentrations 
collagen gelled very quickly, reaching its maximal storage modulus within 2 ± 3 
minutes.  ECM-derived materials were found to have profiles which were much more 
distinct from collagen¶V than those observed spectrophotometrically.   
Chapter 4 ± Generation of ECM Hydrogels 
150 
 
  
(a) 
Figure 4.6 ± Spectrophotometric assessment of gelation kinetics for collagen, 
DBM and DECM (n = 6) via absorbance measurements at 405 nm.  Error bars are 
one standard deviation.  Shown are both raw values (a) and values which are 
normalised (b) such that the initial reading is zero and the maximum value 
reached is one. 
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Figure 4.7 ± Rheological assessment of gelling solutions of collagen, DBM and 
DECM via the application of an oscillating 1% shear strain at a constant strain 
rate of 1 rad s-1 in a humidified atmosphere at 37oC.  Assessment was performed 
at 3 mg mL-1 (a) and 6 mg mL-1 (b) final gel concentrations.  Error bars are one 
standard deviation (n = 6). 
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Both materials showed two-phase evolution of mechanical properties with the first 
phase lasting for around five minutes and contributing the most rapid evolution of 
mechanical properties.  The second phase lasted from this point for at least another 
55 minutes at which point the storage moduli of the gels still appeared to be 
changing.  Measurements were not continued beyond this point as the samples 
began to dry out when studied beyond 60 minutes and this had a significant effect on 
the mechanical properties.  Despite the continued gradual evolution of storage 
moduli at 60 minutes it was clear that DECM-derived hydrogels would never achieve 
moduli as high as those seen for collagen.  DBM-derived hydrogels in contrast had 
already begun to display moduli in excess of those measured for collagen.  Statistical 
analysis of the differences between the storage moduli of the various materials at 60 
minutes seemed to support these conclusions (Table 4.1). 
Rheological analysis of the viscoelastic behaviour of collagen and ECM-derived 
hydrogels was continued with an amplitude sweep of gels which had been allowed 
one hour to form (Figure 4.8).  This was designed to assess the extent to which ECM-
derived hydrogels would display the shear stiffening behaviour expected of collagen.  
It was also intended to derive the failure strain for the ECM-derived materials i.e. the 
strain beyond which the storage modulus was seen to display a rapid fall indicating 
disruption of the hydrogel structure.  At both concentrations both ECM-derived 
materials were found to display shear stiffening as expected for collagen-based 
materials.  DECM gels of both concentrations were found to have statistically-
significantly lower failure strains than collagen and to have lower storage moduli at 
failure (though this difference was only statistically significant for 6 mg mL-1 gels).  
Contrastingly, the only instance in which DBM-derived gels showed significantly 
different performance to collagen was in the case of the failure strain for 6 mg mL-1 
gels. 
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Figure 4.8 ± Rheological assessment of hydrogels derived from collagen, DBM and 
DECM.  An amplitude sweep was performed covering the strain range 0.1 ± 200% 
at a constant shear rate of 1 rad s-1 applied in a humidified atmosphere at 37oC.  
All materials were assessed at 3 mg mL-1 (a) and 6 mg mL-1 (b) gel 
concentrations and were allowed to undergo gelation for one hour prior to 
testing.  Error bars are one standard deviation (n = 6). 
(a) 
(b) 
  
 
 Gel Concentration/ 
mg mL-1 
Gel Type 
Storage Modulus at 60 
Minutes Incubation/ Pa 
Failure Strain/ % 
Storage Modulus at 
Failure/ Pa 
3 
Collagen 55 ± 2 93.6 ± 0 520 ± 80 
DBM 59 ± 6 50 ± 10 540 ± 20 
DECM 32 ± 4* 35 ± 8* 260 ± 80 
6 
Collagen 280 ± 30 64 ± 0 890 ± 130 
DBM 310 ± 30 24 ± 5* 640 ± 80 
DECM 144 ± 8* 30.6 ± 0* 270 ± 40* 
Table 4.1 ± Summary of rheological parameters for ECM-derived hydrogels and collagen gels displayed as mean ± standard deviation (n = 6).  Storage 
moduli at 60 minutes incubation measured after the application of an oscillating 1% shear strain at a constant strain rate of 1 rad s-1 in a humidified 
atmosphere at 37oC for one hour.  Other parameters derived from a subsequent amplitude sweep covering the strain range 0.1 ± 200% at a constant 
shear rate of 1 rad s-1 applied in a humidified atmosphere at 37oC.  Statistically-significant difference (p < 0.05) to equivalent collagen parameter is 
indicated by (*) and to equivalent DBM parameter by (). 
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SEM imaging was used to visualise and compare the structures of collagen and ECM-
derived hydrogels (Figure 4.9).  No apparent visual difference could be discerned 
between the fibrillar structures or fibre diameters of the different types of gel 
irrespective concentration.  All gels presented highly porous structures in which the 
pores were strongly interconnected.  Pore sizes appeared large with respect to the 
fibre diameters, though this size ratio would be expected to be different in the fully 
hydrated gels. 
The final stage of ECM-derived gel characterisation was to examine the response of 
cells to the gels as in vitro culture surfaces.  hOS and mPC cells were cultured on the 
surfaces of collagen, DBM and DECM hydrogels as well as on TCP for 72 hours.  
Figures 4.10 & 4.11 show results utilising 20,000 and 10,000 cells per well seeding 
densities respectively, but similar trends were observed at 5,000 cells per well for 
both cell types except where specifically noted.  No experimental condition was 
examined under which either ECM-derived hydrogel was found to support 
statistically-significantly reduced cell numbers when compared to collagen.  In the 
majority of cases, particularly for mPC cells, the ECM-derived gels supported 
significantly lower cell numbers than TCP.  However under certain conditions cell 
numbers on these gels significantly exceeded those on collagen and achieved 
statistical similarity to those on TCP.  This was most notably the case for mPC cells 
grown on 3 mg mL-1 DECM-derived gels for 72 hours, but was also found to be the 
case for three of the four conditions utilising DECM-derived gels as a growth 
substrate for hOS cells. 
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A 
F E 
D C 
B 
Figure 4.9 ± Representative SEM images of 3 mg mL-1 DECM (A), 6 mg mL-1 
DECM (B), 3 mg mL-1 DBM (C), 6 mg mL-1 DBM (D), 3 mg mL-1 collagen (E) and 6 
mg mL-1 collagen (F) hydrogels.  Gels were subjected to dehydration by washing 
in increasing concentrations of ethanol prior to critical point drying and sputter 
coating with platinum. 
  
  
Figure 4.10 ± Metabolic activity of hOS cells seeded on collagen, DBM and DECM hydrogels or on tissue culture plastic (TCP) assessed via the MTS assay.  
Cells were seeded at 20,000 cells per well onto 100 ǋL gels in 96-well plates (n = 6) after the gels had been allowed to form for one hour at 37oC.  Error 
bars are one standard deviation.  Statistically significant (p < 0.05) differences to equivalent collagen (Į) and 48 hour (ǃ) results and statistical similarity 
to equivalent TCP results (Ǆ) are shown.  
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Figure 4.11 ± Metabolic activity of mPC cells seeded on collagen, DBM and DECM hydrogels or on tissue culture plastic (TCP) assessed via the MTS 
assay.  Cells were seeded at 10,000 cells per well onto 100 ǋL gels in 96-well plates (n = 6) after the gels had been allowed to form for one hour at 
37oC.  Error bars are one standard deviation.  Statistically significant (p < 0.05) difference to equivalent collagen (Į) and 48 hour (ǃ) results and 
statistical similarity to equivalent TCP results (Ǆ) are shown. 
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4.3.3 Fabrication of ECM-Derived Hydrogel Beads 
One of the stated aims of the work presented in this chapter (see Section 4.1.4) was 
to demonstrate the production of beads composed of DBM or DECM hydrogels.  Since 
the gelation kinetics for these highly-processed materials were found to be relatively 
slow, the key challenge in pursuing this aim was the stabilisation of pre-gel liquid 
droplets for sufficient time to allow gelation to be completed.  To provide this 
stabilisation an indirect route to ECM-derived bead production was adopted which 
involved the use of calcium-crosslinked alginate as a temporary support structure 
(see Section 2.19). 
Initially a variety of ratios of alginate solution to DECM digest were tested for bead 
formation and the beads were collected and dried to attempt to quantify the 
efficiency of DECM incorporation (n = 1).  It was found that 1:1 and 2:1 (v:v) 
DECM:alginate ratios resulted in rounded beads which were visually similar to those 
produced using alginate alone.  A 3:1 ratio resulted in highly irregularly-shaped beads 
which were prone to widespread aggregation prior to the completion of gelation and 
this ratio was discounted as a condition for bead production. 
The dry weights of all batches of beads were found to be very much in excess of the 
total masses of alginate and/or DECM which had been included in the preparation.  
This was attributed to the encapsulation of large quantities of salt in the beads and 
made accurate quantification of DECM incorporation impossible.  Instead the 
incorporation efficiency (the proportion of the DECM contained within the pre-gel 
mixture which was retained in the gel beads) was estimated for 2:1 and 3:1 ratios 
relative to the 1:1 ratio.  This estimation was based on the assumption that both 
alginate and DECM gels retained salt at fixed mass ratios across all conditions.  There 
appeared to be no loss of incorporation efficiency upon changing the DECM:alginate 
ratio (Table 4.2).  The 2:1 ratio was chosen for future work based on containing the 
minimal amount of alginate necessary to achieve desirable morphology. 
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DECM:Alginate/ v:v 
Incorporation 
Efficiency (I.E.)/ % 
Mean I.E. ± Standard 
Deviation/ % 
1:1 100 - 
2:1 111, 105.2, 101.2 106 ± 5 
3:1 106.3 - 
Table 4.2 ± Incorporation efficiency of DECM into DECM/alginate beads at a 
variety of ratios of the two constituents.  Incorporation efficiency is defined as the 
proportion of the DECM contained within the pre-gel mixture which is retained 
within the hydrogel beads.  Values are relative to the 1:1 (v:v) ratio condition and 
based on certain assumptions (see Section 4.3.3). 
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Further evaluation of the beads resulting from a 2:1 (v:v) DECM:alginate ratio was 
then undertaken.  This began with a more reliable (n = 3) estimation of the relative 
incorporation efficiency which showed a low degree of batch-to-batch variation 
(Table 4.2).  Subsequently the principle of citrate treatment to remove the alginate 
content was demonstrated and a clear change in the bead opacity and size could be 
discerned (Figure 4.12).  The softness of the resulting beads and the alginate content 
of the suspension fluid meant it was not possible to reliably collect the beads for dry 
weight measurement. 
  
  
 
 
Figure 4.12 ± Representative bright field microscopy images of (left to right) ± hydrogel beads composed of alginate alone, beads produced from a 2:1 
(v:v) ratio of DECM digest to alginate solution and beads produced from the same ratio of DECM to alginate imaged after treatment for 10 minutes with 
0.25 M sodium citrate to remove the alginate component.  Scale bars represent 2 mm. 
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4.4 Discussion 
4.4.1 Successful Demineralisation and Decellularisation of Bovine Bone 
Protocols were developed to demineralise milled bovine bone, to extract lipid content 
and subsequently to decellularise the processed bone.  Powder-form materials were 
extracted after the lipid extraction step (DBM) and after the decellularisation step 
(DECM).  DBM was found to be completely devoid of mineral content, which was 
expected since the protocol utilised was based on procedures which had been 
successfully used previously470,501.  DBM is generally considered to be an acellular 
material473 but in this work acid demineralisation plus chloroform/methanol lipid 
extraction was not found to be sufficient to remove all cells from the matrix.  This 
was evidenced by the presence of visible nuclei in H & E stained histological sections.  
This discrepancy may be explained by the absence of a terminal sterilisation step in 
the protocol used here since this would be expected to cause death and lysis of any 
remaining cells.  It should be noted that despite the presence of these intact cell 
nuclei the dsDNA level present in DBM was still found to be significantly below a 
widely-quoted criterion for successful decellularisation450.  Additionally the levels 
found in DBM in this study compare favourably with those measured in other ECM-
derived materials which have been used successfully both in vitro and in 
vivo400,403,410,412,414,418,427,433,434,437,454,502-504.  Furthermore, as will be discussed below 
(see Section 4.4.2), there is no adverse cell response to this material to suggest 
levels of cell or DNA retention which are detrimental to material performance. 
The trypsin/EDTA enzymatic decellularisation step utilised in this study did not 
produce a fall in the dsDNA level of the material when normalised to total mass.  The 
total dsDNA content was reduced but the overall mass was reduced to a similar 
extent, leading to the proportional lack of change.  This is perhaps to be expected 
due to the use of a non-specific protease treatment for decellularisation which has 
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previously been found to result in significant loss of ECM constituents404-406,505,506.  
The initial aim in this work was not to derive a fully-optimised decellularisation 
protocol but merely to achieve adequate reduction of cellular material.  In future 
work other decellularisation regimes may need to be considered, such as ionic or 
non-ionic detergent treatments. 
The trypsin/EDTA treatment utilised in this work leads to a total elimination of visible 
cell nuclei but only removes around 40% of dsDNA.  This may suggest that it is more 
efficient at causing cell lysis than at removing cellular debris from the matrix.  As a 
result additional DNase and RNase treatments may be important additions to future 
decellularisation protocols422,428,507-509. 
As would be expected for demineralised bone both DBM and DECM were found to be 
composed of around 90% collagen by weight with no significant change caused by 
the enzymatic decellularisation step473,510.  The cell response data obtained (see 
Section 4.4.2) suggests that both DBM and DECM may contain other proteins, PGs or 
GAGs which have a beneficial signalling effect on the proliferation of bone-derived 
cells.  An important step in the further study of these materials and their gel 
derivatives would be to establish what these other constituents are and to what 
extent their activity is maintained in both powder and gel forms.  Other constituents 
which may be expected to be present in these materials include fibronectin511-514, 
osteopontin513,515, bone sialoprotein513-515 and a number of BMPs481,484,510,514,516. 
4.4.2 Production of Hydrogels from Demineralised and Decellularised Bovine 
Bone 
It was demonstrated in the work presented in this thesis that a pepsin solubilisation 
step which has been used to produce hydrogels from a number of soft tissue-derived 
ECMs421,439,451-457 could also be applied to demineralised bone tissue.  The concern in 
taking this approach was that the ECM may have been processed and altered to such 
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an extent that the resulting protein fragments would be incapable of polymerising or 
aggregating to form a hydrogel structure.  This was particularly true for the DECM-
derived material which had been subjected to an additional enzymatic processing 
step.  In practice both DBM and DECM could be digested with pepsin and these 
solubilised materials induced to form hydrogels at concentrations of 1 mg mL-1 and 
above. 
The similarity of the gelation kinetics of ECM-derived materials to those of collagen 
suggested that it was digested collagen fragments that were responsible for gelation.  
Both ECM-derived materials gelled more slowly than collagen with DBM being the 
slower of the two.  Previously reported ECM-derived hydrogels show a very wide 
range of times for complete gelation which extends around an order of magnitude 
either side of the figures obtained in this work (around 45 ± 60 
minutes)451,453,458,459,461,517. 
Spectrophotometric measurements showed the gels that were formed from DBM 
digest to be optically similar to collagen with DECM-derived gels being substantially 
more opaque.  However SEM imaging showed very similar structures of both DBM 
and DECM-derived hydrogels to their corresponding collagen gels.  All gels showed 
randomly-oriented fibrillar structures which were highly porous and had highly 
interconnected pore structures.  This further suggested that collagen and its 
derivative peptides were controlling the gelation and physical structure of these 
materials. 
Rheological analysis suggested that although collagen may be the causative element 
for gelation the complex composition of the pepsin digests was giving rise to a 
dLVWLQFWJHOIRUPDWLRQPHFKDQLVP&ROODJHQ¶VVWRUDJHPRGXOXVUHDFKHGLWVPD[LPXP
value in one continuous phase of change lasting two to three minutes.  On the other 
hand, the storage moduli of ECM-derived hydrogels showed two distinct phases of 
change.  An initial rapid increase was seen for around five minutes after the 
temperature was raised to 37oC.  Following this the rate of change slowed into a 
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second phase during which the storage moduli continued to increase up to the 
maximum 60 minute incubation time studied.  It is likely that these altered gelation 
kinetics were the result of two distinct differences between the pre-gel collagen 
solutions studied and the ECM-derived pepsin digests.  Firstly the collagen peptide 
chains in the pepsin-digested DBM and DECM would have been very much shorter 
than those in the collagen solution.  Secondly the ECM digests contained around 10% 
by weight non-collagenous material and it has previously been shown that the 
presence of other ECM constituents such as GAGs can alter the kinetics of collagen 
gelation518-520. 
The slower gelation kinetics of the ECM-derived materials may in practice make them 
more usable injectable scaffold materials since the window of time during which they 
are able to maintain flow at room temperature is larger.  However it will likely also 
render them more difficult to form into beads and more challenging to use in 
bioplotting applications as suggested in Section 4.1.4.   
The additional enzymatic processing applied to DECM prior to pepsin digestion was 
found to lead to significantly reduced final gel stiffness, but DBM-derived gels were 
ultimately stiffer than collagen equivalents.  The stiffnesses of both types of ECM-
derived gel, as measured by their storage moduli under shear strain, are considerably 
higher than those seen previously for some ECM-derived gels451,453-455,457,517.  This 
suggests they may be more suitable for applications in bone repair, perhaps 
LQGLFDWLQJ D GHJUHH RI µPHFKDQLFDO WLVVXH VSHFLILFLW\¶  ,W VKRXOG EH UHPHPEHUHG
however, that the experimental conditions used to gather these measurements were 
different and that this will have affected the precise values obtained.  The lower 
stiffness of DECM gels for a given gel concentration means that a higher 
concentration would have to be used to achieve similar mechanical properties.  This 
would by definition be a denser gel which may be less conducive to supporting the 
growth of encapsulated cells.  However SEM imaging did show that gels remained 
highly porous even at the higher concentration studied here. 
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In most cases the gels formed from bone-derived materials were found to fail at 
lower strains than collagen gels when subjected to amplitude sweeps.  This 
suggested they would be more likely to fail if used as load-bearing biomaterials in 
vivo.  DECM-derived gels at 6 mg mL-1 faired particularly poorly in this regard as they 
had statistically-significantly lower storage moduli at failure than collagen.  This in 
turn suggested that they would fail under the influence of particularly low stresses.  
It should be noted however, that the properties derived here under shear conditions 
do not relate directly to behaviour under the predominantly compressive loads which 
would be experienced in many bone implantation sites in vivo. 
The mechanical properties of the ECM-derived hydrogels studied here appear to be 
inferior to those of the collagen of which they are predominantly composed.  
However they compare favourably with those of other ECM-derived gels which have 
previously been reported.  Additionally, in the case of bone it is perhaps not 
envisaged that a hydrogel alone would be a suitable biomaterial for all applications 
but rather that it would act as a bioactive supplement for a stronger material of 
either synthetic or natural origin496,521,522. 
The potentially beneficial bioactivity of DECM and DBM-derived gels was 
demonstrated by their successful utilisation as in vitro cell culture substrates.  For all 
combinations of two gel concentrations, two cell types, two time points and two cell 
seeding densities both materials performed at least as well as collagen based on cell 
metabolic activity.  Under some conditions ECM-derived gels significantly 
outperformed collagen and even showed equivalence with tissue culture plastic, the 
gold standard in vitro substrate.  A particularly significant demonstration of this 
occurred when murine primary calvarial cells were cultured at 10,000 cells per 96-
well plate well on 3 mg mL-1 DECM-derived gels.  These primary cells are more 
sensitive to their environment than the cancer-derived hOS cell line and under the 
conditions described they proliferated very significantly between 48 and 72 hour time 
points. 
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Further work is clearly required to understand the sensitivity of bone-relevant cell 
types to the conditions used for culture both on and within bone-derived hydrogels.  
It will also be important to understand which non-collagenous constituents of the 
materials are exerting the beneficial effects seen on cell growth.  As suggested earlier 
these may include fibronectin and bone morphogenetic proteins.  Finally it may be 
instructive to compare the ECM-derived hydrogels produced here with their 
undigested counterparts and with native bone tissue as cell culture substrates.  This 
would allow an understanding of the effects of each processing step on the 
bioactivity and biocompatibility of these materials.  Despite these unknowns the initial 
positive results seen here demonstrate that such hydrogels may have great potential 
as adjuncts to or replacements for DBM in bone grafting procedures. 
4.4.3 Fabrication of ECM-Derived Hydrogel Beads 
As outlined in Section 4.1.4 one of the objectives of the work presented in this 
chapter was to demonstrate the ability of ECM-derived hydrogels to be formed into 
particles or beads.  These bead formulations would constitute injectable suspensions 
with increased room temperature stability compared to pre-gel solutions.  This may 
render them a useful alternative formulation, although they would not then undergo 
gelation after delivery and may not be as well retained at the defect site.  
Formulation into beads would also present the possibility for exogenous growth 
factors to be encapsulated within them for controlled delivery in vitro or in vivo.  In 
the simplest instance these proteins would then be released by diffusion through the 
gel.  However it has been shown recently that decellularised matrices may retain 
binding sites for growth factors such as basic fibroblast growth factor and hepatocyte 
growth factor even when processed to form hydrogels431,517,523.  The presence of 
these functional growth factor binding sites may offer a route to cell-mediated 
release of a wide range of growth factors. 
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The initial protocol evaluated for bead formation was relatively simple, with beads 
produced by ejecting a mixture of alginate and DECM digest into a calcium chloride 
bath at 37oC.  This induced gelation of the alginate into rounded beads which 
retained the DECM digest for sufficient time to allow it to undergo complete gelation.  
Beads could be formed containing 6 mg mL-1 DECM and as little as 0.33% (w/v) 
alginate with no drop in estimated incorporation efficiency relative to beads 
containing 0.5% (w/v) alginate.  Although the DECM-containing beads did not 
maintain the close-to-spherical morphology of alginate-only beads they were fairly 
uniform with sizes around 2 mm. 
The amount of DECM in the beads could not be accurately quantified due to the 
retention of a large amount of salt within them.  However citrate treatment did 
indicate qualitatively the presence of fully-formed DECM-derived hydrogel within the 
beads, since there was a clear change in size and opacity post-treatment but discrete 
beads could still be observed. 
The work described here has demonstrated that the formation of beads consisting of 
DECM-derived hydrogel is possible.  However the protocol used may need refining to 
be suitable for some applications.  The beads are relatively large to be considered as 
easily injectable and fundamentally different protocols may be needed should a very 
large reduction in size be required.  The need to include alginate in the production 
process is perhaps not ideal because if it is retained in the final beads then it acts to 
dilute the bioactivity of the DECM.  Alternatively if it is removed via citrate treatment 
then a portion of any cell population or protein incorporated in the formulation will 
inevitably be lost in production.  To combat these issues water-in-oil emulsion 
techniques could be considered a promising alternative route to bead production524-
526.  However, organic-aqueous interfaces can be detrimental to protein activity527,528 
and protocols of this type would necessitate extensive washing to remove organic 
solvent residues. 
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Arguably a better approach would be to develop alternative methods of delivery of 
the alginate/DECM mixture into the calcium chloride bath in order to produce droplets 
of smaller size.  Further to this a larger calcium chloride bath combined with more 
efficient modes of stirring may prevent the irregular morphology seen with higher 
DECM-to-alginate ratios and allow the alginate content of the beads to be further 
lowered.  Taken together these modifications of a technique which is fundamentally 
effective could alleviate the potential issues foreseen in future applications.
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5. Fabrication of Patterned Constructs via Bioplotting 
5.1 Introduction 
5.1.1 Thermoresponsive Sintering of a Microparticulate Scaffold Material 
Many scaffolds used for bone tissue engineering are composed of calcium phosphate-
based ceramics which can be engineered with excellent mechanical 
properties182,191,194,198.  These scaffolds have been shown to be capable of supporting 
significant proliferation of bone-derived cells in vitro188,191,529.  However the high 
temperature processing required prevents the incorporation of cells or proteins into 
the production process182,191,193,194,198.  This limits the biological functionality which 
the scaffolds can display and it also severely limits the complexity of patterning which 
can be achieved within them. 
The use of synthetic polymers as scaffold materials removes the requirement for very 
high temperature processing.  This strategy also allows an acceptable level of 
mechanical strength to be maintained88,157,178,204,211,530.  However the majority of 
scaffold fabrication techniques still require these polymers to be processed at (mildly) 
elevated temperatures157,204,209-211,530 and/or in the process of organic 
solvents112,178,277,353,531-533.  This can be circumvented by the use of supercritical 
carbon dioxide (scCO2) as a solvent for polymer processing
308,534-539.  The use of 
scCO2 allows proteins to be encapsulated within polymer scaffolds whilst remaining 
active308,534,536,538.  However scCO2 processing requires the application of high 
pressures and this renders these techniques non-cell compatible. 
A novel microparticulate polymer formulation has recently been developed which 
undergoes thermoresponsive liquid sintering under physiological conditions to form 
porous solid scaffolds270-273,540,541.  The microparticles in this formulation are 
composed of a melt blend of poly(lactic-co-glycolic acid) (PLGA) and poly(ethylene 
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glycol) (PEG).  The PEG component acts to lower the glass transition of the mixture 
such that it is just below body temperature270,273.  These microparticles can be 
suspended in an aqueous carrier to form a paste for use as an injectable defect filler.  
When the temperature of the paste is raised to 37oC the microparticles soften and 
form adhesion bridges to one another.  The presence of the aqueous carrier then 
allows the hydrophilic PEG component to leach from the microspheres.  This causes 
the polymer and thus the microparticle-to-microparticle adhesion bridges to resolidify.  
A porous solid scaffold is formed with mechanical properties which are comparable to 
those of cancellous bone270-273,542-545. 
The mild processing conditions used for the fabrication of these PLGA-PEG scaffolds 
allow active proteins to be loaded into them by dissolution in the carrier540.  
Alternatively proteins can be encapsulated in polymer microspheres which are then 
mixed into the formulation and which can deliver them in a time-controlled manner 
(see Chapter 3)272,541.  Cells can also be suspended in the carrier and then be 
retained and proliferate within the fully-formed scaffolds270,272.  The ability to 
formulate these microparticles as injectable pastes also renders them compatible with 
extrusion-based construct fabrication and patterning by bioplotting (see Section 
1.2.6). 
5.1.2 Bioplotting as a Tissue Engineering Construct Fabrication Technology 
Due to the very mild conditions used for bioplotting the technique has predominantly 
been used to produce constructs from natural and synthetic polymer hydrogels (see 
Section 1.2.6)226,227,229,230,232,240,242,243,245-247,249-251,546.  These constructs do not have 
sufficient mechanical strength to be used for the repair of defects in load-bearing 
bones.  A number of publications describe the extrusion at ambient conditions of 
pastes containing ceramic particulates190,547,548.  However as with ceramic scaffolds 
produced via other means, these required very high temperature post-production 
sintering190,547,548 and could not incorporate proteins or cells for biological 
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functionality.  This means that to date the production of bone-appropriate tissue 
engineering constructs via a pure bioplotting approach has not been demonstrated. 
5.1.3 Aims & Objectives 
The overall aim of the work presented in this chapter is to evaluate the potential of 
bioplotting techniques for the production of patterned constructs for osteochondral 
defect repair.  However much of the data obtained is also more widely informative 
and applicable. 
The first step in achieving this aim is to assess the feasibility of bioplotting the PLGA-
PEG microparticulate scaffold material described above.  Should this prove feasible 
then the process will be optimised with the aim of achieving suitable mechanical 
properties for bone repair.  Consideration will also be given to bioplotting of cell-
laden alginate hydrogels similar to those which have been used elsewhere in tissue 
engineering226,227,229,230,232,245,546.  Alginate gels encapsulating chondrocytes or 
mesenchymal stem cells in particular have proved effective for the generation of 
cartilage tissue in vitro and in vivo230,244,245. 
Further to this the production of constructs containing both PLGA-PEG and alginate 
phases will be attempted.  These constructs may be suitable for the repair of bone 
and cartilage simultaneously.  Another important step in the development of 
bioplotting for osteochondral construct fabrication will be to determine whether viable 
cells can be incorporated in the PLGA-PEG phase. 
Finally the ability of a bioplotting platform to simultaneously pattern materials, 
protein signals and cell populations will be considered.  It may be necessary to 
perform patterning of this complexity to achieve truly effective defect repair and this 
ability would also render the technique very widely-applicable. 
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5.2 Materials and Methods 
5.2.1 Use of Fab@Home Bioplotting Platform 
See Section 2.22 for general protocols for bioplotting of PLGA-PEG microparticulate 
SDVWHV DQG DOJLQDWH K\GURJHOV ZLWK RU ZLWKRXW FHOOV  ,Q WKH IROORZLQJ WH[W µ
DOJLQDWHK\GURJHO¶LVXVHGWRUHIHUWRDPL[WXUHFRPSRVHGRIDYYUDWLRRI 2% 
(w/v) alginate solution (Acros Organics) and 1% (w/v) calcium sulphate (Alfa Aesar).  
,QDVLPLODUIDVKLRQµDOJLQDWHK\GURJHO¶UHIHUVWRDYYPL[WXUHRIZY
alginate solution (FMC Biopolymer) and 1% calcium sulphate (Sigma-Aldrich). 
5.2.2 Production of PLGA-PEG Microparticles 
See Section 2.21. 
5.2.3 PLGA Microsphere Fabrication via Refined Double Emulsion Technique 
See Section 2.4.3. 
5.2.4 Microsphere Size Distribution Analysis via Laser Diffraction 
See Section 2.5. 
5.2.5 Scanning Electron Microscopy (SEM) 
See Section 2.6. 
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5.2.6 Unconstrained Compression Testing 
See Section 2.23. 
5.2.7 Micro Computed Tomography (ǋCT) Imaging and Three-Dimensional 
Analysis 
See Section 2.16. 
5.2.8 Live/Dead Staining of Cells in Alginate Hydrogels 
See Section 2.24. 
5.3 Results 
5.3.1 Feasibility of Production of Patterned Constructs Containing PLGA-PEG 
Microparticulate Material via Bioplotting 
The Fab@Home Model 1 platform274 was used for an initial study assessing the 
feasibility of bioplotting as a fabrication technique for osteochondral tissue 
engineering.  Figure 5.1 shows representative images of 2% alginate hydrogel 
constructs produced using this system.  The resolution of a bioplotting process is 
essentially defined by the width of the material filament which is deposited.  This 
provides a lower limit to the size of structure that can be reproduced and is in turn 
limited by the inner diameter of the tip which is used to deposit the material.  In the 
case of the constructs shown in Figure 5.1 this was 630 ǋm but 2% alginate 
hydrogels could also be deposited using tips with inner diameters as small as 250 
ǋm. 
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Figure 5.1 ± Representative images of constructs produced via bioplotting of 2% 
DOJLQDWHK\GURJHOV6KRZQDUHDµJHDU¶WHVWGHVLJQOHIWDQGDFRQVWUXFWVKDSHG
to match a bovine meniscus (right). 
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The next stage in this study was to assess whether the deposition of PLGA-PEG 
microparticulate pastes using the Fab@Home Model 1 was feasible.  Previous studies 
utilising PLGA-PEG microparticles had focused on the 100 ± 200 ǋm size fraction270-
273,540,541.  In this study it was found that microparticles of this size could not be 
deposited by bioplotting even when the inner diameter of the syringe tip was as large 
as 1.36 mm. 
Deposition was achieved using a smaller microparticle size fraction (50 ± 100 ǋm).  A 
number of conditions were varied to achieve and then optimise deposition within 
certain practical constraints.  Parameters considered included the inner diameter of 
the tip, the concentration of medium viscosity carboxymethyl cellulose (CMC) used as 
the carrier liquid, the carrier:solid (v:w) ratio and the material flow rate.  The result 
was optimised with respect to the achievement of total deposition of all material, the 
maintenance of consistent flow during deposition and the ability to discern individual 
deposition paths in constructs which nevertheless maintained their integrity.  Figure 
5.2 shows constructs produced using a tip with an inner diameter of 1.19 mm, 3% 
(w/v) medium viscosity CMC as the carrier, a 1.5:1 carrier:solid ratio and a material 
flow rate of 38.8 ǋL s-1.  These constructs could be sintered for 24 hours at 37oC to 
achieve appreciable mechanical strength and rigidity with minimal change of size and 
shape. 
Another important step in this study was the demonstration that PLGA microspheres 
could be incorporated into PLGA-PEG constructs to provide the potential for 
controlled protein delivery.  Figure 5.3 shows constructs bioplotted using the 
conditions described above excepting that 25% (w/w) of the solid was replaced by 
µ ǋP¶ 3LGA microspheres.  These microspheres had been manually sieved to 
remove the sub-50 ǋm size fraction as this significantly improved the flow of 
microparticulate pastes.  With the inclusion of microspheres the ability to discern by 
eye the location of individual deposition paths was lost.  However the constructs 
could still be sintered with minimal changes in size and shape. 
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Figure 5.2 ± Representative images of constructs produced via bioplotting PLGA-
PEG microparticles suspended in 3% (w/v) medium viscosity CMC at a 1.5:1 (v:w) 
ratio of solid to aqueous carrier.  Images are shown of constructs both before 
(left) and after (right) 24 hours sintering.  Scale bars represent 2 mm. 
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Figure 5.3 ± Representative images of constructs produced via bioplotting of 
PLGA-3(* PLFURSDUWLFOHV DQG µ ǋP¶ 3/*$ PLFURVSKHUHV VXVSHQGHG LQ 
(w/v) medium viscosity CMC at a 1.5:1 (v:w) ratio of solid to aqueous carrier.  
The ratio of microparticles to microspheres was 3:1 (w:w).  Images are shown of 
constructs both before (left) and after (right) 24 hours sintering.  Scale bars 
represent 2 mm. 
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:KHQ LPDJHG YLD 6(0 )LJXUH  DQG ǋ&7 )LJXUH  VFDIIROGV ZHUH VHHQ WR
contain interconnected pore structures.  Microparticle-to-microparticle bridging 
appeared to be very extensive at the surface of the constructs but less so in the 
interior.  This apparently incomplete sintering process was reflected in the 
mechanical properties of the constructs as assessed by unconstrained compression 
testing.  The mean yield stress for the constructs was significantly lower than those 
observed in previous studies of this material at 0.026 MPa (n = 3)270-273. 
The next step in this feasibility study was to evaluate the ability of the Fab@Home 
platform to produce dual material scaffolds containing both alginate and PLGA-PEG 
microparticle phases.  Figure 5.6 shows dual material scaffolds produced using the 
settings described above for individual materials.  It was noted that when constructs 
were sintered under standard conditions the alginate component reverted to an 
aqueous solution and was removed from them.  In this case the alginate was acting 
as a temporary support to stabilise PLGA-PEG microparticle structures which were not 
capable of self-supporting.  The alginate phase could instead be retained if sintering 
was conducted using a 0.66% (w/v) calcium chloride solution in place of the standard 
0.9% (w/v) sodium chloride.  This allowed the alginate to function as a true construct 
component, in which cells and/or proteins could be delivered.  The presence of the 
alginate component did not appear to affect the ability of the PLGA-PEG 
microparticles to sinter in either case. 
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Figure 5.4 ± Representative SEM images of constructs produced via bioplotting of 
PLGA-3(* PLFURSDUWLFOHV DQG µ ǋP¶ 3/*$ PLFURVSKHUHV VXVSHQGHG LQ 
(w/v) medium viscosity CMC at a 1.5:1 (v:w) ratio of solid to aqueous carrier.  
The ratio of microparticles to microspheres was 3:1 (w:w).  Images show 
construct surface (left) and cross-section (right) after 24 hours sintering. 
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Figure 5.5 ± Representative ǋCT-derived cross-sectional images of constructs 
produced via bioplotting of PLGA-3(* PLFURSDUWLFOHV DQG µ ǋP¶ 3/*$
microspheres suspended in 3% (w/v) medium viscosity CMC at a 1.5:1 (v:w) ratio 
of solid to aqueous carrier.  The ratio of microparticles to microspheres was 3:1 
(w:w) and constructs were imaged after 24 hours sintering.  Scale bar represents 
2 mm. 
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Figure 5.6 ± Representative images of constructs produced via bioplotting of 
PGLA-PEG microparticulate and 2% alginate hydrogel phases.  PLGA-PEG phase 
consisted of microparticles suspended in 3% (w/v) medium viscosity CMC at a 
1.5:1 (v:w) ratio of solid to aqueous carrier.  Images are shown before (left) and 
after (right) 24 hours sintering.  Top images show constructs sintered in 0.9% 
(w/v) sodium chloride and bottom images show constructs sintered in 0.66% 
(w/v) calcium chloride.  Scale bars represent 2 mm. 
Chapter 5 ± Patterned Constructs via Bioplotting 
184 
 
Next the ability of cells contained within alginate hydrogels to remain viable across 
the bioplotting process was assessed.  Relevant cell types for osteochondral repair 
strategies were suspended in 2% alginate hydrogels to a final concentration of 
500,000 cells mL-1.  These cell-laden gels were then bioplotted as per the conditions 
described above.  Post-plot viabilities were assessed via live/dead staining and 
compared to pre-plot viabilities as measured via trypan blue staining.  Representative 
images of live/dead stained MC3T3-E1 murine pre-osteoblasts and bovine articular 
chondrocytes are shown in Figure 5.7.  These cell types had mean (± standard 
deviation) post-plot viabilities (n = 3) of 78 ± 9% and 80 ± 2% respectively. 
The final stage of the feasibility study undertaken here was designed to assess the 
ability of the Fab@Home Model 1 to simultaneously pattern materials, cells and 
proteins.  Constructs were produced which contained four different phases ± alginate 
hydrogels encapsulating two different cell populations and PLGA-PEG microparticle 
pastes containing two different types of PLGA microsphere.  Figure 5.8 shows the 
schematic design on which the constructs were based and a representative confocal 
microscopy image of a bioplotted construct.  The latter is also shown in Figure 5.9 
with magnified images of the individual phases.  The fidelity of design replication was 
lowered for these multiple phase constructs relative to single phase constructs.  
However the overall patterns of construct phases were in good general agreement 
with those in the designs. 
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Figure 5.7 ± Representative fluorescence microscopy images of MC3T3-E1 cells 
(top) and bovine chondrocytes (bottom) bioplotted in 2% alginate hydrogel at 
500,000 cells mL-1.  Cells have been live/dead (green/red) stained for 30 minutes 
with 2 ǋM calcein AM and ethidium homodimer-1 respectively.  Scale bars 
represent 10 ǋm. 
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Figure 5.8 ± Schematic (top) showing design of four phase construct and confocal 
microscopy image (bottom) of bioplotted construct produced from design.  
Phases consisted of 2% alginate hydrogel containing MC3T3-E1 cells labelled with 
a far red dye (O), 2% alginate hydrogel containing bovine chondrocytes labelled 
with DAPI (C), PLGA-PEG microparticle paste containing blank PLGA microspheres 
(B) and PLGA-PEG microparticle paste containing PLGA microspheres 
encapsulating FITC-lysozyme (F).  Alginate phases contained 500,000 cells mL-1 
and PLGA-PEG pastes consisted of PLGA-3(*PLFURSDUWLFOHVDQG µ ǋP¶3/*$
microspheres suspended in 3% (w/v) medium viscosity CMC at a 1.5:1 (v:w) ratio 
of solid to aqueous carrier.  The ratio of microparticles to microspheres was 3:1 
(w:w).  Scale bar represents 1 mm. 
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Figure 5.9 ± Confocal microscopy image of four phase bioplotted construct shown in Figure 5.8 with magnified images of individual phases.  Scale bar 
represents 1 mm. 
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5.3.2 Optimisation of Bioplotting of PLGA-Based Microparticulate Scaffold 
Material 
PLGA-PEG microparticulate constructs produced during the feasibility study described 
above had mechanical which were significantly below those required for repair of 
load-bearing bones.  Three possible effects were identified which may have been 
detrimental to the observed mechanical properties.  Firstly the pastes incorporated 
non-sintering microspheres, leading to the formation of less of the adhesion bridges 
from which the strength of the constructs was drawn.  Secondly the constructs 
produced were too large to undergo compression testing intact and instead sections 
had to be punched out of them for this analysis.  This caused considerable damage, 
particularly at the edges of the punched sections.  Finally it had not been possible to 
fully optimise the conditions used for deposition since only one suitable carrier had 
been available and the supply of microparticles had been limited. 
A systematic study was designed which would optimise the deposition of PLGA-PEG 
microparticles using the Fab@Home Model 2 platform with respect to mechanical 
properties and pore structure.  The effects of the first two factors described above 
were eliminated by depositing microparticles without microspheres and into 
cylindrical poly(tetrafluoroethylene) (PTFE) moulds (6 mm diameter, 12 mm height).  
The latter led to the production of constructs of exactly reproducible shape which 
could be compression tested without the need for size reduction.  Since no significant 
change in size was seen during sintering of previous constructs the restriction of 
deposited pastes by the moulds was not considered to exert a significant effect on 
construct architecture. 
An important consideration in this work was to ensure that PLGA-PEG 
microparticulate paste compositions and thus mechanical properties were consistent 
throughout the constructs produced.  Consistency in this sense was very challenging 
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to assess quantitatively and so a simpler qualitative measure was needed.  If a 
microparticulate paste could not be bioplotted in its entirety but instead resulted in a 
wasted remnant of material in the syringe barrel then this indicated that consistency 
was certainly not achieved.  Complete deposition of all material was therefore 
considered as a first criterion for defining conditions under which consistent 
deposition was possible. 
Minimising the amount of carrier needed to achieve complete deposition was 
considered important since smaller amounts of carrier would result in greater 
mechanical strengths and lower levels of post-bioplotting microparticle flow.  As a 
result the first analysis undertaken in this optimisation study was to determine the 
minimum carrier:solid (v:w) ratios needed for a range of aqueous carriers to ensure 
that the entirety of microparticulate pastes prepared with them could be bioplotted.  
Medium viscosity CMC, high viscosity CMC and Pluronic® F127 were considered as 
potential aqueous carriers and were assessed at a range of concentrations (Table 
5.1).  The three carrier/concentration combinations that resulted in the lowest 
minimum ratios were taken forward for further investigation and optimisation.  These 
were 3% (w/v) medium viscosity CMC , 2% (w/v) high viscosity CMC and 3% (w/v) 
high viscosity CMC at corresponding carrier:solid (v:w) ratios of 1.4:1, 1.4:1 and 
1.3:1. 
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Carrier Minimum Carrier:Solid Ratio (v:w) 
0.5% (w/v) Medium Viscosity CMC 1.7:1 
1% (w/v) Medium Viscosity CMC 1.7:1 
2% (w/v) Medium Viscosity CMC 1.6:1 
3% (w/v) Medium Viscosity CMC 1.4:1 
0.5% (w/v) High Viscosity CMC 1.7:1 
1% (w/v) High Viscosity CMC 1.5:1 
2% (w/v) High Viscosity CMC 1.4:1 
3% (w/v) High Viscosity CMC 1.3:1 
0.5% (w/v) Pluronic® F127 1.6:1 
1% (w/v) Pluronic® F127 1.5:1 
2% (w/v) Pluronic® F127 1.5:1 
3% (w/v) Pluronic® F127 1.5:1 
Table 5.1 ± Minimum v:w ratios of a variety of aqueous carriers to PLGA-PEG 
microparticles (solid) required to produce pastes which could be completely 
deposited (i.e. extruded in their entirety) by Fab@Home Model 2 bioplotting 
platform. 
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These three most effective carriers were used to produce constructs for 
unconstrained compression testing at the ratios described above and at one ratio 
HDFKVLGHRIWKHVHYDOXHVQ <LHOGVWUHVVHV)LJXUHDQG<RXQJ¶VPRGXOL
(Figure 5.11) were analysed.  There were no statistically-significant differences 
between different ratios for the same carrier based on either parameter.  The 
majority of results obtained using different carriers were also statistically similar.  
However 2% (w/v) high viscosity CMC at 1.3:1 and 1.4:1 ratios and 3% (w/v) high 
viscosity CMC at 1.3:1 and 1.4:1 ratios showed statistically-significantly (p < 0.05) 
greater values than some of those obtained with 3% (w/v) medium viscosity CMC for 
at least one parameter.  
  
 
  
Figure 5.10 ± Yield stresses for bioplotted PLGA-PEG microparticulate scaffolds as assessed by unconstrained compression testing (n = 3).  PLGA-PEG 
microparticles were suspended in a variety of aqueous carriers at a variety of carrier:solid (v:w) ratios for bioplotting into cylindrical PTFE moulds.  
Samples were tested after 24 hours sintering.  Error bars show one standard deviation and statistically-significant differences are denoted by (*). 
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Figure 5.11 ± <RXQJ¶VPRGXOLIRUELRSORWWHG3/*$-PEG microparticulate scaffolds as assessed by unconstrained compression testing (n = 3).  PLGA-PEG 
microparticles were suspended in a variety of aqueous carriers at a variety of carrier:solid (v:w) ratios for bioplotting into cylindrical PTFE moulds.  
Samples were tested after 24 hours sintering.  Error bars show one standard deviation and statistically-significant differences are denoted by (*). 
* 
* 
* 
* 
* 
* 
* 
Chapter 5 ± Patterned Constructs via Bioplotting 
194 
 
Next ǋCT analysis was undertaken to determine the porosity and mean pore size of 
constructs produced using the three carriers utilised above.  This analysis was 
conducted only on the central of the three ratios investigated earlier (n = 3).  No 
significant differences had been observed between the mechanical properties of 
constructs produced with the same carrier but at different concentrations.  As a result 
of this observation it was considered unlikely that there would be significant pore 
structure differences and so other ratios were not investigated.  No statistically-
significant (p < 0.05) differences were found between the three groups based on 
porosity (Figure 5.12).  However the 2% (w/v) high viscosity CMC group was found 
to have a significantly lower mean pore size than the other groups (Figure 5.13). 
ǋCT analysis of bioplotted constructs also highlighted that the standard PLGA-PEG 
microparticulate scaffold sintering conditions utilised may not have been allowing the 
completion of the sintering process.  This was evidenced by macroscopic reductions 
in diameter of the construct portions which were illuminated by the x-ray source 
during imaging (Figure 5.14).  This shrinkage was thought to be caused by softening 
and/or sintering of microparticles which still contained PEG upon loading into the ǋCT 
instrument. 
Finally constructs produced using the three carriers were subjected to SEM imaging 
to visually confirm the results of the microCT analysis (Figure 5.15).  The structures 
seen in SEM images did appear to reflect the trends seen in Figures 5.12 and 5.13 in 
that the 3% medium viscosity CMC constructs had the largest pores and highest 
overall porosities. 
As a result of all the analyses considered in this optimisation study the most 
promising carriers and ratios for PLGA-PEG bioplotting were considered to be 2% 
(w/v) high viscosity CMC at a 1.4:1 (v:w) carrier:solid ratio and 3% (w/v) high 
viscosity CMC at a 1.3:1 ratio.  
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Figure 5.12 ± Porosities of bioplotted PLGA-PEG microparticulate scaffolds as 
assessed by ǋCT imaging and analysis (n = 3).  PLGA-PEG microparticles were 
suspended in a variety of aqueous carriers at different carrier:solid (v:w) ratios for 
bioplotting into cylindrical PTFE moulds.  Samples were tested after 24 hours 
sintering.  Error bars show one standard deviation. 
0
5
10
15
20
25
30
35
3% Medium Viscosity
1.4 to 1
2% High Viscosity 1.4
to 1
3% High Viscosity 1.3
to 1
P
o
ro
s
it
y
/
 %
 
Chapter 5 ± Patterned Constructs via Bioplotting 
196 
 
 
  
Figure 5.13 ± Mean pore sizes of bioplotted PLGA-PEG microparticulate scaffolds 
as assessed by ǋCT imaging and analysis (n = 3).  PLGA-PEG microparticles were 
suspended in a variety of aqueous carriers at different carrier:solid (v:w) ratios for 
bioplotting into cylindrical PTFE moulds.  Samples were tested after 24 hours 
sintering.  Error bars show one standard deviation and Statistically-significant (p < 
0.05) differences are denoted by (*). 
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Figure 5.14 ± ǋCT transmission images from early (left) and late (right) stages of 
the acquisition process.  Shrinking can be seen due to thermally-mediated 
sintering of constructs which were incompletely sintered upon initiation of the 
acquisition process.  PLGA-PEG microparticles were suspended in 3% (w/v) 
medium viscosity CMC at a 1.4:1 (v:w) ratio of liquid:solid for bioplotting into 
cylindrical PTFE moulds.  Samples were tested after 24 hours sintering. 
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6 mm 
6 mm 
6 mm 
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Figure 5.15 ± Representative SEM images of fracture surfaces of bioplotted PLGA-
PEG microparticulate scaffolds.  PLGA-PEG microparticles were suspended in a 
range of aqueous carriers for bioplotting into cylindrical PTFE moulds.  Samples 
were sintered for 24 hours prior to fracture and imaging.  Top-to-bottom: 3% 
(w/v) medium viscosity CMC used at 1.4:1 (v:w) liquid:solid ratio, 2% (w/v) high 
viscosity CMC at 1.4:1 ratio and 3% (w/v) high viscosity CMC at 1.3:1 ratio. 
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5.3.3 Investigation of the Effect on Cell Viability of the Bioplotting Process 
Following on from the cell-laden hydrogel bioplotting presented earlier (see Section 
5.3.1) a more extensive study was undertaken to assess the compatibility of a 
number of cell types with the bioplotting process.  Cells were suspended at 500,000 
mL-1 in 1.5% alginate hydrogels and pre- and post-plot viabilities were assessed as 
before.  The results of this study are summarised in Table 5.2.  Figure 5.16 shows 
representative fluorescence microscopy images of live/dead stained bioplotted cells in 
1.5% alginate hydrogels.  Mean post-bioplotting cell viabilities were in the range 79 ± 
94% as proportions of pre-plot viabilities.  Mean post-plot viability for C2C12 
myoblasts was found to be statistically-significantly (p < 0.05) higher than that for 
other cell types.  Additionally immortalised human mesenchymal stem cells (ihMSCs) 
had significantly higher post-plot viability than 3T3 fibroblasts and human 
osteosarcoma (hOS) cells. 
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Cell Type Post-Bioplotting Viability/ % 
3T3 Murine Fibroblast 
83 ± 1 
C2C12 Murine Myoblast 
94 ± 1 
Human Osteosarcoma 
79 ± 3 
Human Mesenchymal Stem Cell 
89 ± 2 
Table 5.2 ± Post-bioplotting viabilities of a number of cell types suspended in 
1.5% alginate hydrogels at 500,000 mL-1.  Viabilities were assessed by live/dead 
staining (n = 3) for 30 minutes with 2 ǋ0FDOFHLQ$0HWKLGLXPKRPRGLPHU-1 and 
are displayed as proportions of pre-plot viabilities (mean ± standard deviation). 
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Figure 5.16 ± Representative fluorescence microscopy images of cells bioplotted in 
1.5% alginate hydrogels at 500,000 cells mL-1.  Cells have been live/dead 
(green/red) stained for 30 minutes with 2 ǋM calcein AM and ethidium 
homodimer-1 respectively.  Clockwise from top left ± 3T3 murine fibroblasts, 
C2C12 murine myoblasts, hOS cells and ihMSCs.  Scale bars represent 100 ǋm. 
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The next step in the evaluation of live cell incorporation in alginate bioplotting was to 
understand which steps of the process were causing the largest losses of viability.  
1.5% alginate hydrogel constructs containing ihMSCs were produced via bioplotting 
and the viability of the cells was assessed at three stages of the process.  Viability 
was measured after mixing the alginate solution with the calcium sulphate 
crosslinker, after allowing 30 minutes for crosslinking to occur and after bioplotting (n 
= 3).  Figure 5.17 summarises these results, which showed that the mean cell 
viabilities at all stages of the process were statistically-significantly (p < 0.05) 
different to pre-plot viability but statistically-similar to one another.  An alternative 
presentation of this data is shown in Figure 5.18, depicting the loss of viability across 
each process step as a proportion of the loss across the whole process.  This shows 
that more than 75% of the viability loss was caused by the mixing step, with the 
bioplotting step itself causing only around 20% of the loss (or around 2 ± 4% 
absolute drop in cell viability). 
The final analysis undertaken was designed to assess whether the final concentration 
of alginate within the hydrogels could influence the viability of cells encapsulated 
within them.  In all cases, the w:w ratio of alginate to calcium sulphate was kept 
constant at 6:1.  Across the range considered (1 ± 2% (w/v) alginate concentration) 
no statistically-significant (p < 0.05) variation in cell viability was measured (Figure 
5.19). 
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Figure 5.17 ± Mean viabilities of ihMSCs at various stages of the bioplotting 
process (n = 3).  Cells were suspended in 1.5% alginate hydrogels at 500,000 
mL-1.  Cell viabilities were assessed by live/dead staining for 30 minutes with 2 ǋM 
calcein AM and ethidium homodimer-1 respectively.  Viabilities were measured 
after alginate/calcium sulphate mixing, after 30 minutes wait for crosslinking and 
after bioplotting.  Error bars are one standard deviation and statistically-significant 
differences to initial viability are denoted by (*). 
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5.4 Discussion 
5.4.1 Feasibility of Bioplotting as a Patterned Construct Fabrication Technique 
for Osteochondral Defect Repair 
The initial study undertaken with the Fab@Home Model 1 bioplotting platform 
demonstrated that this technique could be used to produce patterned constructs 
containing materials suitable for osteochondral repair.  Crosslinked alginate hydrogels 
could be deposited to recreate shapes with high resolution and bone and cartilage-
derived cells could be bioplotted within these gels whilst maintaining around 80% 
viability.  The ability of such chondrocyte-loaded alginate gels to generate cartilage 
tissue in vitro is well-established230,244,245. 
It was also shown that the Fab@Home platform could be used to bioplot constructs 
composed of a PLGA-based synthetic polymer microparticle paste which could 
subsequently undergo thermoresponsive liquid sintering to form solid structures270-
273,540,541.  Similar formulations have been shown previously to be capable of forming 
constructs with mechanical properties similar to normal cancellous bone270-273.  PLGA 
microspheres could be incorporated into the microparticle pastes without disrupting 
the sintering process.  SEM and ǋCT imaging confirmed that microparticle-to-
microparticle bridging had occurred and a porous sintered solid had been formed.  
The incorporation of microspheres allows for the temporally-controlled delivery of 
proteins from bioplotted constructs272,541. 
Dual material constructs could also be produced using the Fab@Home Model 1.  
These constructs contained both alginate hydrogel and PLGA-PEG microparticulate 
phases.  The inclusion of alginate hydrogel phases did not disrupt the successful 
sintering of the PLGA-PEG phases contained within the same constructs.  By 
appropriate choice of liquid sintering medium the alginate phases of dual material 
scaffolds could either be retained or removed during the sintering process.  The 
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former allowed the gel to act as a reservoir for cells and/or proteins whilst the latter 
allowed it to act as a temporary reinforcement to prevent collapse of non-self-
supporting PLGA-PEG structures. 
Finally the work undertaken showed that it was possible to use a bioplotting 
construct fabrication technique to simultaneously and independently pattern 
materials, cell populations and protein signals.  This suggested that techniques of this 
type could be used to produce constructs for simultaneous repair of multiple tissues 
in complex osteochondral defects. 
The initial study described above demonstrated that bioplotting techniques have 
great potential for tissue engineering and modelling.  However weaknesses were 
identified in the process and constructs as applied and produced at this stage.  The 
mechanical properties of the constructs were inferior to those of constructs produced 
from PLGA-PEG microparticles in previous studies270-273.  Though the particular paste 
formulations used in this and previous studies differ the key consideration is that the 
mechanical properties measured here were not sufficient for the support of defects in 
load-bearing bones.  Additionally the cell viabilities measured in bioplotted alginate 
hydrogels were at the lower end of those published in other bioplotting 
studies226,229,230,232,234,238,240,242,243,249,549.  As a result of these identified weaknesses 
more systematic evaluation and optimisation was undertaken using a Fab@Home 
Model 2 bioplotting system. 
5.4.2 Optimisation of Bioplotting of PLGA-PEG Microparticle Pastes 
A study was undertaken which was designed to maximise the mechanical properties 
of bioplotted PLGA-PEG microparticulate constructs in order to render them more 
suitable for bone defect repair.  The study also assessed the pore structures of these 
constructs as maintenance of adequate porosity and pore size are important 
considerations for ensuring tissue ingrowth in vivo.  Two different inherent viscosities 
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of CMC were assessed as viscosity modifiers for use in carrier solutions along with 
Pluronic® F127 as a lubricant for microparticle-microparticle interactions.  The most 
promising combinations of carrier and concentration were chosen on the basis of 
requiring the smallest carrier:solid (v:w) ratio to achieve complete deposition of all 
material.  Complete deposition was considered to be a minimum requirement for 
achieving consistency of paste composition throughout the bioplotting process. 
On the basLV RI WKH \LHOG VWUHVVHV DQG <RXQJ¶V PRGXOL RI ELRSORWWHG 3/*$-PEG 
constructs 2 and 3% (w/v) high viscosity CMC appeared to be the most promising 
carriers for construct fabrication.  In particular these carriers performed well when 
mixed with microparticles at the minimum carrier:solid ratios derived earlier.  At 
these ratios the constructs had yield stresses of 1.22 and 1.15 MPa respectively and 
<RXQJ¶VPRGXOL RI  DQG 0SD  7KHVH SURSHUWLHV DUH ORZHU WKDQ WKRVH IRU
many ceramic182,191,194,198 and synthetic polymer88,157,178,204,211,530 constructs used in 
bone tissue engineering.  However they are within the normal ranges for cancellous 
bone542-545. 
The mean porosities of constructs produced using these carriers at these ratios were 
relatively low at only 10.8 and 12.4% for 2 and 3% high viscosity CMC respectively.  
These values are reflected in the relatively dense structures seen via SEM imaging 
and they are lower than those of some other bone tissue engineering constructs with 
similar or better mechanical properties88,157,191,194,198,204,211,530.  The mean pore sizes 
for constructs produced using these carriers were 65.3 and 76.6 ǋP  ,W KDV EHHQ
suggested that an optimal construct for bone regeneration needs to contain a 
significant amount of pores of around 200 ±  ǋP LQ VL]H LQ RUGHU WRPD[LPLVH
tissue ingrowth550-553.  The pores produced here were clearly smaller than this 
suggested range but equally they were large enough to allow cell motion through 
and proliferation in the constructs.  Additionally the pore size distributions of 
bioplotted constructs showed small but appreciable population fractions which were 
within this optimal size range (data not shown). 
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Further progress on improving both the overall porosity and pore sizes of bioplotted 
PLGA-PEG microparticle constructs may be required for successful application in vivo.  
The simplest way to achieve this would be via the use of larger microparticles with a 
more uniform size distribution.  Greater uniformity would result in less efficient 
packing and thus greater porosity whilst larger microparticle sizes would result in 
larger pores.  Work so far on PLGA-PEG microparticle bioplotting suggests that using 
larger rough milled microparticles may not be a feasible option.  Additionally it is 
difficult to ensure uniformity of size in a population of objects with irregular shapes 
and potentially very high aspect ratios.   
One option which may be feasible is the use of PLGA-PEG microspheres as the solid 
component of the pastes.  Microparticles with regular spherical morphology would 
pack less efficiently than those with irregular morphology.  Microspheres would also 
flow over one another more efficiently which may allow carrier:solid ratios and tip 
inner diameters to be lowered relative to the values used in this work.  These 
changes could result in improved mechanical properties and improved patterning 
resolution respectively. 
5.4.3 Evaluation of the Effect of the Bioplotting Process on the Viability of 
Cells in Hydrogels 
Following on from the results of the feasibility study described earlier (see Sections 
5.3.1 and 5.4.1) cells derived from a number of tissues were bioplotted in 1.5% 
alginate hydrogels and their post-plot viabilities assessed.  These were typically in the 
range 75 ± 95% as proportions of pre-plot viability.  This range is in good agreement 
with the viabilities reported in other studies involving bioplotting of cell-laden 
alginate226,229,230,232 and other hydrogels226,234,238,240,242,243,249,549.  Statistically-
significant (p < 0.05) differences were seen between different cell types and 
understanding the reasons for these differences will be a key step in the further 
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optimisation of bioplotting protocols.  It may be supposed that cells derived from 
tissues which experience very large mechanical loads, such as bone, would be more 
resilient to the stresses imposed on them during bioplotting.  However in this case 
hOS cells were found to withstand the process less successfully than C2C12 
myoblasts, suggesting that the reasons for such variation are more complex than this 
one single factor. 
It was identified that the key step of the sample preparation and bioplotting process 
which was most detrimental to cell viability was the significant amount of mixing 
needed to combine the alginate and calcium sulphate solutions.  This step caused 
over 75% of the observed loss of viability whilst the deposition itself caused only 
20% of it (equating to around a 2 ± 4% absolute loss of viability).  This suggests that 
the loss of cell viability across the bioplotting process as a whole could potentially be 
very low for cells encapsulated in materials which require less mixing or other 
processing to formulate them for extrusion.  It also suggests that the results obtained 
here are comparable with those obtained in previous studies which involved the 
deposition of cells in alginate solutions without calcium crosslinking226,232.  
The final concentration of alginate in crosslinked, cell-laden hydrogels was varied 
whilst keeping the alginate:calcium sulphate (w:w) ratio constant and the effect on 
cell viability post-mixing was assessed.  Within the range studied varying this 
parameter did not significantly affect the cell viability.  The range studied was 
relatively narrow but it was difficult to vary the alginate concentration further.  
Utilising lower concentrations resulted in materials which were not sufficiently solid to 
allow retention of structure after deposition.  Hydrogels with higher alginate 
concentrations could not be produced utilising the alginate considered in this study as 
it was not soluble at sufficiently high concentrations.  Only one previous study has 
directly compared post-plot cell viabilities for alginate hydrogels of different 
concentrations232.  This study was performed using a very different range of 
concentrations (5 ± 10% (w/v)) and a different alginate product but nevertheless 
Chapter 5 ± Patterned Constructs via Bioplotting 
211 
 
also found no significant effect of concentration.  Other studies have utilised alginate 
concentrations individually across the range 1.33 ± 2% (w/v) and no very large 
differences in post-plot cell viability have been observed226,229,230. 
Another parameter which could be considered when optimising the bioplotting of cell-
laden hydrogels would be the cell density within them.  It may be expected that 
increasing the cell density would lead to a greater level of cell damage and death 
since they would then constitute a larger volume fraction of the material and thus be 
less likely to be stress shielded by the gel. 
As well as optimising the cell density it may be possible to find alternative mixing 
protocols which would result in lower mechanical loading of the cell-laden hydrogels.  
Previous work indicates that the extensive mixing utilised in the work presented in 
this chapter is necessary to ensure consistency of material properties through the 
bioplotting process554.  This suggests that significant reduction of the amount of 
mixing may not be possible.  As a result it may be important to consider automation 
or at least improved control of the mixing process which is currently used.  In the 
current protocol mixing is by hand and the mixing rate is controlled only by operator 
judgement.  This results in a process which is relatively poorly-controlled and 
potentially has a very high degree of variability.  Superior control of the process 
would allow the mixing rate to be varied and optimised for both mixing efficiency and 
eventual cell viability.  Such control could be exercised via the use of programmable 
syringe pumps or similar to drive the motion of the syringe plungers at more tightly-
defined rates. 
5.4.4 The Potential of Bioplotting for Patterned Construct Fabrication 
The feasibility study presented in Section 5.3.1 demonstrated that the Fab@Home 
bioplotting platform could produce constructs containing patterned materials, 
patterned protein signals and patterned cell populations.  However it also highlighted 
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that WKH µTXDOLW\¶RI UHVXOW WKDWFRXOGEHREWDLQHGZLWKPXOWLSOHVFDIIROGSKDVHVZDV
inferior to that obtained when only a single phase was needed.  The processes used 
to produce complex constructs require further optimisation from a practical and 
logistical sWDQGSRLQWWRHQVXUHWKDWWKLVµTXDOLW\¶LVLPSURYHG 
An additional requirement is the demonstration that patterns generated during 
construct production are converted into patterns of cell behaviour in vitro or tissue 
formation in vivo.  This issue was discussed earlier in relation to 
microinjection/micromanipulation-based patterning (see Section 3.4.5).  
Requirements include the demonstration that patterns of cell populations can be 
maintained when cells are afforded the opportunity to adhere and move through the 
constructs.  Also needed is evidence that signal patterns generated by protein release 
from patterned microspheres can be stabilised by the ability of cells to act as signal 
sinks.  Furthermore it is necessary to demonstrate that these stabilised patterns can 
then be converted into patterned cellular behaviour. 
In order to achieve truly functional patterning and cell-populated construct phases 
which are suitable for bone repair the incorporation of viable cells in bioplotted PLGA-
PEG pastes is an important step.  This has not been demonstrated in the work 
presented here but other results in this chapter along with those obtained 
previously270,272 suggest it is achievable.  The work presented in this chapter has 
demonstrated that the deposition step of the bioplotting process does not cause 
significant cell death, at least for cells deposited in alginate hydrogels.  Previous work 
utilising PLGA-PEG microparticle pastes has shown that constructs can be formed 
from this material containing populations of live cells which go on to proliferate post-
production270,272.  The existence of these prior studies does not render the successful 
bioplotting of viable cells in PLGA-PEG microparticle pastes a trivial achievement.  
However it does suggest that with appropriate optimisation of the process it should 
be possible. 
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6. Conclusions & Future Work 
6.1 Three-Dimensional Patterning in Tissue Engineering 
As highlighted in the introduction to this thesis (see Chapter 1) three-dimensional 
patterning technologies are likely be important in the development of future tissue 
engineering therapies and engineered tissue models.  In vitro tissue models which 
could reproduce some of the structural complexity and cell-cell interactions of native 
tissue would be a useful alternative or addition to pre-clinical animal models for drug 
screening and development.  Future tissue engineering therapies may also benefit 
from, or even require the heterogeneous distribution of construct constituents to 
achieve fully-functional tissue repair.  This may be particularly true for applications 
involving large, complex defects incorporating multiple tissue types. 
The work presented in this thesis has addressed aspects of such three-dimensional 
patterning strategies in tissue engineering.  Some of the work focused on the 
production of biomaterial formulations for use in patterning.  Poly(lactic-co-glycolic 
acid)-based (PLGA-based) microsphere formulations were considered (see Chapter 3) 
along with hydrogels derived from the extracellular matrix (ECM) of bovine bone (see 
Chapter 4).  The remainder of the work related to the patterning techniques 
themselves.  The techniques utilised were microinjection/micromanipulation (MM) 
(see Chapter 3) and bioplotting (see Chapter 5).  These techniques were intended to 
address different aims, with the former used to attempt patterning of individual 
PLGA-based microspheres within in vitro culture environments.  This was envisaged 
to be useful for the deduction of fundamental cell and molecular biology by 
replication of developmental and repair environments and processes.  In contrast 
bioplotting was intended as an approach to patterning materials, cells and protein 
signals at a higher level.  The constructs created by this coarser patterning were 
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intended to be useful both as in vitro tissue models and potential future tissue 
engineering therapies. 
6.2 Production and Patterning of PLGA-Based Microspheres 
Double emulsion-based protocols were developed for the production of PLGA 
microspheres with size distributions centred on means of around 15 and 100 ǋm and 
with low batch-to-batch variabilities.  These distinctly-different size distributions could 
give rise to distinctly-different release kinetics294,343,346.  These release kinetics could 
be further modified by supplementing the PLGA of which the microspheres were 
composed with a PLGA-poly(ethylene glycol)-PLGA (PLGA-PEG-PLGA) triblock 
FRSRO\PHUµ7ULEORFN¶267.  The hydrophilic PEG component of the copolymer acted to 
increased water ingress into the microspheres and thus accelerate protein release in 
a dose-dependent manner.  Further tailoring of the Triblock concentration and/or the 
combination of multiple microsphere types into a single formulation would allow more 
sophisticated control of the protein release profiles.  In particular the combination of 
a fast-releasing type with a slow-releasing type may have the potential to generate a 
zero-order release profile for sustained and consistent biological action. 
Both sizes of microsphere could be suspended in water and delivered via ejection 
from microlitre syringes at densities as high as 75% (w/v).  The number of 
microspheres contained within individual ejection volumes was used as a measure of 
the consistency of the delivery process.  Based upon this output the delivery of 
microspheres suspended in water alone was subject to very significant variation.  In 
some, though not all cases supplementing the suspension fluid with carboxymethyl 
cellulose (CMC) led to improved ejection-to-ejection consistency.  This was attributed 
to the fact that CMC addition could significantly extend the time taken for 
microspheres to settle out of suspension.  Further work is needed to deduce optimal 
conditions for the delivery of microsphere suspensions but this was not undertaken 
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here since microlitre syringes proved to be insufficiently precise delivery systems for 
the intended patterning work. 
A semi-automated MM system was successfully used to pattern microspheres 
individually into agarose hydrogels with inter-microsphere spacings as small as 100 
ǋm.  This suggested that the technology may have the potential to produce 
environments for the deduction of fundamental cell and developmental biology.  
However further work is required on a number of aspects of the process in order to 
fully realise this potential.  The protocol used for patterning in this work was highly-
dependent on operator skill and did not allow the production of patterns containing 
more than a few microspheres.  Furthermore agarose is not a suitable cell culture 
environment due to its poor cell adhesion properties358,359 and the gelatin conjugation 
process555 which was used here to overcome this problem proved promising but 
unreliable (see Appendix).  Alternative modification with RGD-containing peptide 
sequences131,140 and logistically-different patterning protocols may allow truly 
effective three-dimensional patterning into hydrogels which could support cell 
growth.  Finally the ability to pattern cells in addition to microspheres via MM 
techniques would allow still greater control over the assessment of cellular responses 
to protein gradient environments. 
6.3 Production of Hydrogels from the Extracellular Matrix of Bovine Bone 
The work presented in Chapter 4 includes the generation of demineralised bone 
matrix (DBM) powder from bovine bone and the subsequent decellularisation of this 
material to produce decellularised extracellular matrix (DECM).  Both of these 
materials could be solubilised by enzymatic digestion and the resulting solutions could 
undergo temperature- and pH-responsive gelation at physiological conditions.  These 
materials may therefore be suitable for use as injectable scaffolds for tissue 
engineering therapies.  This idea is further supported by the positive results obtained 
when utilising these ECM-derived hydrogels as in vitro cell culture surfaces.  Across 
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two cell types and a number of different conditions the ECM-derived gels consistently 
outperformed collagen and could in some cases match tissue culture plastic, the gold 
standard culture surface.  Further work is nevertheless required to understand the 
observed significant response differences between different cell types and to deduce 
the identity of any beneficial DBM and DECM constituents. 
These solubilised ECM-derived materials may be incorporated into both patterning 
techniques considered in this thesis.  Work presented in Chapter 4 showed that, by 
the use of an alginate intermediate, these materials could be formed into beads.  
These beads have inherent bioactivity but could also potentially be used to 
encapsulate proteins for subsequent release by cell-mediated degradation of the 
beads.  As a result ECM-derived hydrogel beads may be useful for MM-based 
strategies in tissue modelling.  A similar approach to that used for bead formation 
could also be used to bioplot ECM-derived gel constructs.  This approach would help 
to circumvent any issues which may be caused by the relatively slow gelation kinetics 
of these materials.  One limitation to this approach would be that cell encapsulation 
in the hybrid alginate/ECM material would inevitably be associated with significant 
losses during the alginate elimination step. 
6.4 Bioplotting for the Production of Patterned Tissue Engineering Constructs 
As has been found in a number of previous studies226,229,230,232,234,238,240,242,243,249,549 the 
work presented in Chapter 5 demonstrated that alginate hydrogels could be 
bioplotted containing cells which retained a high degree of viability (around 75% or 
more).  It also established that the majority of the loss of viability which was 
observed was due to sample preparation and not the bioplotting process itself.  This 
suggested that hydrogels of similar rheological properties but requiring less physical 
mixing during preparation could be used to bioplot cells with only around 2 ± 4% loss 
of viability.  Future work may seek to further explore the cell type-to-cell type 
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differences in post-plot viability observed here in order to tailor bioplotting protocols 
to individual populations. 
A novel application of bioplotting was also considered in which it was used to extrude 
pastes composed of thermoresponsive PLGA-PEG microparticles suspended in 
aqueous carriers.  These extruded pastes could be sintered under physiological 
conditions resulting in constructs with bone-appropriate mechanical properties270-273 
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porosities of these constructs were lower than would be desirable and may need to 
be increased in order to achieve effective tissue repair in future in vivo applications.  
Additional work may also be needed to increase the number of pores falling within 
the 200 ± 400 ǋm size range which has been considered ideal for achieving in vivo 
bone ingrowth550-553.  Achieving these aims may be significantly aided by the use of 
PLGA-PEG microspheres in place of the rough milled microparticles used in this work.  
This would reduce the packing efficiency of individual objects within the pastes 
resulting in increased porosity.  The improved flow properties of microspheres 
relative to microparticles may also allow the use of larger objects, giving rise to 
increased pore sizes. 
Work presented in this thesis also demonstrated the capability of the Fab@Home 
bioplotting platform to produce dual material constructs containing both alginate and 
PLGA-PEG phases.  Furthermore it showed that the platform could produce 
constructs containing four separate phases and patterns of materials, cell populations 
and protein signals.  This complex patterning capability gives the technique excellent 
and widely-applicable potential for use in tissue engineering and in vitro modelling 
and particularly in construct fabrication for osteochondral repair.  Lessons learnt 
during the bioplotting of cell-laden alginate hydrogels are especially widely-applicable 
since it can be assumed that the rheological properties of the hydrogel are the 
dominant factor in determining the cell response to applied mechanical stresses.  This 
means that the fate of cells bioplotted in alginate gels should be similar to that of 
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cells in other hydrogels with similar rheological properties, regardless of their 
biochemical nature. 
6.5 Current & Future Directions 
Overall it can be said that the results presented here have helped to demonstrate and 
extend the potential of three-dimensional patterning techniques in tissue engineering.  
The application of MM techniques in this field has been very limited but in this thesis 
it has been shown that they can be powerful tools for the recreation of complex 
heterogeneous signal environments in vitro.  Previously-published studies utilising 
bioplotting in this field have almost exclusively used hydrogels as construct 
materials226,227,229,230,232,240,242,243,245-247,249-251,546 and this has limited the application of 
the technique to bone tissue engineering.  Here the potential of bioplotting in this 
specific area has been enhanced by the utilisation of synthetic polymer 
microparticulate pastes as scaffold materials.  These can be extruded and sintered at 
mild conditions but nevertheless achieve bone-appropriate mechanical properties270-
273. 
The use of synthetic polymer microspheres and/or ECM-derived hydrogel beads as 
protein delivery vehicles allows these signals to be presented in a temporally-
controlled manner.  This is in addition to the spatial control exerted by the patterning 
technologies themselves.  Indeed MM techniques in particular could even be used to 
introduce new protein-loaded elements and/or cell populations during post-
production in vitro culture. 
Taken together these techniques potentially allow the recreation of tissue 
architecture and cellular microenvironments across a very large range of length 
scales.  This may be useful for a range of applications, from the replication of key 
developmental processes to the restoration of large volumes of lost tissue.
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Appendix ± Modification of Agarose to Improve its 
Cell Compatibility 
A1 - Introduction 
Agarose was chosen as a substrate for microinjection/micromanipulation-based 
patterning partly due to its excellent optical properties.  Additionally the 
cooling/setting-based gelation mechanism allowed effective positioning of 
microspheres without residual damage to the hydrogel.  However agarose is known 
to allow only poor adhesion of cells in in vitro culture358,359.  To allow cells to be 
grown on or in hydrogels in which protein signals had been patterned it was 
necessary to modify the agarose to improve its cell adhesiveness.  This was achieved 
by conjugating gelatin to it using a protocol based on one which was previously 
published555.   
A2 ± Materials & Methods 
A2.1 ± Agarose-Gelatin Conjugate Synthesis 
First 0.4 g of agarose was dissolved in 10 mL dimethyl sulphoxide (DMSO) at 80oC 
and the resulting solution cooled to room temperature.  Following this 17.545 mg of 
1,1-carbonyldiimidazole (CDI) in 4 mL DMSO was added to the agarose solution and 
the mixture stirred for one hour at room temperature.  This allowed reaction of the 
CDI with hydroxyl groups on the agarose molecules.  Subsequently 0.4 g of gelatin in 
6 mL DMSO was added and stirred for 16 hours at room temperature to allow the 
CDI bound to the agarose chains to react with amine groups on the gelatin 
molecules.  The resulting material was dialysed against 4 L dH2O for 2 days to 
remove DMSO and unreacted CDI (dialysis tubing ± catalogue number D0405, Sigma-
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Aldrich, Poole, UK).  During this period the water was changed three times per day to 
ensure sink conditions.  After removal from the dialysis tubing the hydrogel product 
was broken into fragments by rapid ejection from a 10 mL Luer lock syringe.  These 
hydrogel fragments were soaked in 0.1 M sodium bicarbonate buffer (4 L, pH 8.5) for 
4 days at room temperature to remove uncrosslinked gelatin.  During this soak the 
buffer was changed a total of 6 times.  Finally the hydrogel product was washed in  
4 L dH2O for one day to remove the bicarbonate buffer and during this time the 
water was changed twice.  At the end of this period the final product was snap frozen 
in liquid nitrogen and lyophilised for five days before dry mass measurement to 
assess the degree of gelatin incorporation.  The lyophilised material could be stored 
at room temperature and reconstituted by addition of dH2O or PBS and incubation at 
80oC with regular agitation. 
A2.2 ± PrestoBlueTM Assay to Measure Cell Proliferation on Agarose-Based 
Hydrogels 
The agarose-gelatin conjugate material used in this study was kindly provided by 
Giles Kirby (University of Nottingham).  Solutions were prepared at 1% (w/v) of 
agarose, agarose-gelatin conjugate and a mixture of agarose and gelatin at the same 
mass ratio as contained within the conjugate.  These solutions were transferred to 
the wells of 12-well tissue culture plates (200 ǋL per well) and the plates incubated 
at 4oC for 2 hours to form hydrogels.  Immortalised human mesenchymal stem cells 
(ihMSCs) were seeded on the gels and also on tissue culture plastic (TCP) at 20,000 
cells per well in 1 mL of complete medium (n = 6).  Medium was changed once per 
day for 7 days and total cell metabolism on the gels assessed at 1, 3, 5 and 7 days.  
Results for each surface were assessed relative to cell-free controls incubated under 
the same conditions. 
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Resazurin (7-Hydroxy-3H-phenoxazin-3-one 10-oxide) is a non-fluorescent blue 
compound which becomes the red-fluorescent dye resorufin when reduced in the 
intracellular environment of living cells.  This has been exploited in the development 
of several resazurin-based cell viability assays, among which is the PrestoBlueTM Cell 
Viability Reagent assay. 
This assay was used to perform the cell metabolism assessment described above.  To 
the 1 mL of culture medium in each well 111 ǋL of PrestoBlueTM reagent was added 
and the combination incubated at 37oC in the dark for 30 minutes.  From each well 
100 ǋL of reaction mixture was transferred to a black 96-well plate well and the 
fluorescence intensity read at 560 nm excitation and 590 nm emission. 
A3 ± Results & Discussion 
A3.1 ± Agarose-Gelatin Conjugate Preparation 
In the course of the work presented here three different batches of conjugate were 
fabricated by two different operators (one batch prepared by Giles Kirby).  The mass 
fractions of gelatin in these batches were found to be 25.2, 26.0 and 25.8%.  These 
figures were in good agreement with those presented in the original publication555 
and also indicated a low level of bath-to-batch variability for the process. 
However two of the batches prepared were found to be incompletely dissolved in 
either PBS or water at concentrations as low as 0.5% (w/v).  This observation was 
made even after two hours incubation in a water bath at 80oC.  The cause of this lack 
of solubility is not yet fully understood but it can most likely be attributed either to 
agarose-agarose or gelatin-gelatin conjugation occurring instead of the intended 
agarose-gelatin interaction.  A fuller understanding of the alterations to the reaction 
mechanism that caused this issue may allow it to be prevented in future conjugate 
production. 
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A3.2 ± Cell Compatibility of Agarose-Gelatin Conjugate Hydrogels 
One day after seeding very few ihMSCs were seen on agarose or agarose-gelatin 
mixture hydrogels and those that were present showed rounded morphology.  By 
three days after seeding these hydrogels were largely absent in the wells where they 
had been created suggesting they had dissolved or degraded.  These materials were 
therefore deemed to be unsuitable as in vitro cell culture substrates.   
Figure A1 shows representative phase contrast images of ihMSCs on the other two 
surfaces (TCP and agarose-gelatin conjugate).  These images show that cells cultured 
on the conjugate hydrogel exhibited similar morphology to those cultured on TCP.  
Total cell metabolism on the hydrogels as assessed via the PrestoBlueTM assay was 
statistically-significantly (p < 0.05) lower than that on TCP at all time points (Figure 
A2). 
When the results on both surfaces were normalised to their own day 1 results these 
significant differences were no longer seen at day 3 or day 7.  This suggested that 
the difference between the two surfaces was one of differing levels of initial cell 
adhesion rather than differing rates of proliferation.  This in turn suggested that 
agarose-gelatin conjugate hydrogels could function as excellent cell growth 
environments. 
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Figure A1 - Representative phase contrast images showing ihMSCs cultured on 
agarose-gelatin conjugate hydrogel (left) or TCP (right) and imaged at various 
time points.  Top-to-bottom ± one day, three days, five days and seven days after 
seeding at 20,000 cells per well in 12-ZHOOSODWHV6FDOHEDUVUHSUHVHQWǋP 
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Figure A2 ± Total ihMSC metabolism on TCP and on an agarose-gelatin conjugate 
hydrogel at a variety of time points as measured by PrestoBlueTM assay (n = 6).  
Cells were seeded at 20,000 cells per well in 12-well plates at time zero.  
Fluorescence intensities are shown both as measured (A) and normalised to day 1 
results (B).  Error bars are on standard deviation and statistically-significant 
differences (p < 0.05) between the two groups are denoted by (*). 
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